



# 長谷川好規 教授 略歴

## 学 歴

昭和49年3月～昭和55年3月:岐阜県立岐阜高等学校  
昭和55年3月～昭和58年4月:徳島大学医学部医学科  
昭和58年4月～昭和62年3月:名古屋大学大学院医学研究科(内科学第一専攻)

## 職 歴

昭和55年4月:社会保険中京病院臨床研修医  
昭和57年4月:社会保険中京病院内科医員  
昭和57年7月:厚生連高山久美愛病院内科医員  
昭和62年7月:米国カリフォルニア大学医学部ロサンゼルス校客員研究員  
平成元年11月:法務技官医務課長  
平成6年10月:名古屋大学助手・医学部附属病院第一内科  
平成14年7月:名古屋大学講師・医学部附属病院呼吸器内科  
平成19年5月:名古屋大学教授・大学院医学系研究科・病態内科学講座 呼吸器内科学分野  
平成22年10月:名古屋大学総長補佐(～平成26年3月)  
平成24年4月:名古屋大学大学院医学系研究科副研究科長(～平成29年3月)  
平成25年4月:名古屋大学医学部附属病院副病院長(～平成28年3月)  
平成25年4月:名城大学客員教授兼任  
平成28年4月:名古屋大学総長補佐(～平成31年3月)  
平成31年5月:独立行政法人国立病院機構 理事 名古屋医療センター院長

## 賞

平成11年10月:愛知県医師会難病研究者表彰

## 学会開催

第116回日本内科学会総会会長(平成31年5月)  
第60回日本呼吸器学会学術講演会会長(令和2年4月開催予定)



## 学術活動

### 《日本医学会総会》

第30回日本医学会総会 2019中部 総務委員長

### 《日本内科学会》

日本内科学会 筆頭副理事長(平成30年5月～)  
日本内科学会 理事(平成25年4月～平成27年3月、平成29年4月～)  
日本内科学会 認定医、研修医指導医

### 《日本呼吸器学会》

日本呼吸器学会 理事長(平成30年4月～)  
日本呼吸器学会 専門医、指導医、評議員、代議員  
ガイドライン施行管理委員会委員長、教育委員会委員長、  
学術部会統合委員会委員長、財務委員会委員長

### 《日本肺癌学会》

日本肺癌学会 理事(2008.11～2018.10)  
総務委員(2011.2～2018.10)  
将来計画委員長(2011.2～2016.7)  
教育研修委員長(2016.7～2018.10)

### 《日本アレルギー学会》

日本アレルギー学会 認定医(April 1, 1991) 専門医(April 1, 1994) 指導医(April 1, 2005)  
評議員(October 28, 1992-2005: 2005年より代議員～)

### 《日本呼吸ケア・リハビリテーション学会》

日本呼吸ケア・リハビリテーション学会 理事(2012.11～)常任理事(現在)

### 《日本結核病学会》

日本結核病学会 理事(April, 2001～)

### 《国際学会》


American College of Chest Physicians F.C.C.P (December 03, 1993)  
American Thoracic Society Full Member  
American Society of Clinical Oncology Active Member



# 学位取得者

(指導教授 長谷川好規先生)

学位記番号	授与年月日	氏名	主論文題目
医博第2169号	H19.12.28	若原 恵子	Repeated instillations of <i>Dermatophagoides farinae</i> into the airways can induce Th2-dependent airway hyperresponsiveness, eosinophilia and remodeling in mice- Effect of intratracheal treatment of fluticasone propionate- ( <i>Dermatophagoides farinae</i> の気道への繰り返し投与はマウスにTh2依存性の気道過敏性、好酸球性炎症および気道リモデリングをおこしうる-プロピオン酸フルチカゾンによる経気道的治療の効果)
医博第2170号	H20.1.31	高橋 孝輔	SLC11A1 (formerly NRAMP1) polymorphisms associated with multidrug-resistant tuberculosis SLC11A1 (NRAMP1)遺伝子多型と多剤耐性結核の関連)
医博第2230号	H20.3.25	清水 淳市	mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity of cisplatin, carboplatin and gemcitabine in human lung cancer cell lines (ヒト肺癌細胞株において、RRM1、ERCC1、ERCC2 の mRNA 発現はシスプラチン、カルボプラチン、ゲムシタビンの化学療法感受性と関連しない)
医博第2287号	H20.10.31	池ノ内 紀祐	Role of Ca <sup>2+</sup> mobilization in desensitization of $\beta$ -adrenoceptors by platelet-derived growth factor in airway smooth muscle (PDGFにより生じる気道平滑筋の $\beta$ アドレナリン受容体耐性化におけるカルシウム動態の役割)
医博第2302号	H21.1.30	芝崎 正崇	Up-regulation of Surfactant Protein Production in a Mouse Model of Secondary Pulmonary Alveolar Proteinosis (続発性肺胞蛋白症のマウスモデルにおけるサーファクタントプロテインの産出亢進)
医博第2351号	H21.3.25	鈴木 裕太郎	Activation of P13K-AKT pathway on human malignant mesothelioma cells (悪性中皮腫細胞における細胞内シグナル伝達系P13K/AKT経路の活性化)
医博第2354号	H21.3.25	松野 匡克	Dual Pathway Activated by tert-Butyl Hydroperoxide in Human Airway Anion Secretion (ヒト気道の陰イオン分泌においてtert-Butyl Hydroperoxideにより活性化される二つの経路)
医博第2359号	H21.3.25	岩田 晋	Regulation of endothelin-1-induced interleukin-6 production by Ca <sup>2+</sup> influx in human airway smooth muscle cells (ヒト気道平滑筋細胞におけるエンドセリン-1によって引き起こされるインターロイキン-6産出のCa <sup>2+</sup> 流入による制御)





学位記番号	授与年月日	氏名	主論文題目
医博第2387号	H21.5.29	長尾美紀	Variations in amount of TSST-1 produced by clinical methicillin resistant Staphylococcus aureus (MRSA) isolates and allelic variation in accessory gene regulator (agr)locus (メチシリン耐性黄色ブドウ球菌のTSST-1産出量の多様性およびaccessory gene regulator領域の遺伝子変異)
医博第2393号	H21.6.30	前田真男	Characterization of interaction between CLP36 and palladin (CLP36とpalladinの間の相互作用とその特徴)
医博第2403号	H21.9.30	白木晶	Role of Ca <sup>2+</sup> mobilization and Ca <sup>2+</sup> sensitization in 8-iso-PGF2 $\alpha$ -induced contraction in airway smooth muscle (8-iso-PGF2 $\alpha$ による気道平滑筋収縮におけるCa <sup>2+</sup> 動態とCa <sup>2+</sup> 感受性の役割)
医博第2418号	H21.11.30	高木康之	Erythromycin- induced CXCR4 expression on microvascular endothelial cells (エリスロマイシンにおける微小血管内皮細胞でのCXCR4表面発現誘導効果)
医博第2430号	H22.1.29	後藤康洋	Epigenetic Profiles Distinguish Malignant Pleural Mesothelioma from Lung Adenocarcinoma (エピジェネティックプロファイルが悪性胸膜中皮腫と肺腺がんを鑑別する)
医博第2432号	H22.1.29	本多豊大	Differential TH1/TH2 Chemokine Expression in Interstitial Pneumonia (間質性肺炎におけるTH1/TH2ケモカイン発現の検討)
医博第2496号	H22.3.31	岩木舞	Mechanical stretch enhances IL-8 production in pulmonary microvascular endothelial cells (機械的伸展刺激は肺微小血管内皮細胞からのIL-8産生を誘導する)
医博第2516号	H22.5.31	浅野俊明	Thalidomide Attenuates Airway Hyperresponsiveness and Eosinophilic Inflammation in a Murine Model of Allergic Asthma (サリドマイドはアレルギー性喘息モデルマウスにおいて気道過敏性と好酸球性炎症を減弱させる)
医博第2519号	H22.6.30	田中繁	Functions of base selection step in human DNA polymerase $\alpha$ (ヒトDNAポリメラーゼ $\alpha$ の塩基選択機能)
医博第2533号	H22.9.30	森瀬昌宏	Heterologous regulation of anion transporters by menthol in human airway epithelial cells (ヒト気道の陰イオン輸送体に対するmentholの非定型的な制御)





学位記番号	授与年月日	氏名	主論文題目
医博第2540号	H22.11.30	下方 智也	Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer (日本人がん患者における薬物動態解析に基づいたカルボプラチン投与量の前向き評価)
医博第2559号	H23.3.25	進藤 有一郎	Health-Care-Associated Pneumonia Among Hospitalized Patients in a Japanese Community Hospital (日本の市中病院の入院患者における医療ケア関連肺炎)
医博第2573号	H23.3.25	竹山 佳宏	Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells (EMT制御因子ZEB1のノックダウンは肺ガン細胞の足場非依存性増殖を抑制する)
医博第2595号	H23.3.25	日比野 佳孝	Capsaicinoids regulate airway anion transporters through Rho kinase- and cAMP-dependent mechanisms (カプサイシン様物質はRhoキナーゼおよびcAMPに依存した機序を介して気道の陰イオン輸送体を制御する)
医博第2633号	H23.5.31	中村 俊信	Attenuation of Transforming Growth Factor- $\beta$ -Stimulated Collagen Production in Fibroblasts by Quercetin-Induced Heme Oxygenase-1 (ケルセチンにより誘導されたHeme Oxygenase-1による線維芽細胞におけるTGF- $\beta$ 誘導コラーゲン産生の減弱)
医博第2654号	H23.10.31	森 明美	Effects of specific prostanoid EP receptor agonists on cell proliferation and intracellular Ca <sup>2+</sup> concentrations in human airway smooth muscle cells (ヒト気道平滑筋細胞における選択的EP受容体アゴニストの細胞増殖能と細胞内Ca <sup>2+</sup> 濃度に対する調節効果)
医博第2670号	H23.12.28	小川 紫都	Patterns of recurrence and outcome in patients with surgically resected small cell lung cancer (小細胞肺癌に対する根治的肺切除術後患者における再発形式と生命予後)
医博第2671号	H23.12.28	堀尾 美穂子	Transient but Not Stable ZEB1 Knockdown Dramatically Inhibits Growth of Malignant Pleural Mesothelioma Cells : Implications of Gene Expression Changes Resulting from ZEB1knockdown (安定でなく一時的なZEB1ノックダウンは悪性胸膜中皮腫細胞の増殖を劇的に抑制する:ZEB1ノックダウンによって起こる様々な遺伝子発現変化の関与)
医博第2677号	H24.1.31	森岡 正貴	Microtubule Dynamics Regulate Cyclic Stretch-Induced Cell Alignment in Human Airway Smooth Muscle Cells (微小管dynamicsはヒト気道平滑筋細胞における繰り返し伸展刺激による細胞整列を制御する)



学位記番号	授与年月日	氏名	主論文題目
医博第2688号	H24.3.26	麻生裕紀	Prostaglandin E2 enhances interleukin-8 production via EP4 receptor in human pulmonary microvascular endothelial cells (PGE2 はヒト肺微小血管内皮細胞においてEP4レセプターを介してIL-8産生を誘導する)
医博第2744号	H24.3.26	田村真理子	GENETIC POLYMORPHISMS OF THE ADENOSINE TRIPHOSPHATE-BINDING CASSETTE TRANSPORTERS (ABCG2, ABCB1) AND GEFITINIB TOXICITY (ABCトランスポーター (ABCG2, ABCB1)の遺伝子多型とゲフィチニブの毒性について)
医博第2745号	H24.3.26	林悠太	Quercetin protects against pulmonary oxidant stress via heme oxygenase-1 induction in lung epithelial cells (ケルセチンは肺上皮細胞においてheme oxygenase-1誘導を介して肺の酸化ストレスから保護する)
医博第2754号	H24.3.30	中島治典	Involvement of the Transcription Factor Twist in Phenotype Alteration Through Epithelial-Mesenchymal Transition in Lung Cancer Cells (肺癌細胞の上皮間葉転換を介した表現型変化における転写因子Twistの関与)
医博第2761号	H24.4.27	牧野靖	Role of sphingosine 1-phosphate in $\beta$ -adrenoceptor desensitization via Ca <sup>2+</sup> sensitization in airway smooth muscle (気道平滑筋の $\beta$ アドレナリン受容体耐性化におけるカルシウム感受性を介したスフィンゴシン1リン酸の役割)
医博第2778号	H24.7.31	阪本考司	Differential modulation of surfactant protein D under acute and persistent hypoxia in acute lung injury (急性肺傷害においてサーファクタントプロテインDの発現は急性および遷延性低酸素条件下で異なる調節を受ける)
医博第2805号	H24.12.28	長谷哲成	Pivotal role of epithelial cell adhesion molecule in the survival of lung cancer cells (肺癌細胞の生存におけるepithelial cell adhesion moleculeの重要な役割)
医博第2829号	H25.3.25	菅沼伸一	STIM1 Regulates Platelet-Derived Growth Factor-Induced Migration and Ca <sup>2+</sup> Influx in Human Airway Smooth Muscle Cells (STIM1 はヒト気道平滑筋細胞においてPDGFによる細胞遊走とCa <sup>2+</sup> 流入を制御する)
医博第2843号	H25.3.25	Momen Hafez Kamel Ahmed Elshazley	The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma (時計遺伝子BMAL1は悪性胸膜中皮腫の新規の治療標的である)



学位記番号	授与年月日	氏名	主論文題目
医博第2855号	H25.3.25	水谷 武史	Nongenomic Effects of Fluticasone Propionate and Budesonide on Human Airway Anion Secretion (プロピオン酸フルチカゾンとブデソニドの非ゲノム効果によるヒト気道アニオン分泌の発生とその機序)
医博第2856号	H25.3.25	吉田 健也	TIMELESS is overexpressed in lung cancer and its expression correlates with poor patient survival (TIMELESSは肺癌で過剰発現し、その発現が患者の生存期間不良と関連する)
医博第2871号	H25.3.25	小栗 知世	Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer. (日本人大腸癌患者におけるオキサリプラチンによる末梢神経障害と遺伝的多型との関連)
医博第2986号	H26.3.25	田中 一大	LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade (LIMドメインを持つ蛋白質AJUBAは、Hippoシグナル経路を介して悪性中皮腫細胞の増殖を抑制する)
医博第2987号	H26.3.25	渡邊 文子	Quadriceps weakness contributes to exercise capacity in nonspecific interstitial pneumonia (大腿四頭筋筋力低下は非特異性間質性肺炎の運動耐容能と関連する)
医博第3021号	H26.4.30	小川 知美	Prospective analysis of efficacy and safety of an individualized-midazolam-dosing protocol for sedation during prolonged bronchoscopy (気管支鏡検査時の鎮静術におけるミダゾラム個別化投与の有効性、安全性の検討)
医博第3032号	H26.6.30	青山 大輔	Involvement of TGF $\beta$ -Induced Phosphorylation of the PTEN C-Terminus on TGF $\beta$ -Induced Acquisition of Malignant Phenotypes in Lung Cancer Cells (TGF $\beta$ 誘導による肺癌細胞の悪性表現型獲得におけるPTEN-C末端リン酸化の関与)
医博第3036号	H26.7.31	今井 直幸	Echoic Features of Lymph Nodes with Sarcoidosis Determined by Endobronchial Ultrasound (超音波気管支内視鏡を用いたサルコイドーシス患者におけるリンパ節の超音波所見の解析)
医博第3079号	H26.12.26	高原 紀博	Real-Time Imaging of ATP Release Induced by Mechanical Stretch in Human Airway Smooth Muscle Cells (ヒト気道平滑筋細胞における機械的伸展刺激によるATPリアルタイムイメージング法)







学位記番号	授与年月日	氏名	主論文題目
医博第3099号	H27.3.25	深津 明日樹	RASSF3 downregulation increases malignant phenotypes of non-small cell lung cancer (RASSF3の発現低下により非小細胞肺癌の悪性度が増加する)
医博第3109号	H27.3.25	高嶋 浩司	Protective effects of intratracheally administered quercetin on lipopolysaccharide-induced acute lung injury (LPSによる急性肺傷害モデルに対するケルセチン気管内投与の保護効果の検討)
医博第3110号	H27.3.25	村田 直彦	Ca <sup>2+</sup> influx and ATP release mediated by mechanical stretch in human lung fibroblasts (ヒト肺線維芽細胞における機械的伸展刺激を介したCa <sup>2+</sup> 流入とATP放出)
医博第3128号	H27.3.25	伊藤 亮太	Molecular Epidemiological Characteristics of Klebsiella pneumoniae Associated with Bacteremia among Patients with Pneumonia (肺炎患者における菌血症と関連を認めた肺炎桿菌の分子疫学的特性)
医博第3167号	H27.5.29	大須賀 さと子 (高橋)	Risk stratification by the lower limit of normal of FEV1/FVC for postoperative outcomes in patients with COPD undergoing thoracic surgery (COPD合併肺癌外科手術症例の術後アウトカムに対するFEV1/FVC正常下限を用いたリスク階層化)
医博第3202号	H27.10.30	山下 良	Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells (miR-221とmiR-222の非小細胞肺癌における増殖抑制効果について)
医博第3230号	H28.2.29	楠瀬 公章	Direct regulation of transforming growth factor $\beta$ -induced epithelial-mesenchymal transition by the protein phosphatase activity of unphosphorylated PTEN in lung cancer cells (肺癌細胞における非リン酸化PTENの蛋白脱リン酸化酵素活性によるTGF $\beta$ 誘導上皮間葉系移行への直接的制御)
医博第3264号	H28.3.25	織田 恒幸	Distinct Characteristics of Pleuroparenchymal Fibroelastosis With Usual Interstitial Pneumonia Compared With Idiopathic Pulmonary Fibrosis (特発性肺線維症と比較した上葉優位型肺線維症の臨床学的特徴)
医博第3316号	H28.5.31	島津 哲子	Factors Influencing Sustainable Efficacy of Smoking Cessation Treatment with Varenicline beyond Nine Months (バレニクリンによる禁煙治療開始後9か月以降の禁煙成功率と予測因子についての検討)





学位記番号	授与年月日	氏名	主論文題目
医博第3332号	H28.7.29	祖開理紗	Respiratory mechanics measured by forced oscillation technique in rheumatoid arthritis-related pulmonary abnormalities: frequency-dependence, heterogeneity and effects of smoking (関節リウマチ関連肺病変における強制オシレーション法による肺メカニクス評価:周波数依存性、多様性、喫煙の影響)
医博第3340号	H28.9.27	渡辺尚宏	Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis (特発性肺線維症合併進展型小細胞肺癌に対する化学療法)
医博第3360号	H28.10.31	松崎明日香	Clinical impact of the lower limit of normal of FEV1/FVC on survival in lung cancer patients undergoing thoracic surgery (肺癌外科手術症例の長期予後における一秒率正常下限の臨床的影響に関する検討)
医博第3391号	H29.2.28	足立崇	Molecular typing and genetic characterization of Mycobacterium avium subsp. hominissuis isolates from humans and swine in Japan (日本のMycobacterium avium subspecies hominissuisのヒト・ブタ由来株における分子タイピングと遺伝的特徴)
医博第3420号	H29.3.27	松田俊明	COPD Assessment Test for measurement of health status in patients with idiopathic pulmonary fibrosis: A cross-sectional study (特発性肺線維症患者におけるCOPDアセスメントテストの有用性についての横断的研究)
医博第3430号	H29.3.27	表紀仁	Lung-Dominant Connective Tissue Disease Clinical, Radiologic, and Histologic Features (肺病変先行型膠原病 臨床、放射線、病理学的な特徴)
医博第3440号	H29.3.27	加藤俊夫	Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy? (プラチナベース併用化学療法をうける高齢者進行非小細胞肺癌患者において重篤な有害事象と早期治療中止の予測は可能か?)
医博第3495号	H29.7.31	高橋光太	Real-time imaging of mechanically and chemically induced ATP release in human lung fibroblasts (ヒト肺線維芽細胞からの機械的および化学的刺激によるATP放出リアルタイムイメージング法)
医博第3514号	H29.10.31	鈴木嘉洋	Airway basophils are increased and activated in eosinophilic asthma (好酸球性喘息症例において気道中の好塩基球は増加し活性化されている)





学位記番号	授与年月日	氏名	主論文題目
医博第3523号	H29.11.30	各務智彦	Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer (肺癌治療標的としてのプロテアソームサブユニット PSMA6 の同定)
医博第3524号	H29.11.30	野木森 健一	Increased expression levels of ppGalNAc-T13 in lung cancers: Significance in the prognostic diagnosis (肺癌におけるppGalNAc-T13 発現レベルの亢進: 予後診断における意義)
医博第3531号	H29.12.28	十九浦 宏明	Efficacy of prophylactic treatment for oxycodone-induced nausea and vomiting among patients with cancer pain (POINT): A randomized, placebo-controlled, double-blind trial (がん患者におけるオキシコドン誘発性の悪心・嘔吐に対するプロクロルペラジンの予防効果: 無作為化プラセボ対照二重盲検比較試験)
医博第3569号	H30.3.26	林 浩昭	Smoking Cessation as a Possible Risk Factor for the Development of Aspirin-Exacerbated Respiratory Disease in Smokers (現喫煙者において禁煙はアスピリン喘息発症の危険因子となりうる)
医博第3576号	H30.3.26	浅野 周一	Matrix stiffness regulates migration of human lung fibroblasts (基質硬度はヒト肺線維芽細胞の遊走能を制御する)
医博第3700号	H31.3.25	奥村 隼也	Mortality in patients with community-onset pneumonia at low risk of drug-resistant pathogens: Impact of $\beta$ -lactam plus macrolide combination therapy (市中発症肺炎の耐性菌低リスク群では $\beta$ ラクタムとマクロライドの併用療法により30日予後が改善していた)
医博第3732号	H31.3.25	富田 康裕	Obesity, but not metabolic syndrome, as a risk factor for late-onset asthma in Japanese women (メタボリックシンドロームではおぼろげに肥満が日本人女性において中年発症喘息のリスク因子となる)
医博第3733号	H31.3.25	宮沢 亜矢子	Regulation of PD-L1 expression by matrix stiffness in lung cancer cells (肺癌細胞株における基質硬度によるPD-L1 発現の制御)
医博第3734号	H31.3.25	山野 泰彦	Multidimensional improvement in connective tissue disease-associated interstitial lung disease: Two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus (メチルプレドニゾン大量療法2コース後の少量プレドニゾンとタクロリムスの維持療法による膠原病関連間質性肺炎の多面的改善)



学位記番号	授与年月日	氏名	主論文題目
医博第3762号	H31.3.25	大舘満	Predominance of Serogroup 19 CC320/271 among Penicillin-Nonsusceptible Streptococcus pneumoniae Isolates after Introduction of the PCV7 Vaccine in Several Regions on Japan (日本における7価肺炎球菌ワクチン導入後のペニシリン非感性肺炎球菌株での血清型19 CC320/271の流行)
医博第3763号	H31.3.25	松下明弘	TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation (Hippo経路の調節不全によるTAZ活性化はサイトカイン遺伝子の発現と中皮細胞の形質転換を促進する)
論医博第3274号	H20.5.30	小林麻里	Mast cell tryptase causes homologous desensitization of $\beta$ -adrenoceptors by $Ca^{2+}$ sensitization in tracheal smooth muscle (肥満細胞トリプターゼは気管平滑筋においてカルシウム感受性を介して同種型 $\beta$ アドレナリン受容体の耐性化を生じる)
論医博第3308号	H21.10.30	住田敦	Th1/Th2 Immune Response in Lung Fibroblasts in Interstitial Lung Disease (間質性肺疾患での肺線維芽細胞によるTh1/Th2免疫応答)
論医博第3325号	H22.6.30	高田和外	Management of spontaneous pneumomediastinum based on clinical experience of 25 cases (25例の臨床経験に基づく特発性縦隔気腫の管理)
論医博第3360号	H24.3.26	大橋能理	Paradoxical Effects of Hydrogen Peroxide on Human Airway Anion Secretion (過酸化水素のヒト気道アニオン分泌に対する逆説的作用)
論医博第3364号	H24.7.31	市川元司	Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: A multi-center phase II study (ドセタキセルとカルボプラチンの前治療に耐性もしくは治療後に再発した非小細胞肺癌に対する毎週投与方法によるパクリタキセル二次治療:多施設第II相試験)
論医博第3408号	H26.7.31	多賀収	Predictors of the Need to Initiate Noninvasive Ventilation in Stable Outpatients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (安定期の慢性閉塞性肺疾患外来患者において急性増悪時に非侵襲的人工呼吸管理となる予測因子の検討)
論医博第3413号	H26.10.31	杉下美保子	Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer (乳がん患者におけるGSTP1遺伝子多型と発熱性好中球減少症との薬理遺伝学的関係)



学位記番号	授与年月日	氏名	主論文題目
論医博第3414号	H26.10.31	橋本泉	Aqueous fraction of <i>Sauropus androgynus</i> might be responsible for bronchiolitis obliterans ( <i>Sauropus androgynus</i> の水溶性分画は閉塞性細気管支炎の発症に関与している可能性がある)
論医博第3444号	H28.9.27	岡地 祥太郎	Endobronchial ultrasound transbronchial needle aspiration in older people (高齢者における超音波気管支鏡ガイド下針生検)
論医博第3445号	H28.9.27	高納崇	Hypoxia-induced modulation of PTEN activity and EMT phenotypes in lung cancers (肺癌において低酸素により誘導されるPTEN 活性と EMT 表現型の調節)
論医博第3483号	H30.4.27	魚津 桜子	Feasibility of tissue re-biopsy in non-small cell lung cancers resistant to previous epidermal growth factor receptor tyrosine kinase inhibitor therapies (上皮成長因子受容体チロシンキナーゼ阻害薬による治療に対し抵抗性となった非小細胞肺癌における組織再生検 の可能性に関する研究)





## 英文論文

1. Depression of afferent arc of the in vivo cytotoxic T-cell immunity by bacterial lipopolysaccharides. Mizoguchi K, Nakashima I, Hasegawa Y, Isobe K, Kato N, Shimokata K, Kawashima K, Nagase F, Ando K, Yoshida T, Lai H.  
**Cellular Immunology**. 1985 (95): 330-339
2. Genetic and stimulatory cell type requirements for inducing class I major histocompatibility complex alloantigen-specific in vivo cytotoxic T cell immunity. Mizoguchi K, Nakashima I, Isobe K, Ando K, Nagase F, Kato N, Kawashima K, Shimokata K, Hasegawa Y.  
**European Journal of Immunology**. 1985 (15): 487-494.
3. Direct activation of sendai virus (HVJ)- specific cell-mediated immunity of mice for second set rejection of the virus-infected syngeneic tumor by noninfectious virus-sensitized spleen cells. Kamihira O, Nakashima I, Hasegawa T, Ando K, Isobe K, Nagase F, Hasegawa Y, Yoshida T, Kawashima K, Yoshida T, Yokochi T.  
**Immunology Letters**. 1985 (11): 75-81.
4. Human IgE antibody to the carbohydrate-containing third domain of chicken ovomucoid. Matsuda T, Nakamura R, Nakashima I, Hasegawa Y, Shimokata K.  
**Biochemical Biophysical Research Communications**. 1985 (129): 505-510.
5. Augmentation of antibody response of mice to inhaled protein antigens by simultaneously inhaled bacterial lipopolysaccharides. Mizoguchi K, Nakashima I, Hasegawa Y, Isobe K, Nagase F, Kawashima K, Shimokata K, Kato N.  
**Immunobiology**. 1986 (173): 63-71.
6. Aberrancy in immunogenicity and cell-surface expression of H-2 antigen on erythrocytes. Nakashima I, Yoshida T, Yokochi T, Ohashi K, Nagase F, Isobe K, Hasegawa Y, Ando K, Inagi R.  
**Immunogenetics**. 1986(24): 32-40.
7. Diagnostic value of cancer antigen 15-3(CA15-3) detected by monoclonal antibodies (115D8 and DF3) in exudative pleural effusions. Shimokata K, Totani Y, Nakanishi K, Yamamoto M, Hasegawa Y, Kawatsu H, Sasou H, Murate T, Ichiyama S, Kurasawa T, Miyachi T, Niwa Y.  
**European Respiratory Journal**. 1988 (1): 341-344.
8. Dynamics of cytotoxic T lymphocyte precursors in vivo assessed by change in the radiation sensitivity. Evidence for development of radiation-sensitive memory cells without clonal expansion. Hasegawa Y, Nakashima I, Ando K, Mizoguchi K, Nagase F, Isobe K, Kawashima K, Shimokata K, Yoshida T, Iwamoto T.  
**Scandinavian Journal of Immunology**. 1988 (28): 43-53.



9. Biphasic radiation-sensitivity of the transplantation immunity for rejection of an allogeneic ascites tumor.  
Hasegawa Y, Nakashima I, Mizoguchi K, Nagase F, Isobe K, Shimokata K, Kawashima K, Ando K, Yoshida T, Iwamoto T, Hasegawa T.  
**Immunobiology**. 1988 (177): 120-133.
10. Induction and characterization of minor histocompatibility antigens: specific primary cytotoxic T lymphocyte responses in vitro.  
Ando K, Nakashima I, Nagase F, Isobe K, Kawashima K, Hasegawa Y, Yoshida T, Iwamoto T, Hasegawa T, Muro Y, Ohashi M.  
**Journal of Immunology**. 1988 (140): 723-729.
11. Induction of antitumor immunity in mice by allo-major histocompatibility complex class I gene transfectant with strong antigen expression.  
Isobe K, Hasegawa Y, Iwamoto T, Hasegawa T, Kawashima K, Ding L, Nakashima I.  
**Journal of the National Cancer Institute**. 1989 (81): 1823-1828.
12. Mode of alloantibody-mediated blockade of allo-sensitization for tumor allograft rejection.  
Lai H, Hasegawa Y, Mizoguchi K, Yoshida T, Isobe K, Shimokata K, Kawashima K, Nakashima I.  
**Immunobiology**. 1989 (179): 33-43.
13. Calcium-independent pathway of tumor necrosis factor-mediated lysis of target cells.  
Hasegawa Y, Bonavida B.  
**Journal of Immunology**. 1989 (142): 2670-2676.
14. Cytokine content in pleural effusion: Comparison between tuberculous and carcinomatous pleurisy.  
Shimokata K, Saka H, Murate T, Hasegawa Y, Hasegawa T.  
**Chest**. 1991 (99): 1103-1107.
15. Human alveolar macrophages of anergic patients with lung cancer lack the responsiveness to recombinant interferon gamma.  
Kawatsu H, Hasegawa Y, Takagi E, Shimokata K.  
**Chest**. 1991 (100): 1277-1280.
16. A possible site of in vivo action of cyclosporin A for transplantation immunity : comparative study with cyclophosphamide.  
Hasegawa Y, Isobe K, Nagase F, Shimokata K, Nakashima I.  
**Immunobiology**. 1991 (183): 408-417.
17. Immunosuppressive activity induced by nitric oxide in culture supernatant of activated rat alveolar macrophages.  
Kawabe T, Isobe K, Hasegawa Y, Nakashima I, Shimokata K.  
**Immunology**. 1992 (76): 72-78.
18. Gene transfer of herpes simplex virus type I thymidine kinase gene as a drug sensitivity gene into human lung cancer cell lines using retroviral vectors.  
Hasegawa Y, Emi N, Shimokata K, Abe A, Kawabe T, Hasegawa T, Kirioka T, Saito H.  
**American Journal of Respiratory Cell and Molecular Biology**. 1993 (8): 655-661.



19. Fever and bacteremia following flexible bronchoscopy.  
Watanabe A, Saka H, Shimokata K, Hasegawa Y, Senda K, Minami H, Nomura F, Sakai S.  
**Journal of Broncology**. 1994 (1): 5-8.
20. Humoral and cellular immunity to an encoded protein induced by direct DNA injection.  
Katsumi A, Emi N, Abe A, Hasegawa Y, Ito M, Saito H.  
**Human Gene Therapy**. 1994 (5): 11335-1339.
21. Expression of tumor necrosis factor receptors in human lung cancer cells and normal lung tissues.  
Shimomoto H, Hasegawa Y, Nozaki Y, Takagi N, Shibagaki T, Nakao A, Shimokata K.  
**American Journal of Respiratory Cell and Molecular Biology**. 1995 (13): 271-278.
22. Detection of Pneumocystis carinii, Mycobacterium tuberculosis, and cytomegalovirus in human immunodeficiency virus (HIV)-infected patients with hemophilia by polymerase chain reaction of induced sputum samples.  
Shimomoto H, Hasegawa Y, Takagi N, Ichiyama S, Takamatsu J, Saito H, Shimokata K.  
**Internal Medicine**. 1995 (34): 967-981.
23. Expression of cell adhesion molecules in the lungs of patients with idiopathic pulmonary fibrosis.  
Nakao A, Hasegawa Y, Tsuchiya Y, Shimokata K.  
**Chest**. 1995 (108): 233-239.
24. Evaluation of Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test and Roche PCR-Microwell Plate Hybridization Method (AMPLICOR MYCOBACTERIUM) for direct detection of mycobacteria.  
Ichiyama S, Inuma Y, Tawada Y, Yamori S, Hasegawa Y, Shimokata K, Nakashima N.  
**Journal of Clinical Microbiology**. 1996 (34): 130-133.
25. Adenosine deaminase isozymes in tuberculous pleural effusion.  
Shibagaki T, Hasegawa Y, Saito H, Yamori S, Shimokata K.  
**Journal of Laboratory and Clinical Medicine**. 1996 (127): 348-352.
26. Detection of human cytomegalovirus DNA from allogeneic bone marrow transplant recipients with interstitial pneumonitis.  
Takagi N, Hasegawa Y, Ichiyama S, Nomura F, Hirabayashi N, Shimokata K.  
**American Journal of Medical Science**. 1996 (312): 1-7.
27. Nitric oxide as an inflammatory mediator of radiation pneumonitis in rats.  
Nozaki Y, Hasegawa Y, Takeuchi A, Zuo-Heng Fan, Isobe K, Nakashima I, Shimokata K.  
**American Journal of Physiology**. 1996 (312): 1-7.
28. Large-restriction-fragment analysis of Mycobacterium kansasii genomic DNA and its application in molecular typing.  
Inuma Y, Ichiyama S, Hasegawa Y, Shimokata K, Kawahara S, Matsushima T.  
**Journal of Clinical Microbiology**. 1997 (35): 596-599.





29. Combination effects of cisplatin, vinorelbine and irinotecan in non-small-cell lung cancer cell lines in vitro. Mogi H, Hasegawa Y, Watanabe A, Nomura F, Saka H, Shimokata K.  
**Cancer Chemotherapy and Pharmacology**. 1997 (39): 299-204.
30. A clinical and bacteriologic investigation of invasive streptococcal infections in Japan on the basis of serotypes, toxin production, and genomic DNA fingerprints. Nakashima K, Ichiyama S, Inuma Y, Hasegawa Y, Ohta M, Ooe K, Shimizu Y, Igarashi H, Murai T, Shimokata K.  
**Clinical Infectious Diseases**. 1997 (25): 260-266.
31. Mycobacterium growth indicator tube testing in conjunction with the AccuProbe or the AMPLICOR-PCR assay for detecting and identifying mycobacteria from sputum samples. Ichiyama S, Inuma Y, Yamori S, Hasegawa Y, Shimokata K, Nakashima N.  
**Journal of Clinical Microbiology**. 1997 (35): 2022-2025.
32. Exfoliative toxin detection using reversed passive latex agglutination: clinical and epidemiologic applications. Kawabata A, Ichiyama S, Inuma Y, Hasegawa Y, Ohta M, Shimokata K.  
**Journal of Clinical Microbiology**. 1997 (35): 1984-1987.
33. Diagnostic value of the strand displacement amplification method compared to those of roche amplicor PCR and culture for detecting mycobacteria in sputum samples. Ichiyama S, Ito Y, Sugiura F, Inuma Y, Yamori S, Shimojima M, Hasegawa Y, Shimokata K, Nakashima N.  
**Journal of Clinical Microbiology**. 1997 (35): 3082-3085.
34. Mechanism of nitric oxide-dependent killing of Mycobacterium bovis BCG in human alveolar macrophages. Nozaki Y, Hasegawa Y, Ichiyama S, Nakashima I, Shimokata K.  
**Infection and Immunity**. 1997 (65): 3644-3647.
35. Polymerase chain reaction of pleural biopsy specimens for rapid diagnosis of tuberculous pleuritis. Takagi N, Hasegawa Y, Ichiyama S, Shibagaki T, Shimokata K.  
**The International Journal of Tuberculosis and Lung Disease**. 1998 (2): 338-341.
36. Bystander tumoricidal effect and gap junctional communication in lung cancer cell lines. Imaizumi K, Hasegawa Y, Kawabe T, Emi N, Saito H, Naruse K, Shimokata K.  
**American Journal of Respiratory Cell and Molecular Biology**. 1998(18): 205-212.
37. Effect of gene transfer of tumor necrosis factor receptors into human lung carcinoma cell line. Ohara H, Hasegawa Y, Kawabe T, Ichiyama S, Hara T, Shimono Y, Saito H, Shimokata K.  
**Japanese Journal of Cancer Research**. 1998 (89): 589-595.
38. Diagnostic value of the Amplicor PCR assay for initial diagnosis and assessment of treatment response for pulmonary tuberculosis. Inuma Y, Ichiyama S, Yamori S, Oohama J, Takagi N, Hasegawa Y, Shimokata K, Nakashima N.  
**Microbiology and Immunology**. 1998 (42): 281-287.



39. IgG-mediated anaphylaxis via Fc  $\gamma$  receptor in CD40-deficient mice.  
Wakayama H, Hasegawa Y, Kawabe T, Saito H, Kikutani H, Shimokata K.  
**Clinical and Experimental Immunology**. 1998(114): 154-160.
40. Estimation of the area under the concentration-versus-time curve of carboplatin following irinotecan using a limited sampling model.  
Asai G, Ando Y, Saka H, Ando M, Sugiura S, Sakai S, Hasegawa Y, Shimokata K.  
**European Journal of Clinical Pharmacology**. 1998 (54): 725-727.
41. Prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer.  
Ando M, Ando Y, Sugiura S, Minami H, Saka H, Sakai S, Shimokata K, Hasegawa Y.  
**Japanese Journal of Cancer Research**. 1999(90):249-253.
42. Constrictive bronchiolitis obliterans and paraneoplastic pemphigus.  
Hasegawa Y, Ichiyama S, Shimokata K, Saito H.  
**European Respiratory Journal**. 1999 (5): 934-937.
43. Pharmacological analysis of etoposide in elderly patients with lung cancer.  
Ando M, Minami H, Ando U, Sakai S, Shimono Y, Sugiura S, Saka H, Shimokata K, Hasegawa Y.  
**Clinical Cancer Research**. 1999(5): 1690-1695.
44. Autologous blood-patch pleurodesis for secondary spontaneous pneumothorax with persistent air leak.  
Ando M, Yamamoto M, Kitagawa C, Kumazawa A, Sato M, Shima K, Watanabe A, Shimokata K, Hasegawa Y.  
**Respiratory Medicine**. 1999 (93): 432-434.
45. Enhancement of tumoricidal activity of alveolar macrophage via CD40/CD40-ligand interaction.  
Imaizumi K, Kawabe T, Ichiyama S, Kikutani H, Yagita H, Shimokata K, Hasegawa Y.  
**American Journal of Physiology**. 1999(277): L49-L57.
46. 12-O-tetradecanoylphorbol-13-acetate-induced apoptosis is mediated by tumor necrosis factor  $\alpha$  in human monocytic U937 cells.  
Takada Y, Hachiya M, Osawa Y, Hasegawa Y, Ando K, Kobayashi Y, Akashi M.  
**Journal of Biological Chemistry**. 1999 (274): 28286-28292.
47. Evaluation of a PC-based teleconferencing system for reading chest radiographs.  
Xu Z, Yamauchi K, Ikeda M, Yang S, Hasegawa Y.  
**Journal of Telemedicine and Telecare**. 1999 (5): 122-155.
48. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.  
Ando Y, Tateishi T, Sekido Y, Yamamoto T, Satou T, Hasegawa Y, Kobayashi S, Katsumata Y, Shimokata K, Saito H.  
**Journal of the National Cancer Institute**. 1999 (91): 1587-1588.
49. Prediction equation for glomerular filtration rate.  
Ando Y, Hasegawa Y.  
**Annals of Internal Medicine**. 1999 (131): 629-630.



50. Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells.  
Horio Y, Hasegawa Y, Sekido Y, Roth J A, Shimokata K.  
**Cancer Gene Therapy**. 2000 (7): 537-544.
51. Avoidance of bone marrow suppression using A-5021 as a nucleoside analog for retrovirus-mediated herpes simplex virus type I thymidine kinase gene therapy.  
Hasegawa Y, Nishiyama Y, Imaizumi K, Ono N, Kinoshita T, Hatano S, Saito H, Shimokata K.  
**Cancer Gene Therapy**. 2000 (7): 557-562.
52. RET finger protein is a transcriptional repressor and interacts with enhancer of polycomb that has dual transcriptional functions.  
Shimono Y, Murakami H, Hasegawa Y, Takahashi M.  
**Journal of Biological Chemistry**. 2000 (275): 39411-39419.
53. Abolition of anti-glomerular basement membrane antibody-mediated glomerulonephritis in FcR gamma-deficient mice.  
Wakayama H, Hasegawa Y, Kawabe T, Hara T, Matsuo S, Mizuno M, Takai T, Kikutani H, Shimokata K.  
**European Journal of Immunology**. 2000 (30): 1182-1190.
54. Infrequent mutation of the hBUB1 and hBUBR1 genes in human lung cancer.  
Sato M, Sekido Y, Horio Y, Takahashi M, Saito H, Minna JD, Shimokata K, Hasegawa Y.  
**Japanese Journal of Cancer Research**. 2000 (91): 504-509.
55. In vivo development of decreased susceptibility to vancomycin in clinical isolates of methicillin-resistant *Staphylococcus aureus*.  
Sugino Y, Iinuma Y, Ichiyama S, Ito Y, Ohkawa S, Nakashima N, Shimokata K, Hasegawa Y.  
**Diagnostic Microbiology and Infectious Disease**. 2000 (38): 159-167.
56. Effect of erythromycin on matrix metalloproteinase-9 (MMP-9) and cell migration.  
Hashimoto N, Kawabe T, Hara T, Imaizumi K, Wakayama H, Saito H, Shimokata K, Hasegawa Y.  
**Journal of Laboratory and Clinical Medicine**. 2000 (137): 176-183.
57. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level.  
Ando M, Minami H, Ando Y, Saka H, Sakai S, Yamamoto M, Sasaki Y, Shimokata K, Hasegawa Y.  
**Clinical Cancer Research**. 2000(6): 4733-4738.
58. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis  
Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y.  
**Cancer Research**. 2000 (60): 6921-6926.
59. Thymus-dependent modulation of Ly49 inhibitory receptor expression on NK1.1+ T cells.  
Hara T, Nishimura H, Hasegawa Y, Yoshikai Y.  
**Immunology**. 2001 (11): 269-273.



60. Genetic polymorphisms of thiopurine S-methyltransferase and 6-mercaptopurine toxicity in Japanese children with acute lymphoblastic leukemia.  
Ando M, Ando Y, Hasegawa Y, Sekido Y, Shimokata K, Horibe K.  
**Pharmacogenetics**. 2001 (11): 269-273.
61. Telomerase activation and p53 mutations in urethane-induced A/J mouse lung tumor development.  
Ohno J, Horio Y, Sekido Y, Hasegawa Y, Takahashi M, Nishizawa J, Saito H, Ishikawa F, Shimokata K.  
**Carcinogenesis**. 2001 (22): 751-756.
62. Induction of antitumor immunity by transduction of CD40 ligand gene and interferon- $\gamma$  gene into lung cancer.  
Noguchi M, Imaizumi K, Kawabe T, Wakayama H, Hara T, Hashimoto N, Takahashi M, Shimokata K, Hasegawa Y.  
**Cancer Gene Therapy**. 2001 (8): 421-429.
63. Genetic alteration of the  $\beta$ -catenin gene (CTNNB1) in human lung cancer malignant mesothelioma and identification of a new 3p21.3 homozygous deletion.  
Shigemitsu K, Sekido Y, Usami N, Mori S, Sato M, Horio Y, Hasegawa Y, Bader SA, Gazdar AF, Minna JD, Hida T, Yoshioka H, Imaizumi M, Ueda Y, Takahashi M, Shimokata K.  
**Oncogene**. 2001 (20): 4249-4257.
64. Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer.  
Sato M, Ando M, Minami H, Ando Y, Ando M, Yamamoto M, Sakai S, Watanabe A, Ikeda T, Sekido Y, Saka H, Shimokata K, Hasegawa Y.  
**Cancer Chemotherapy and Pharmacology**. 2001 (48): 481-487.
65. A double fistula, broncho-cavitary-cutaneous communication caused by cancer invasion.  
Isomuran T, Noguchi M, Murate T, Hasegawa Y.  
**Internal Medicine**. 2001 (147): 1238-1240.
66. Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer.  
Ando M, Ando Y, Hasegawa Y, Shimokata K, Minami H, Wakai K, Ohno Y, Sakai S.  
**British Journal of Cancer**. 2001 (85): 1634-1639.
67. Critical involvement of CD40 in protection against herpes simplex virus infection in a murine model of genital herpes.  
Inagaki-Ohara K, Kawabe T, Hasegawa Y, Hashimoto N, Nishiyama Y.  
**Archives of Virology**. 2002 (147): 187-194.
68. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.  
Ando Y, Ueoka H, Sugiyama T, Ichiki M, Shimokata K, Hasegawa Y.  
**The Drug Monit**. 2002 Feb; 24 (1): 111-6.
69. Perfusion and Ventilation Isotope Lung Scans in Constrictive Bronchiolitis Obliterans: A Series of Three Cases.  
Hasegawa Y, Imaizumi K, Sekido Y, Inuma Y, Kawabe T, Hashimoto N, and Shimokata K.  
**Respiration**. 2002 (69): 550-555.



70. Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients.  
Ando M, Ando Y, Sekido Y, Ando M, Shimokata K, Hasegawa Y.  
**Jpn J Cancer Res.** 2002 May; 93 (5): 591-7.
71. The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16 (INK4a) and RASSF1A in human lung cancer cell lines. Sato M, Horio Y, Sekido Y, Minna JD, Shimokata K, Hasegawa Y.  
**Oncogene.** 2002 Jul 18; 21 (31): 4822-9.
72. Establishment of a large cell lung cancer cell line (Y-ML-1B) producing granulocyte colony-stimulating factor.  
Sekido Y, Sato M, Usami N, Shigemitsu K, Mori S, Maeda O, Yokoi T, Hasegawa Y, Yoshioka H, Shimokata K.  
**Cancer Genet Cytogenet.** 2002 Aug; 137 (1): 33-42.
73. Evaluation of a commercially available serologic assay for antibodies against tuberculosis-associated glycolipid antigen.  
Inuma Y, Senda K, Takakura S, Ichiyama S, Tano M, Abe T, Yamamoto T, Nakashima K, Baba H, Hasegawa Y, Shimokata K.  
**Clin Chem Lab Med.** 2002 Aug; 40 (8): 832-6.
74. NRAMP1 polymorphisms, susceptibility and clinical features of tuberculosis.  
Abe T, Inuma Y, Ando M, Yokoyama T, Yamamoto T, Nakashima K, Takagi N, Baba H, Hasegawa Y, Shimokata K.  
**Journal of Infection.** 2003 (46): 215-220.
75. Perfusion and ventilation isotope lung scans in constrictive bronchiolitis obliterans. A series of three cases.  
Hasegawa Y, Imaizumi K, Sekido Y, Inuma Y, Kawabe T, Hashimoto N, Shimokata K.  
**Respiration.** 2002; 69 (6): 550-5.
76. Beta-catenin inhibits cell growth of a malignant mesothelioma cell line, NCI-H28, with a 3p21.3 homozygous deletion.  
Usami N, Sekido Y, Maeda O, Yamamoto K, Minna JD, Hasegawa Y, Yoshioka H, Imaizumi M, Ueda Y, Takahashi M, Shimokata K.  
**Oncogene.** 2003 Sep 11; 22 (39): 7923-30.
77. Characterization of six base pair deletion in the putative HNF1-binding site of human PXR promoter.  
Uno Y, Sakamoto Y, Yoshida K, Hasegawa T, Hasegawa Y, Koshino T, Inoue I.  
**J Hum Genet.** 2003; 48 (11): 594-597.
78. GADD34 induces p53 phosphorylation and p21/WAF1 transcription.  
Yagi A, Hasegawa Y, Xiao H, Haneda M, Kojima E, Nishikimi A, Hasegawa T, Shimokata K, Isobe K.  
**J Cell Biochem.** 2003 Dec 15; 90 (6): 1242-9.



79. Two-dimensional gel electrophoresis analysis of the abundance of virulent exoproteins of group A streptococcus caused by environmental changes.  
Nakamura T, Hasegawa T, Torii K, Hasegawa Y, Shimokata K, Ohta M.  
**Arch Microbiol.** 2004 Jan; 181 (1): 74-81.
80. CD40 plays a crucial role in lipopolysaccharide-induced acute lung injury.  
Hashimoto N, Kawabe T, Imaizumi K, Hara T, Okamoto M, Kojima K, Shimokata K, Hasegawa Y.  
**Am J Respir Cell Mol Biol.** 2004 Jun; 30 (6): 808-15.
81. Evaluation of automated ribotyping system for characterization and identification of verocytotoxin-producing Escherichia coli isolated in Japan.  
Ito Y, Iinuma Y, Baba H, Sugino Y, Hasegawa Y, Shimokata K, Ichiyama S, Hasegawa T, Ohta M.  
**Jpn J Infect Dis.** 2003 Oct-Dec; 56 (5-6): 200-4.
82. Comparative study of acute effects of single doses of fexofenadine, olopatadine, d-chlorpheniramine and placebo on psychomotor function in healthy volunteers.  
Kamei H, Noda Y, Ishikawa K, Senzaki K, Muraoka I, Hasegawa Y, Hindmarch I, Nabeshima T.  
**Hum Psychopharmacol.** 2003 Dec; 18 (8): 611-8.
83. Pulmonary cryptococcosis with a solitary focal ground-glass opacity on high-resolution computed tomography.  
Sato M, Okamoto M, Takagi Y, Ikeda T, Niimi T, Fukatsu E, Maruyama K, Nara Y, Shimokata K, Hasegawa Y.  
**Intern Med.** 2004 Feb; 43 (2): 117-9.
84. Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells.  
Ito G, Uchiyama M, Kondo M, Mori S, Usami N, Maeda O, Kawabe T, Hasegawa Y, Shimokata K, Sekido Y.  
**Cancer Res.** 2004 Jun 1; 64 (11): 3838-43.
85. Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay.  
Hasegawa Y, Sarashina T, Ando M, Kitagawa C, Mori A, Yoneyama M, Ando Y, Shimokata K.  
**Clin Chem.** 2004 Aug; 50(8): 1479-80.
86. Polymorphisms in the prostaglandin E2 receptor subtype 2 gene confer susceptibility to aspirin-intolerant asthma: a candidate gene approach.  
Jinnai N, Sakagami T, Sekigawa T, Kakihara M, Nakajima T, Yoshida K, Goto S, Hasegawa T, Koshino T, Hasegawa Y, Inoue H, Suzuki N, Sano Y, Inoue I.  
**Hum Mol Genet.** 2004 Dec 15; 13 (24): 3203-17.
87. Evaluation of interferon-gamma, interferon-gamma-inducing cytokines, and interferon-gamma-inducible chemokines in tuberculous pleural effusions.  
Okamoto M, Kawabe T, Iwasaki Y, Hara T, Hashimoto N, Imaizumi K, Hasegawa Y, Shimokata K.  
**J Lab Clin Med.** 2005 Feb; 145 (2): 88-93.



88. Outbreak of Bronchiolitis obliterans associated with consumption of *Sauropus androgynus* in Japan-- alert of food-associated pulmonary disorders from Japan.  
Oonakahara K, Matsuyama W, Higashimoto I, Machida K, Kawabata M, Arimura K, Osame M, Hayashi M, Ogura T, Imaizumi K, Hasegawa Y.  
**Respiration**. 2005 Mar-Apr; 72 (2): 221.
89. Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.  
Ando M, Saka H, Ando Y, Minami H, Kuzuya T, Yamamoto M, Watanabe A, Sakai S, Shimokata K, Hasegawa Y.  
**Cancer Chemother Pharmacol**. 2005 Jun; 55 (6): 552-8.
90. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity.  
Kitagawa C, Ando M, Ando Y, Sekido Y, Wakai K, Imaizumi K, Shimokata K, Hasegawa Y.  
**Pharmacogenet Genomics**. 2005 Jan; 15 (1): 35-41.
91. Interstitial lung disease associated with gefitinib.  
Kataoka K, Taniguchi H, Hasegawa Y, Kondoh Y, Kimura T, Nishiyama O, Imaizumi K, Kawabe T, Kume H, Shimokata K.  
**Respir Med**. 2006 Apr; 100 (4): 698-704.
92. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.  
Kondo M, Yokoyama T, Fukui T, Yoshioka H, Yokoi K, Nagasaka T, Imaizumi K, Kume H, Hasegawa Y, Shimokata K, Sekido Y.  
**Lung Cancer**. 2005 Dec; 50 (3): 385-91.
93. Irinotecan therapy in a 12-year-old girl with recurrent brain stem glioma and without functional polymorphisms in UGT1A1 activity: case report.  
Ishikawa K, Kajita Y, Hasegawa Y, Noda Y, Yoshida J, Nabeshima T.  
**J Neurooncol**. 2005 Sep; 74 (3): 283-6.
94. Clinical pharmacogenetics of irinotecan (CPT-11)  
Ando Y, Hasegawa Y.  
**Drug Metab Rev**. 2005; 37 (3): 565-74. Review.
95. Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan.  
Ando M, Hasegawa Y, Ando Y.  
**Invest New Drugs**. 2005 Dec; 23 (6): 539-45.
96. T-helper type 1/T-helper type 2 balance in malignant pleural effusions compared to tuberculous pleural effusions.  
Okamoto M, Hasegawa Y, Hara T, Hashimoto N, Imaizumi K, Shimokata K, Kawabe T.  
**Chest**. 2005 Dec; 128 (6): 4030-5.





97. Expression of macrophage-derived chemokine (MDC)CCL22 in human lung cancer.  
Nakanishi T, Imaizumi K, Hasegawa Y, Kawabe T, Hashimoto N, Okamoto M, Shimokata K.  
**Cancer Immunol Immunother.** 2006 Nov; 55(11): 1320-9.
98. Pulmonary infectious complications associated with anti-TNFalpha therapy (infliximab)for rheumatoid arthritis.  
Imaizumi K, Sugishita M, Usui M, Kawabe T, Hashimoto N, Hasegawa Y.  
**Intern Med.** 2006; 45 (10): 685-88.
99. Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular Assay.  
Hasegawa Y, Ando Y, Shimokata K.  
**Expert Rev Mol Diagn.** 2006 Jul; 6 (4): 527-33. Review.
100. Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer.  
Hashimoto N, Imaizumi K, Honda T, Kawabe T, Nagasaka T, Shimokata K, Hasegawa Y.  
**Lung Cancer.** 2006 Sep; 53 (3): 387-90.
101. EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification.  
Yokoyama T, Kondo M, Goto Y, Fukui T, Yoshioka H, Yokoi K, Osada H, Imaizumi K, Hasegawa Y, Shimokata K, Sekido Y.  
**Cancer Sci.** 2006 Aug; 97 (8): 753-9.
102. Phase I/II trial of docetaxel and carboplatin as a first-line therapy in patients with stage IV non-small-cell lung cancer.  
Kataoka K, Suzuki R, Taniguchi H, Noda Y, Shindoh J, Matsumoto S, Watanabe Y, Honda K, Suzuki K, Baba K, Imaizumi K, Kume H, Hasegawa Y, Takagi K.  
**Lung.** 2006 May-Jun; 184 (3): 133-9.
103. Pharmacogenetic approach for cancer treatment-tailored medicine in practice.  
Hasegawa Y, Ando Y, Ando M, Hashimoto N, Imaizumi K, Shimokata K.  
**Ann N Y Acad Sci.** 2006 Nov; 1086: 223-32. Review.
104. Macrophage-derived chemokine in malignant and tuberculous pleural effusions.  
Okamoto M, Imaizumi K, Hasegawa Y, Hashimoto N, Sumida A, Shibazaki M, Takagi K, Shimokata K, Kawabe T.  
**Respirology.** 2007 Jul; 12 (4): 581-4.
105. UGT1A1\*6 and UGT1A1\*27 for individualized irinotecan chemotherapy.  
Ando Y, Fujita K, Sasaki Y, Hasegawa Y.  
**Curr Opin Mol Ther.** 2007 Jun; 9 (3): 258-62. Review.
106. SLC11A1 (formerly NRAMP1) polymorphisms associated with multidrug-resistant tuberculosis.  
Takahashi K, Hasegawa Y, Abe T, Yamamoto T, Nakashima K, Imaizumi K, Shimokata K.  
**Tuberculosis (Edinb).** 2008 Jan; 88(1): 52-7.



107. A novel Ca<sup>2+</sup> influx pathway activated by mechanical stretch in human airway smooth muscle cells.  
Ito S, Kume H, Naruse K, Kondo M, Takeda N, Iwata S, Hasegawa Y, Sokabe M.  
**Am J Respir Cell Mol Biol.** 2008 Apr; 38 (4): 407-13.
108. mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines.  
Shimizu J, Horio Y, Osada H, Hida T, Hasegawa Y, Shimokata K, Takahashi T, Sekido Y, Yatabe Y.  
**Respirology.** 2008 Jun; 13 (4): 510-7.
109. A phase II study of carboplatin and paclitacel with meloxicam.  
Suzuki R, Yamamoto M, Saka H, Taniguchi H, Shindoh J, Tanikawa Y, Nomura F, Gonda H, Imaizumi K, Hasegawa Y, Shimokata K.  
**Lung Cancer.** 2009 Jan; 63 (1): 72-6.
110. TH1/TH2 immune response in lung fibroblasts in interstitial lung disease.  
Sumida A, Hasegawa Y, Okamoto M, Hashimoto N, Imaizumi K, Yatsuya H, Yokoi T, Takagi K, Shimokata K, Kawabe T.  
**Arch Med Res.** 2008 Jul; 39 (5): 503-10.
111. Inhibition by the cold receptor agonists menthol and icilin of airway smooth muscle contraction.  
Ito S, Kume H, Shiraki A, Kondo M, Makino Y, Kamiya K, Hasegawa Y.  
**Pulm Pharmacol Ther.** 2008 Oct; 21 (5): 812-7.
112. Dual pathway activated by tert-butyl hydroperoxide in human airway anion secretion.  
Matsuno T, Ito Y, Ohashi T, Morise M, Takeda N, Shimokata K, Imaizumi K, Kume H, Hasegawa Y.  
**J Pharmacol Exp Ther.** 2008 Nov; 327 (2): 453-64.
113. Comparison of severity scoring systems A-DROP and CURB-65 for community-acquired pneumonia.  
Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Imaizumi K, Hasegawa Y.  
**Respirology.** 2008 Sep; 13 (5): 731-5.
114. YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation.  
Yokoyama T, Osada H, Murakami H, Tatematsu Y, Taniguchi T, Kondo Y, Yatabe Y, Hasegawa Y, Shimokata K, Horio Y, Hida T, Sekido Y.  
**Carcinogenesis.** 2008 Nov; 29 (11): 2139-46.
115. Up-regulation of surfactant protein production in a mouse model of secondary pulmonary alveolar proteinosis.  
Shibasaki M, Hashimoto K, Okamoto M, Hayashi Y, Imaizumi K, Hashimoto N, Ozaki N, Yokoi T, Takagi K, Hasegawa Y, Shimokata K, Kawabe T.  
**Am J Respir Cell Mol Biol.** 2009 May; 40 (5): 536-42.
116. Implication of clinical pathway care for community-acquired pneumonia in a community hospital: early switch from an intravenous beta-lactam plus a macrolide to an oral respiratory fluoroquinolone.  
Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Imaizumi K, Hasegawa Y.  
**Intern Med.** 2008; 47 (21): 1865-74.



117. Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital.  
Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Hashimoto N, Imaizumi K, Sato T, Hasegawa Y.  
**Chest**. 2009 Mar; 135(3): 633-640.
118. Regulation of endothelin-1-induced interleukin-6 production by Ca<sup>2+</sup> influx in human airway smooth muscle cells.  
Iwata S, Ito S, Iwaki M, Kondo M, Sashio T, Takeda N, Sokabe M, Hasegawa Y, Kume H.  
**Eur J Pharmacol**. 2009 Mar 1; 605 (1-3): 15-22.
119. Involvement of heme oxygenase-1 in kaempferol-induced anti-allergic actions in RBL-2H3 cells.  
Hirose E, Matsushima M, Takagi K, Ota Y, Ishigami K, Hirayama T, Hayashi Y, Nakamura T, Hashimoto N, Imaizumi K, Baba K, Hasegawa Y, Kawabe T.  
**Inflammation**. 2009 Apr; 32 (2): 99-108.
120. Activation of the PI3K-AKT pathway in human malignant mesothelioma cells.  
Suzuki Y, Murakami H, Kawaguchi K, Taniguchi T, Fujii M, Shinjo K, Kondo Y, Osada H, Shimokata K, Horio Y, Hasegawa Y, Hida T, Sekido Y.  
**Mol Med Rep**. 2009 Mar-Apr; 2 (2): 181-8.
121. Variations in amount of TSST-1 produced by clinical methicillin resistant Staphylococcus aureus (MRSA) isolates and allelic variation in accessory gene regulator (agr) locus.  
Nagao M, Okamoto A, Yamada K, Hasegawa T, Hasegawa Y, Ohta M.  
**BMC Microbiol**. 2009 Mar 10; 9: 52.
122. Characterization of interaction between CLP36 and palladin.  
Maeda M, Asano E, Ito D, Ito S, Hasegawa Y, Hamaguchi M, Senga T.  
**FEBS J**. 2009 May; 276 (10): 2775-85.
123. Heme oxygenase-1 mediates the anti-allergic actions of quercetin in rodent mast cells.  
Matsushima M, Takagi K, Ogawa M, Hirose E, Ota Y, Abe F, Baba K, Hasegawa T, Hasegawa Y, Kawabe T.  
**Inflamm Res**. 2009 Oct; 58 (10): 705-15.
124. An influence of Interferon-gamma gene polymorphisms on treatment response to tuberculosis in Japanese population.  
Shibasaki M, Yagi T, Yatsuya H, Okamoto M, Nishikawa M, Baba H, Hashimoto N, Senda K, Kawabe T, Nakashima K, Imaizumi K, Shimokata K, Hasegawa Y.  
**J Infect**. 2009 Jun; 58 (6): 467-9.
125. Impact of microarousal associated with increased negative esophageal pressure in sleep-disordered breathing.  
Sukegawa M, Noda A, Yasuda Y, Nakata S, Sugiura T, Miyata S, Honda K, Hasegawa Y, Nakashima T, Koike Y.  
**Sleep Breath**. 2009 Nov; 13 (4): 369-73.



126. Erythromycin-induced CXCR4 expression on microvascular endothelial cells.  
Takagi Y, Hashimoto N, Phan SH, Imaizumi K, Matsuo M, Nakashima H, Hashimoto I, Hayashi Y, Kawabe T, Shimokata K, [Hasegawa Y](#).  
**Am J Physiol Lung Cell Mol Physiol.** 2009 Sep; 297 (3): L420-31.
127. Actin cytoskeleton regulates stretch-activated Ca<sup>2+</sup> influx in human pulmonary microvascular endothelial cells.  
Ito S, Suki B, Kume H, Numaguchi Y, Ishii M, Iwaki M, Kondo M, Naruse K, [Hasegawa Y](#), Sokabe M.  
**Am J Respir Cell Mol Biol.** 2010 Jul; 43 (1): 26-34.
128. Idiopathic pulmonary veno-occlusive disease.  
Iwaki M, Imaizumi K, Yokoi T, Kondo M, Kawaguchi K, [Hasegawa Y](#).  
**Intern Med.** 2009; 48 (15): 1289-92.
129. Transmission of bacterial infections to healthcare workers during intubation and respiratory care of patients with severe pneumonia.  
Baba H, Iinuma Y, Imaizumi K, [Hasegawa Y](#), Hasegawa T, Ohta M, Paterson DL.  
**Infect Control Hosp Epidemiol.** 2009 Oct; 30 (10): 1019-21.
130. Mechanical stretch enhances IL-8 production in pulmonary microvascular endothelial cells.  
Iwaki M, Ito S, Morioka M, Iwata S, Numaguchi Y, Ishii M, Kondo M, Kume H, Naruse K, Sokabe M, [Hasegawa Y](#).  
**Biochem Biophys Res Commun.** 2009 Nov 20; 389 (3): 531-6.
131. Protective effect of geranylgeranylacetone, an inducer of heat shock protein 70, against drug-induced lung injury/fibrosis in an animal model.  
Fujibayashi T, Hashimoto N, Jijiwa M, [Hasegawa Y](#), Kojima T, Ishiguro N.  
**BMC Pulm Med.** 2009 Sep 16; 9: 45.
132. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis.  
Hashimoto N, Phan SH, Imaizumi K, Matsuo M, Nakashima H, Kawabe T, Shimokata K, [Hasegawa Y](#).  
**Am J Respir Cell Mol Biol.** 2010 Aug; 43 (2): 161-72.
133. Serum KL-6 in fibrotic NSIP: Correlations with physiologic and radiologic parameters.  
Sakamoto K, Taniguchi H, Kondoh Y, Johkoh T, Sumikawa H, Kimura T, Nishiyama O, Kato K, Kataoka K, Ono K, Kitaichi M, [Hasegawa Y](#).  
**Respir Med.** 2010 Jan; 104 (1): 127-33.
134. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.  
Goto Y, Shinjo K, Kondo Y, Shen L, Toyota M, Suzuki H, Gao W, An B, Fujii M, Murakami H, Osada H, Taniguchi T, Usami N, Kondo M, [Hasegawa Y](#), Shimokata K, Matsuo K, Hida T, Fujimoto N, Kishimoto T, Issa JP, Sekido Y.  
**Cancer Res.** 2009 Dec 1; 69 (23): 9073-82.
135. Virtual bronchoscopy-guided transbronchial biopsy for aiding the diagnosis of peripheral lung cancer.  
Iwano S, Imaizumi K, Okada T, [Hasegawa Y](#), Naganawa S.  
**Eur J Radiol.** 2011 Jul; 79 (1): 155-9.



136. Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: a multi-center phase II study.  
Ichikawa M, Suzuki R, Kataoka K, Noda Y, Shindoh J, Matsumoto S, Tanikawa Y, Suzuki K, Baba K, Shindo Y, Kondo M, Imaizumi K, Kume H, Hasegawa Y, Takagi K, Taniguchi H.  
**Lung Cancer**. 2010 Sep; 69 (3): 319-22.
137. Differential Th1/Th2 chemokine expression in interstitial pneumonia.  
Honda T, Imaizumi K, Yokoi T, Hashimoto N, Hashimoto I, Kawabe T, Matsuo M, Iwano S, Shimokata K, Hasegawa Y.  
**Am J Med Sci**. 2010 Jan; 339 (1): 41-8.
138. Functions of base selection step in human DNA polymerase alpha.  
Tanaka S, Cao K, Niimi A, Limsirichaikul S, Miao HQ, Nakamura N, Murate T, Hasegawa Y, Takahashi T, Suzuki M.  
**DNA Repair (Amst)**. 2010 May 4; 9 (5): 534-41.
139. Heterologous regulation of anion transporters by menthol in human airway epithelial cells.  
Morise M, Ito Y, Matsuno T, Hibino Y, Mizutani T, Ito S, Hashimoto N, Kondo M, Imaizumi K, Hasegawa Y.  
**Eur J Pharmacol**. 2010 Jun 10; 635(1-3): 204-11.
140. Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (**EMT**) gene, suppresses anchorage-independent cell growth of lung cancer cells.  
Takeyama Y, Sato M, Horio M, Hase T, Yoshida K, Yokoyama T, Nakashima H, Hashimoto N, Sekido Y, Gazdar AF, Minna JD, Kondo M, Hasegawa Y.  
**Cancer Lett**. 2010 Oct 28; 296 (2): 216-24.
141. Thalidomide attenuates airway hyperresponsiveness and eosinophilic inflammation in a murine model of allergic asthma.  
Asano T, Kume H, Taki F, Ito S, Hasegawa Y.  
**Biol Pharm Bull**. 2010; 33 (6): 1028-32.
142. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis.  
Oguri T, Shimokata T, Inada M, Ito I, Ando Y, Sasaki Y, Hasegawa Y.  
**Cancer Chemother Pharmacol**. 2010 Sep; 66 (4): 813-7.
143. Recurrent vascular catheter-related bacteremia caused by *Delftia acidovorans* with different antimicrobial susceptibility profiles.  
Kawamura I, Yagi T, Hatakeyama K, Ohkura T, Ohkusu K, Takahashi Y, Kojima S, Hasegawa Y.  
**J Infect Chemother**. 2011 Feb; 17 (1): 111-3.
144. Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial.  
Usami N, Yokoi K, Hasegawa Y, Taniguchi H, Shindo J, Yamamoto M, Suzuki R, Imaizumi K, Kondo M, Shimokata K; Central Japan Lung Study Group.  
**Int J Clin Oncol**. 2010 Dec; 15 (6): 583-7.



145. Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer.  
Shimokata T, Ando Y, Yasuda Y, Hamada A, Kawada K, Saito H, Matsuo S, Kondo M, Imaizumi K, Hasegawa Y.  
**Cancer Sci.** 2010 Dec; 101 (12): 2601-5.
146. Noninvasive ventilation in patients with acute exacerbation of pulmonary tuberculosis sequelae.  
Aso H, Kondoh Y, Taniguchi H, Kimura T, Nishiyama O, Kato K, Kataoka K, Hasegawa Y.  
**Intern Med.** 2010; 49(19):2077-83.
147. Attenuation of transforming growth factor- $\beta$ -stimulated collagen production in fibroblasts by quercetin-induced heme oxygenase-1.  
Nakamura T, Matsushima M, Hayashi Y, Shibasaki M, Imaizumi K, Hashimoto N, Shimokata K, Hasegawa Y, Kawabe T.  
**Am J Respir Cell Mol Biol.** 2011 May; 44 (5): 614-20.
148. Phase II study of S-1 monotherapy as a first-line treatment for elderly patients with advanced nonsmall-cell lung cancer: the Central Japan Lung Study Group trial 0404.  
Nishiyama O, Taniguchi H, Kondoh Y, Takada K, Baba K, Saito H, Sugino Y, Yamamoto M, Ogasawara T, Kondo M, Imaizumi K, Hasegawa Y, Suzuki R, Shimokata K; Central Japan Lung Study Group.  
**Anticancer Drugs.** 2011 Sep; 22 (8): 811-6.
149. Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study.  
Kameda H, Tokuda H, Sakai F, Johkoh T, Mori S, Yoshida Y, Takayanagi N, Taki H, Hasegawa Y, Hatta K, Yamanaka H, Dohi M, Hashimoto S, Yamada H, Kawai S, Takeuchi T, Tateda K, Goto H.  
**Intern Med.** 2011; 50 (4): 305-13.
150. Effects of specific prostanoid EP receptor agonists on cell proliferation and intracellular Ca<sup>2+</sup> concentrations in human airway smooth muscle cells.  
Mori A, Ito S, Morioka M, Aso H, Kondo M, Sokabe M, Hasegawa Y.  
**Eur J Pharmacol.** 2011 May 20; 659 (1): 72-8.
151. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes.  
Matsumura Y, Shindo Y, Iinuma Y, Yamamoto M, Shirano M, Matsushima A, Nagao M, Ito Y, Takakura S, Hasegawa Y, Ichiyama S.  
**BMC Infect Dis.** 2011 Mar 25; 11:76.
152. Capsaicinoids regulate airway anion transporters through Rho kinase- and cyclic AMP-dependent mechanisms.  
Hibino Y, Morise M, Ito Y, Mizutani T, Matsuno T, Ito S, Hashimoto N, Sato M, Kondo M, Imaizumi K, Hasegawa Y.  
**Am J Respir Cell Mol Biol.** 2011 Oct; 45 (4): 684-91.



153. Pivotal role of epithelial cell adhesion molecule in the survival of lung cancer cells.  
Hase T, Sato M, Yoshida K, Girard L, Takeyama Y, Horio M, Elshazley M, Oguri T, Sekido Y, Shames DS, Gazdar AF, Minna JD, Kondo M, Hasegawa Y.  
**Cancer Sci.** 2011 Aug; 102 (8): 1493-500.
154. Emerging problems regarding severity assessment and treatment strategies for patients with pneumonia: controversies surrounding the HCAP concept.  
Shindo Y, Hasegawa Y.  
**Intern Emerg Med.** 2011 Oct; 6 (5): 389-91.
155. Involvement of the transcription factor twist in phenotype alteration through epithelial-mesenchymal transition in lung cancer cells.  
Nakashima H, Hashimoto N, Aoyama D, Kohnoh T, Sakamoto K, Kusunose M, Imaizumi K, Takeyama Y, Sato M, Kawabe T, Hasegawa Y.  
**Mol Carcinog.** 2012 May; 51(5):400-10.
156. Real-time marker-free patient registration for electromagnetic navigated bronchoscopy: a phantom study.  
Deguchi D, Feuerstein M, Kitasaka T, Suenaga Y, Ide I, Murase H, Imaizumi K, Hasegawa Y, Mori K.  
**Int J Comput Assist Radiol Surg.** 2012 May; 7 (3): 359-69.
157. Patterns of recurrence and outcome in patients with surgically resected small cell lung cancer.  
Ogawa S, Horio Y, Yatabe Y, Fukui T, Ito S, Hasegawa Y, Mitsudomi T, Hida T.  
**Int J Clin Oncol.** 2012 Jun;17 (3): 218-24.
158. A new microarray system to detect Streptococcus pneumoniae serotypes.  
Tomita Y, Okamoto A, Yamada K, Yagi T, Hasegawa Y, Ohta M.  
**J Biomed Biotechnol.** 2011; 2011: 352736.
159. Mesenchymal stem cells stably transduced with a dominant-negative inhibitor of CCL2 greatly attenuate bleomycin-induced lung damage.  
Saito S, Nakayama T, Hashimoto N, Miyata Y, Egashira K, Nakao N, Nishiwaki S, Hasegawa M, Hasegawa Y, Naoe T.  
**Am J Pathol.** 2011 Sep; 179 (3): 1088-94.
160. Pleural plaque profiles on the chest radiographs and CT scans of asbestos-exposed Japanese construction workers.  
Elshazley M, Shibata E, Hisanaga N, Ichihara G, Ewis AA, Kamijima M, Ichihara S, Sakai K, Sato M, Kondo M, Hasegawa Y.  
**Ind Health.** 2011; 49 (5): 626-33.
161. A clinical trial for therapeutic drug monitoring using microchip-based fluorescence polarization immunoassay.  
Tachi T, Hase T, Okamoto Y, Kaji N, Arima T, Matsumoto H, Kondo M, Tokeshi M, Hasegawa Y, Baba Y.  
**Anal Bioanal Chem.** 2011 Oct; 401 (7): 2301-5.





162. ARHGAP18, a GTPase-activating protein for RhoA, controls cell shape, spreading, and motility. Maeda M, Hasegawa H, Hyodo T, Ito S, Asano E, Yuang H, Funasaka K, Shimokata K, Hasegawa Y, Hamaguchi M, Senga T. **Mol Biol Cell**. 2011 Oct; 22 (20): 3840-52.
163. CD40/CD40 ligand interactions in immune responses and pulmonary immunity. Kawabe T, Matsushima M, Hashimoto N, Imaizumi K, Hasegawa Y. **Nagoya J Med Sci**. 2011 Aug; 73 (3-4): 69-78. Review.
164. Microtubule dynamics regulate cyclic stretch-induced cell alignment in human airway smooth muscle cells. Morioka M, Parameswaran H, Naruse K, Kondo M, Sokabe M, Hasegawa Y, Suki B, Ito S. **PLoS One**. 2011; 6 (10): e26384.
165. Prostaglandin E2 enhances interleukin-8 production via EP4 receptor in human pulmonary microvascular endothelial cells. Aso H, Ito S, Mori A, Morioka M, Suganuma N, Kondo M, Imaizumi K, Hasegawa Y. **Am J Physiol Lung Cell Mol Physiol**. 2012 Jan 15; 302 (2): L266-73.
166. Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells. Horio M, Sato M, Takeyama Y, Elshazley M, Yamashita R, Hase T, Yoshida K, Usami N, Yokoi K, Sekido Y, Kondo M, Toyokuni S, Gazdar AF, Minna JD, Hasegawa Y. **Ann Surg Oncol**. 2012 Jul; 19 Suppl 3: S634-45.
167. Acute exacerbation of IPF following diagnostic bronchoalveolar lavage procedures. Sakamoto K, Taniguchi H, Kondoh Y, Wakai K, Kimura T, Kataoka K, Hashimoto N, Nishiyama O, Hasegawa Y. **Respir Med**. 2012 Mar; 106 (3): 436-42.
168. Quercetin protects against pulmonary oxidant stress via heme oxygenase-1 induction in lung epithelial cells. Hayashi Y, Matsushima M, Nakamura T, Shibasaki M, Hashimoto N, Imaizumi K, Shimokata K, Hasegawa Y, Kawabe T. **Biochem Biophys Res Commun**. 2012 Jan 6; 417 (1): 169-74.
169. Three cases of bronchial asthma preceding IgG4-related autoimmune pancreatitis. Ito S, Ko SB, Morioka M, Imaizumi K, Kondo M, Mizuno N, Hasegawa Y. **Allergol Int**. 2012 Mar; 61 (1): 171-4.
170. Inspiratory capacity as a preoperative assessment of patients undergoing thoracic surgery. Matsuo M, Hashimoto N, Usami N, Imaizumi K, Wakai K, Kawabe T, Yokoi K, Hasegawa Y. **Interact Cardiovasc Thorac Surg**. 2012 May; 14(5): 560-4.
171. Possible Involvement of Sphingosine-1-Phosphate/G/RhoA pathways in adherence of eosinophils to pulmonary endothelium. Sashio T, Kume H, Takeda N, Asano T, Tsuji S, Kondo M, Hasegawa Y, Shimokata K. **Allergol Int**. 2012 Jun; 61 (2): 283-93.



172. Role of sphingosine-1-phosphate in  $\beta_1$ -adrenoceptor desensitization via  $Ca^{2+}$  sensitization in airway smooth muscle.  
Makino Y, Kume H, Oguma T, Sugishita M, Shiraki A, Hasegawa Y, Honjo H, Kamiya K.  
**Allergol Int.** 2012 Jun; 61 (2): 311-22.
173. Interstitial pneumonia and nodular regenerative hyperplasia of the liver as initial manifestations of polyarteritis nodosa.  
Tanaka I, Imaizumi K, Hashimoto I, Asai N, Yokoi T, Matsuno T, Hasegawa Y.  
**Intern Med.** 2012; 51 (6): 635-8.
174. Emerging evidence of epithelial-to-mesenchymal transition in lung carcinogenesis.  
Sato M, Shames DS, Hasegawa Y.  
**Respirology.** 2012 Oct; 17 (7): 1048-59.
175. The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma.  
Elshazley M, Sato M, Hase T, Yamashita R, Yoshida K, Toyokuni S, Ishiguro F, Osada H, Sekido Y, Yokoi K, Usami N, Shames DS, Kondo M, Gazdar AF, Minna JD, Hasegawa Y.  
**Int J Cancer.** 2012 Dec 15; 131 (12): 2820-31.
176. Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.  
Tamura M, Kondo M, Horio M, Ando M, Saito H, Yamamoto M, Horio Y, Hasegawa Y.  
**Nagoya J Med Sci.** 2012 Feb; 74 (1-2): 133-40.
177. Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma.  
Shinjo K, Okamoto Y, An B, Yokoyama T, Takeuchi I, Fujii M, Osada H, Usami N, Hasegawa Y, Ito H, Hida T, Fujimoto N, Kishimoto T, Sekido Y, Kondo Y.  
**Carcinogenesis.** 2012 Jul; 33 (7): 1277-85.
178. Differential modulation of surfactant protein D under acute and persistent hypoxia in acute lung injury.  
Sakamoto K, Hashimoto N, Kondoh Y, Imaizumi K, Aoyama D, Kohnoh T, Kusunose M, Kimura M, Kawabe T, Taniguchi H, Hasegawa Y.  
**Am J Physiol Lung Cell Mol Physiol.** 2012 Jul 1; 303 (1): L43-53.
179. Nongenomic effects of fluticasone propionate and budesonide on human airway anion secretion.  
Mizutani T, Morise M, Ito Y, Hibino Y, Matsuno T, Ito S, Hashimoto N, Sato M, Kondo M, Imaizumi K, Hasegawa Y.  
**Am J Respir Cell Mol Biol.** 2012 Nov; 47 (5): 645-51.
180. STIM1 regulates platelet-derived growth factor-induced migration and  $Ca^{2+}$  influx in human airway smooth muscle cells.  
Suganuma N, Ito S, Aso H, Kondo M, Sato M, Sokabe M, Hasegawa Y.  
**PLoS One.** 2012; 7 (9): e45056.



181. Aqueous fraction of *Sauropus androgynus* might be responsible for bronchiolitis obliterans. Hashimoto I, Imaizumi K, Hashimoto N, Furukawa H, Noda Y, Kawabe T, Honda T, Ogawa T, Matsuo M, Imai N, Ito S, Sato M, Kondo M, Shimokata K, Hasegawa Y. **Respirology**. 2013 Feb; 18 (2): 340-7.
182. Detection of loci for allergic asthma using SMXA recombinant inbred strains of mice. Ohno T, Okamoto M, Hara T, Hashimoto N, Imaizumi K, Matsushima M, Nishimura M, Shimokata K, Hasegawa Y, Kawabe T. **Immunogenetics**. 2013 Jan; 65 (1): 17-24.
183. Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis. Watanabe N, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Nishiyama O, Kondo M, Hasegawa Y. **Respiration**. 2013; 85(4):326-31.
184. TIMELESS is overexpressed in lung cancer and its expression correlates with poor patient survival. Yoshida K, Sato M, Hase T, Elshazley M, Yamashita R, Usami N, Taniguchi T, Yokoi K, Nakamura S, Kondo M, Girard L, Minna JD, Hasegawa Y. **Cancer Sci**. 2013 Feb; 104 (2): 171-7.
185. Febrile complications after endobronchial ultrasound-guided transbronchial needle aspiration for intrapulmonary mass lesions of lung cancer--a series of 3 cases. Oguri T, Imai N, Imaizumi K, Elshazley M, Hashimoto I, Hashimoto N, Hasegawa Y. **Respir Investig**. 2012 Dec; 50 (4): 162-5.
186. Differential regulation of airway smooth muscle cell migration by E-prostanoid receptor subtypes. Aso H, Ito S, Mori A, Suganuma N, Morioka M, Takahara N, Kondo M, Hasegawa Y. **Am J Respir Cell Mol Biol**. 2013 Mar; 48 (3): 322-9.
187. Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis. Kimura M, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Nishiyama O, Aso H, Sakamoto K, Hasegawa Y. **Respiration**. 2013; 85 (6): 456-63.
188. Quadriceps weakness contributes to exercise capacity in nonspecific interstitial pneumonia. Watanabe F, Taniguchi H, Sakamoto K, Kondoh Y, Kimura T, Kataoka K, Ogawa T, Arizono S, Nishiyama O, Hasegawa Y. **Respir Med**. 2013 Apr; 107 (4): 622-8.
189. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. Nakagawa T, Takeuchi S, Yamada T, Ebi H, Sano T, Nanjo S, Ishikawa D, Sato M, Hasegawa Y, Sekido Y, Yano S. **Cancer Res**. 2013 Apr 15; 73 (8): 2428-34.



190. Endobronchial ultrasound transbronchial needle aspiration in older people.  
Okachi S, Imai N, Imaizumi K, Hase T, Shindo Y, Sakamoto K, Aso H, Wakahara K, Hashimoto I, Ito S, Hashimoto N, Sato M, Kondo M, Hasegawa Y.  
**Geriatr Gerontol Int.** 2013 Oct; 13 (4): 986-92.
191. Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer.  
Oguri T, Mitsuma A, Inada-Inoue M, Morita S, Shibata T, Shimokata T, Sugishita M, Nakayama G, Uehara K, Hasegawa Y, Ando Y.  
**Int J Clin Pharmacol Ther.** 2013 Jun; 51 (6): 475-81.
192. Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis.  
Watanabe N, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Nishiyama O, Kondo M, Hasegawa Y.  
**Int J Clin Oncol.** 2014 Apr; 19(2):260-5.
193. COPD and disease-specific health status in a working population.  
Nishimura K, Mitsuma S, Kobayashi A, Yanagida M, Nakayasu K, Hasegawa Y, Jones PW.  
**Respir Res.** 2013 Jun 2;14:61. doi: 10.1186/1465-9921-14-61.
194. Echoic features of lymph nodes with sarcoidosis determined by endobronchial ultrasound.  
Imai N, Imaizumi K, Ando M, Shimokata T, Ogawa T, Ito S, Hashimoto N, Sato M, Kondo M, Hasegawa Y.  
**Intern Med.** 2013; 52 (13): 1473-8.
195. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia.  
Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, Goto Y, Fukui Y, Iwaki M, Okumura J, Yamaguchi I, Yagi T, Tanikawa Y, Sugino Y, Shindoh J, Ogasawara T, Nomura F, Saka H, Yamamoto M, Taniguchi H, Suzuki R, Saito H, et al.  
**Am J Respir Crit Care Med.** 2013 Oct 15; 188 (8): 985-95.
196. Predictors of the need to initiate noninvasive ventilation in stable outpatients with acute exacerbation of chronic obstructive pulmonary disease.  
Taga S, Taniguchi H, Watanabe N, Kondoh Y, Kimura T, Kataoka K, Aso H, Sakamoto K, Hasegawa Y.  
**Intern Med.** 2013; 52 (16): 1781-6.
197. Influence of cheek support on respiratory impedance measured by forced oscillation technique.  
Uchida A, Ito S, Suki B, Matsubara H, Hasegawa Y.  
**Springerplus.** 2013 Jul 25;2:342.
198. Opioid use in end-of-life care in patients with interstitial pneumonia associated with respiratory worsening.  
Tsukuura H, Nishimura K, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Watanabe N, Hasegawa Y.  
**J Pain Palliat Care Pharmacother.** 2013 Aug; 27 (3): 214-9.



199. RASSF3 downregulation increases malignant phenotypes of non-small cell lung cancer.  
Fukatsu A, Ishiguro F, Tanaka I, Kudo T, Nakagawa K, Shinjo K, Kondo Y, Fujii M, Hasegawa Y,  
Tomizawa K, Mitsudomi T, Osada H, Hata Y, Sekido Y.  
**Lung Cancer**. 2014 Jan; 83 (1): 23-9.
200. Involvement of TGF $\beta$ -induced phosphorylation of the PTEN C-terminus on TGF $\beta$ -induced  
acquisition of malignant phenotypes in lung cancer cells.  
Aoyama D, Hashimoto N, Sakamoto K, Kohnoh T, Kusunose M, Kimura M, Ogata R, Imaizumi K,  
Kawabe T, Hasegawa Y.  
**PLoS One**. 2013 Nov 22; 8 (11): e81133.
201. Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-  
small cell lung cancer.  
Fukihara J, Watanabe N, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Matsuda T, Yokoyama T,  
Hasegawa Y.  
**Oncology**. 2014; 86 (2): 86-93.
202. Reply: HCAP not busy being born is busy dying.  
Shindo Y, Hasegawa Y.  
**Am J Respir Crit Care Med**. 2014 Feb 1; 189 (3): 366-7.
203. Clinical impact of prevalence and severity of COPD on the decision-making process for therapeutic  
management of lung cancer patients.  
Hashimoto N, Matsuzaki A, Okada Y, Imai N, Iwano S, Wakai K, Imaizumi K, Yokoi K, Hasegawa Y.  
**BMC Pulm Med**. 2014 Feb 5; 14: 14.
204. Changes in plasma levels of B-type natriuretic peptide with acute exacerbations of chronic obstructive  
pulmonary disease.  
Nishimura K, Nishimura T, Onishi K, Oga T, Hasegawa Y, Jones PW.  
**Int J Chron Obstruct Pulmon Dis**. 2014 Feb 5; 9: 155-62.
205. Efficacy of combined therapy with cyclosporin and low-dose prednisolone in interstitial pneumonia  
associated with connective tissue disease.  
Watanabe N, Sakamoto K, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Ono K, Fukuoka J,  
Nishiyama O, Hasegawa Y.  
**Respiration**. 2014; 87 (6): 469-77.
206. Reply: isolation of drug-resistant pathogens does not always require use of broad-spectrum antibiotics  
in pneumonia.  
Shindo Y, Hasegawa Y.  
**Am J Respir Crit Care Med**. 2014 Mar 15; 189 (6): 757-8.
207. Cefepime monotherapy for febrile neutropenia in patients with lung cancer.  
Saito H, Takahashi K, Okuno M, Saka H, Imaizumi K, Hasegawa Y, Tanikawa Y, Yamamoto M,  
Taniguchi H, Shindoh J, Suzuki R, Shimokata K; Central Japan Lung Study Group..  
**J Infect Chemother**. 2014 Jun; 20 (6): 365-9.



208. Prospective analysis of efficacy and safety of an individualized-midazolam-dosing protocol for sedation during prolonged bronchoscopy.  
Ogawa T, Imaizumi K, Hashimoto I, Shindo Y, Imai N, Uozu S, Shimokata T, Ito S, Hashimoto N, Sato M, Kondo M, Hasegawa Y.  
**Respir Investig.** 2014 May; 52 (3): 153-9.
209. Real-time imaging of ATP release induced by mechanical stretch in human airway smooth muscle cells.  
Takahara N, Ito S, Furuya K, Naruse K, Aso H, Kondo M, Sokabe M, Hasegawa Y.  
**Am J Respir Cell Mol Biol.** 2014 Dec; 51 (6): 772-82.
210. Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer.  
Sugishita M, Imai T, Kikumori T, Mitsuma A, Shimokata T, Shibata T, Morita S, Inada-Inoue M, Sawaki M, Hasegawa Y, Ando Y.  
**Breast Cancer.** 2016 Mar; 23 (2): 195-201.
211. First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901.  
Takahashi K, Saito H, Hasegawa Y, Ando M, Yamamoto M, Kojima E, Sugino Y, Kimura T, Nomura F, Ogasawara T, Shindoh J, Yoshida N, Suzuki R.  
**Cancer Chemother Pharmacol.** 2014 Oct; 74 (4): 721-7.
212. Carboplatin dosing for adult Japanese patients.  
Ando Y, Shimokata T, Yasuda Y, Hasegawa Y.  
**Nagoya J Med Sci.** 2014 Feb; 76 (1-2): 1-9. Review.
213. Ca<sup>2+</sup> influx and ATP release mediated by mechanical stretch in human lung fibroblasts.  
Murata N, Ito S, Furuya K, Takahara N, Naruse K, Aso H, Kondo M, Sokabe M, Hasegawa Y.  
**Biochem Biophys Res Commun.** 2014 Oct 10; 453(1): 101-5.
214. Significance of pulmonary arterial pressure as a prognostic indicator in lung-dominant connective tissue disease.  
Suzuki A, Taniguchi H, Watanabe N, Kondoh Y, Kimura T, Kataoka K, Matsuda T, Yokoyama T, Sakamoto K, Nishiyama O, Hasegawa Y.  
**PLoS One.** 2014 Sep 30; 9 (9): e108339.
215. Phase II study of erlotinib for previously treated patients with EGFR wild-type non-small-cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System.  
Morise M, Taniguchi H, Saka H, Shindoh J, Suzuki R, Kojima E, Hase T, Ando M, Kondo M, Saito H, Hasegawa Y.  
**Mol Clin Oncol.** 2014 Nov; 2 (6): 991-996.
216. Distinct characteristics of pleuroparenchymal fibroelastosis with usual interstitial pneumonia compared with idiopathic pulmonary fibrosis.  
Oda T, Ogura T, Kitamura H, Hagiwara E, Baba T, Enomoto Y, Iwasawa T, Okudela K, Takemura T, Sakai F, Hasegawa Y.  
**Chest.** 2014 Nov; 146 (5): 1248-1255.



217. Protective effects of intratracheally administered quercetin on lipopolysaccharide-induced acute lung injury.  
Takashima K, Matsushima M, Hashimoto K, Nose H, Sato M, Hashimoto N, Hasegawa Y, Kawabe T.  
**Respir Res.** 2014 Nov 21; 15:150.
218. Endobronchial ultrasound echoic image of pulmonary hamartoma.  
Kajikawa S, Imai N, Takashima K, Imaizumi K, Hasegawa Y.  
**Respirol Case Rep.** 2014 Jun; 2(2): 85-6.
219. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis.  
Ogura T, Taniguchi H, Azuma A, Inoue Y, Kondoh Y, Hasegawa Y, Bando M, Abe S, Mochizuki Y, Chida K, Kliglich M, Fujimoto T, Okazaki K, Tadayasu Y, Sakamoto W, Sugiyama Y.  
**Eur Respir J.** 2015 May; 45 (5): 1382-92.
220. Lobar analysis of collapsibility indices to assess functional lung volumes in COPD patients.  
Kitano M, Iwano S, Hashimoto N, Matsuo K, Hasegawa Y, Naganawa S.  
**Int J Chron Obstruct Pulmon Dis.** 2014 Dec 9; 9: 1347-56.
221. Magnetic resonance imaging of tumor with a self-traceable phosphorylcholine polymer.  
Yamada H, Hasegawa Y, Imai H, Takayama Y, Sugihara F, Matsuda T, Tochio H, Shirakawa M, Sando S, Kimura Y, Toshimitsu A, Aoyama Y, Kondo T.  
**J Am Chem Soc.** 2015 Jan 21; 137 (2): 799-806.
222. Synergistic effect of bolus exposure to zinc oxide nanoparticles on bleomycin-induced secretion of pro-fibrotic cytokines without lasting fibrotic changes in murine lungs.  
Wu W, Ichihara G, Hashimoto N, Hasegawa Y, Hayashi Y, Tada-Oikawa S, Suzuki Y, Chang J, Kato M, D'Alessandro-Gabazza CN, Gabazza EC, Ichihara S.  
**Int J Mol Sci.** 2014 Dec 30; 16 (1): 660-76.
223. Molecular epidemiological characteristics of *Klebsiella pneumoniae* associated with bacteremia among patients with pneumonia.  
Ito R, Shindo Y, Kobayashi D, Ando M, Jin W, Wachino J, Yamada K, Kimura K, Yagi T, Hasegawa Y, Arakawa Y.  
**J Clin Microbiol.** 2015 Mar; 53 (3): 879-86.
224. Evaluation of the effects of quercetin on damaged salivary secretion.  
Takahashi A, Inoue H, Mishima K, Ide F, Nakayama R, Hasaka A, Ryo K, Ito Y, Sakurai T, Hasegawa Y, Saito I.  
**PLoS One.** 2015 Jan 28; 10 (1): e0116008.
225. Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells.  
Yamashita R, Sato M, Kakumu T, Hase T, Yogo N, Maruyama E, Sekido Y, Kondo M, Hasegawa Y.  
**Cancer Med.** 2015 Apr; 4 (4): 551-64.
226. Impact of airflow limitation on carotid atherosclerosis in coronary artery disease patients.  
Hamrah MS, Suzuki S, Ishii H, Shibata Y, Tatami Y, Osugi N, Ota T, Kawamura Y, Tanaka A, Aso H, Takeshita K, Sakamoto J, Hasegawa Y, Murohara T.  
**Respiration.** 2015; 89 (4): 322-8.





227. Evaluation of emphysema using three-dimensional computed tomography: association with postoperative complications in lung cancer patients.  
Kawakami K, Iwano S, Hashimoto N, Hasegawa Y, Naganawa S.  
**Nagoya J Med Sci.** 2015 Feb; 77 (1-2): 113-22.
228. Lung-Dominant Connective Tissue Disease: Clinical, Radiologic, and Histologic Features.  
Omote N, Taniguchi H, Kondoh Y, Watanabe N, Sakamoto K, Kimura T, Kataoka K, Johkoh T, Fujimoto K, Fukuoka J, Otani K, Nishiyama O, Hasegawa Y.  
**Chest.** 2015 Dec; 148 (6): 1438-1446.
229. Risk stratification by the lower limit of normal of FEV1/FVC for postoperative outcomes in patients with COPD undergoing thoracic surgery.  
Osuka S, Hashimoto N, Sakamoto K, Wakai K, Yokoi K, Hasegawa Y.  
**Respir Investig.** 2015 May; 53 (3): 117-23.
230. Extension of the Calvert formula to patients with severe renal insufficiency.  
Oguri T, Shimokata T, Ito I, Yasuda Y, Sassa N, Nishiyama M, Hamada A, Hasegawa Y, Ando Y.  
**Cancer Chemother Pharmacol.** 2015 Jul; 76 (1): 53-9.
231. Factors secreted from dental pulp stem cells show multifaceted benefits for treating acute lung injury in mice.  
Wakayama H, Hashimoto N, Matsushita Y, Matsubara K, Yamamoto N, Hasegawa Y, Ueda M, Yamamoto A.  
**Cytotherapy.** 2015 Aug; 17 (8): 1119-29.
232. Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: an observational cohort study.  
Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Goto Y, Fukui Y, Iwaki M, Okumura J, Yamaguchi I, Yagi T, Tanikawa Y, Sugino Y, Shindoh J, Ogasawara T, Nomura F, Saka H, Yamamoto M, Taniguchi H, Suzuki R, Saito H, Kawamura T, et al.  
**Lancet Infect Dis.** 2015 Sep; 15 (9): 1055-1065.
233. Arginine methylation of ubiquitin-associated protein 2-like is required for the accurate distribution of chromosomes.  
Maeda M, Hasegawa H, Sugiyama M, Hyodo T, Ito S, Chen D, Asano E, Masuda A, Hasegawa Y, Hamaguchi M, Senga T.  
**FASEB J.** 2016 Jan; 30 (1): 312-23.
234. Massive mediastinal cryptococcosis in a young immunocompetent patient.  
Okachi S, Wakahara K, Kato D, Umeyama T, Yagi T, Hasegawa Y.  
**Respirol Case Rep.** 2015 Sep; 3(3):95-8.
235. Direct regulation of transforming growth factor $\beta$ -induced epithelial-mesenchymal transition by the protein phosphatase activity of unphosphorylated PTEN in lung cancer cells.  
Kusunose M, Hashimoto N, Kimura M, Ogata R, Aoyama D, Sakamoto K, Miyazaki S, Ando A, Omote N, Imaizumi K, Kawabe T, Hasegawa Y.  
**Cancer Sci.** 2015 Dec; 106 (12): 1693-704.



236. Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians.  
Tsukuura H, Ando Y, Gyawali B, Matsumoto M, Sugishita M, Honda K, Urakawa H, Maeda O, Hasegawa Y.  
**J Palliat Med.** 2015 Nov; 18 (11): 977-80.
237. Omalizumab reduces cysteinyl leukotriene and,  $9\alpha$ ,  $11\beta$  prostaglandin F<sub>2</sub> overproduction in aspirin-exacerbated respiratory disease.  
Hayashi H, Mitsui C, Nakatani E, Fukutomi Y, Kajiwaru K, Watai K, Sekiya K, Tsuburai T, Akiyama K, Hasegawa Y, Taniguchi M.  
**J Allergy Clin Immunol.** 2016 May; 137 (5): 1585-1587.e4.
238. Targeting ceramide synthase 6-dependent metastasis-prone phenotype in lung cancer cells.  
Suzuki M, Cao K, Kato S, Komizu Y, Mizutani N, Tanaka K, Arima C, Tai MC, Yanagisawa K, Togawa N, Shiraiishi T, Usami N, Taniguchi T, Fukui T, Yokoi K, Wakahara K, Hasegawa Y, Mizutani Y, Igarashi Y, Inokuchi J, Iwaki S, Fujii S, et al.  
**J Clin Invest.** 2016 Jan; 126 (1): 254-65.
239. Respiratory mechanics measured by forced oscillation technique in rheumatoid arthritis-related pulmonary abnormalities: frequency-dependence, heterogeneity and effects of smoking.  
Sokai R, Ito S, Iwano S, Uchida A, Aso H, Kondo M, Ishiguro N, Kojima T, Hasegawa Y.  
**Springerplus.** 2016 Mar 15; 5: 335.
240. Phase II Study of Carboplatin and Pemetrexed in Advanced EGFR-wild-type Non-squamous Non-small Cell Lung Cancer: The Central Japan Lung Study Group Trial 0906.  
Kimura T, Taniguchi H, Watanabe N, Saka H, Kogure Y, Shindo J, Ogasawara T, Kojima E, Hasegawa Y, Yamamoto M, Suzuki R, Ando M, Kondo M, Saito H.  
**Anticancer Res.** 2016 Apr; 36 (4): 1767-71.
241. Mean pulmonary arterial pressure as a prognostic indicator in connective tissue disease associated with interstitial lung disease: a retrospective cohort study.  
Takahashi K, Taniguchi H, Ando M, Sakamoto K, Kondoh Y, Watanabe N, Kimura T, Kataoka K, Suzuki A, Ito S, Hasegawa Y.  
**BMC Pulm Med.** 2016 Apr 19; 16 (1): 55.
242. Hypoxia-induced modulation of PTEN activity and EMT phenotypes in lung cancers.  
Kohnoh T, Hashimoto N, Ando A, Sakamoto K, Miyazaki S, Aoyama D, Kusunose M, Kimura M, Omote N, Imaizumi K, Kawabe T, Hasegawa Y.  
**Cancer Cell Int.** 2016 Apr 18; 16: 33.
243. Clinical impact of the lower limit of normal of FEV1/FVC on survival in lung cancer patients undergoing thoracic surgery.  
Matsuzaki A, Hashimoto N, Okachi S, Taniguchi T, Kawaguchi K, Fukui T, Wakai K, Yokoi K, Hasegawa Y.  
**Respir Investig.** 2016 May; 54 (3): 184-92.



244. Impact of Thin-Section Computed Tomography-Determined Combined Pulmonary Fibrosis and Emphysema on Outcomes Among Patients With Resected Lung Cancer. Hashimoto N, Iwano S, Kawaguchi K, Fukui T, Fukumoto K, Nakamura S, Mori S, Sakamoto K, Wakai K, Yokoi K, Hasegawa Y. **Ann Thorac Surg**. 2016 Aug; 102(2):440-7.
245. Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy? Kato T, Morise M, Ando M, Kojima E, Ogasawara T, Suzuki R, Shindoh J, Matsumoto M, Sugino Y, Ogawa M, Nozaki Y, Hase T, Kondo M, Saito H, Hasegawa Y. **J Cancer Res Clin Oncol**. 2016 Jul; 142 (7): 1629-40.
246. Factors influencing sustainable efficacy of smoking cessation treatment with varenicline beyond nine months. Shimadu S, Hamajima N, Okada Y, Oguri T, Murohara T, Ban N, Sato M, Hasegawa Y. **Nagoya J Med Sci**. 2016 May; 78 (2): 205-13.
247. Factors Affecting the Diagnostic Yield of Transbronchial Biopsy Using Endobronchial Ultrasonography with a Guide Sheath in Peripheral Lung Cancer. Okachi S, Imai N, Imaizumi K, Iwano S, Ando M, Hase T, Aso H, Morise M, Wakahara K, Ito S, Hashimoto N, Sato M, Kondo M, Hasegawa Y. **Intern Med**. 2016; 55 (13): 1705-12.
248. Acute respiratory distress syndrome due to severe pulmonary tuberculosis treated with extracorporeal membrane oxygenation: A case report and review of the literature. Omote N, Kondoh Y, Taniguchi H, Kimura T, Kataoka K, Hasegawa R, Hasegawa Y. **Respir Med Case Rep**. 2016 Jun 10; 19: 31-3.
249. Genotype frequencies for polymorphisms related to chemotherapy-induced nausea and vomiting in a Japanese population. Goto A, Kotani H, Miyazaki M, Yamada K, Ishikawa K, Shimoyama Y, Niwa T, Hasegawa Y, Noda Y. **J Pharm Health Care Sci**. 2016 Jul 21; 2: 16.
250. The COPD assessment test and St George's Respiratory Questionnaire: are they equivalent in subjects with COPD? Morishita-Katsu M, Nishimura K, Taniguchi H, Kimura T, Kondoh Y, Kataoka K, Ogawa T, Watanabe F, Arizono S, Nishiyama O, Nakayasu K, Imaizumi K, Hasegawa Y. **Int J Chron Obstruct Pulmon Dis**. 2016 Jul 7; 11: 1543-51.
251. Exercise hypoxaemia as a predictor of pulmonary hypertension in COPD patients without severe resting hypoxaemia. Nakahara Y, Taniguchi H, Kimura T, Kondoh Y, Arizono S, Nishimura K, Sakamoto K, Ito S, Ando M, Hasegawa Y. **Respirology**. 2017 Jan; 22 (1): 120-125.
252. Increased expression levels of ppGalNAc-T13 in lung cancers: Significance in the prognostic diagnosis. Nogimori K, Hori T, Kawaguchi K, Fukui T, Mii S, Nakada H, Matsumoto Y, Yamauchi Y, Takahashi M, Furukawa K, Tetsuya O, Yokoi K, Hasegawa Y, Furukawa K. **Int J Oncol**. 2016 Oct; 49 (4): 1369-76.



253. Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy.  
Sato K, Sato N, Xu B, Nakamura Y, Nagaya T, Choyke PL, Hasegawa Y, Kobayashi H.  
**Sci Transl Med.** 2016 Aug 17; 8 (352): 352ra110.
254. Antineutrophil Cytoplasmic Antibody-associated Vasculitis Superimposed on Infection-related Glomerulonephritis Secondary to Pulmonary Mycobacterium avium Complex Infection.  
Asano S, Mizuno S, Okachi S, Aso H, Wakahara K, Hashimoto N, Ito S, Kozaki Y, Katsuno T, Maruyama S, Hasegawa Y.  
**Intern Med.** 2016; 55 (17): 2439-45.
255. Molecular typing and genetic characterization of Mycobacterium avium subsp. hominissuis isolates from humans and swine in Japan.  
Adachi T, Ichikawa K, Inagaki T, Moriyama M, Nakagawa T, Ogawa K, Hasegawa Y, Yagi T.  
**J Med Microbiol.** 2016 Nov; 65 (11): 1289-1295.
256. An Analysis of Behavioral and Genetic Risk Factors for Chemotherapy-Induced Nausea and Vomiting in Japanese Subjects.  
Mukoyama N, Yoshimi A, Goto A, Kotani H, Ishikawa K, Miyazaki N, Miyazaki M, Yamada K, Kikkawa F, Hasegawa Y, Ozaki N, Noda Y.  
**Biol Pharm Bull.** 2016; 39 (11): 1852-1858.
257. Changes in exercise capacity, muscle strength, and health-related quality of life in esophageal cancer patients undergoing esophagectomy.  
Inoue T, Ito S, Ando M, Nagaya M, Aso H, Mizuno Y, Hattori K, Nakajima H, Nishida Y, Niwa Y, Kodera Y, Koike M, Hasegawa Y.  
**BMC Sports Sci Med Rehabil.** 2016 Nov 3; 8: 34.
258. COPD Assessment Test for measurement of health status in patients with idiopathic pulmonary fibrosis: A cross-sectional study.  
Matsuda T, Taniguchi H, Ando M, Kondoh Y, Kimura T, Kataoka K, Sakamoto K, Suzuki A, Furukawa T, Hasegawa Y.  
**Respirology.** 2017 May; 22 (4): 721-727.
259. Soluble thrombomodulin in bronchoalveolar lavage fluid is an independent predictor of severe drug-induced lung injury.  
Suzuki A, Taniguchi H, Kondoh Y, Ando M, Watanabe N, Kimura T, Kataoka K, Yokoyama T, Sakamoto K, Hasegawa Y.  
**Respirology.** 2017 May; 22 (4): 744-749.
260. The Japanese Respiratory Society Noninvasive Positive Pressure Ventilation (NPPV) Guidelines (second revised edition).  
Akashiba T, Ishikawa Y, Ishihara H, Imanaka H, Ohi M, Ochiai R, Kasai T, Kimura K, Kondoh Y, Sakurai S, Shime N, Suzukawa M, Takegami M, Takeda S, Tasaka S, Taniguchi H, Chohnabayashi N, Chin K, Tsuboi T, Tomii K, Narui K, Hasegawa N, et al.  
**Respir Investig.** 2017 Jan; 55 (1): 83-92.



261. Exogenous induction of unphosphorylated PTEN reduces TGF $\beta$ -induced extracellular matrix expressions in lung fibroblasts.  
Kimura M, Hashimoto N, Kusunose M, Aoyama D, Sakamoto K, Miyazaki S, Ando A, Omote N, Imaizumi K, Kawabe T, Hasegawa Y.  
**Wound Repair Regen.** 2017 Jan; 25 (1): 86-97.
262. Prognostic evaluation by oxygenation with positive end-expiratory pressure in acute exacerbation of idiopathic pulmonary fibrosis: A retrospective cohort study.  
Suzuki A, Taniguchi H, Ando M, Kondoh Y, Kimura T, Kataoka K, Matsuda T, Yokoyama T, Sakamoto K, Hasegawa Y.  
**Clin Respir J.** 2018 Mar; 12 (3): 895-903.
263. The St. George's Respiratory Questionnaire as a prognostic factor in IPF.  
Furukawa T, Taniguchi H, Ando M, Kondoh Y, Kataoka K, Nishiyama O, Johkoh T, Fukuoka J, Sakamoto K, Hasegawa Y.  
**Respir Res.** 2017 Jan 17; 18 (1): 18.
264. Progression of mean pulmonary arterial pressure in idiopathic pulmonary fibrosis with mild to moderate restriction.  
Teramachi R, Taniguchi H, Kondoh Y, Ando M, Kimura T, Kataoka K, Suzuki A, Furukawa T, Sakamoto K, Hasegawa Y.  
**Respirology.** 2017 Jul; 22 (5): 986-990.
265. Modulation of immunological activity on macrophages induced by diazinon.  
Ogasawara N, Matsushima M, Kawamura N, Atsumi K, Yamaguchi T, Ochi H, Kusatsugu Y, Oyabu S, Hashimoto N, Hasegawa Y, Ueyama J, Kawabe T.  
**Toxicology.** 2017 Mar 15; 379:22-30.
266. Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer.  
Kakumu T, Sato M, Goto D, Kato T, Yogo N, Hase T, Morise M, Fukui T, Yokoi K, Sekido Y, Girard L, Minna JD, Byers LA, Heymach JV, Coombes KR, Kondo M, Hasegawa Y.  
**Cancer Sci.** 2017 Apr; 108 (4): 732-743.
267. Hemosiderin-laden macrophages are an independent factor correlated with pulmonary vascular resistance in idiopathic pulmonary fibrosis: a case control study.  
Fukihara J, Taniguchi H, Ando M, Kondoh Y, Kimura T, Kataoka K, Furukawa T, Johkoh T, Fukuoka J, Sakamoto K, Hasegawa Y.  
**BMC Pulm Med.** 2017 Feb 6; 17 (1): 30.
268. Responsiveness to bronchodilator procaterol in COPD as assessed by forced oscillation technique.  
Ito S, Uchida A, Isobe Y, Hasegawa Y.  
**Respir Physiol Neurobiol.** 2017 Jun; 240: 41-47.
269. Twocases of autoimmune pulmonary alveolar proteinosis with rheumatoid arthritis.  
Ito S, Wakahara K, Kojima T, Takahashi N, Nishiwaki K, Yamaguchi E, Hasegawa Y.  
**Allergol Int.** 2017 Jul; 66(3):507-509.



270. Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting. Yoh K, Goto Y, Naito Y, Kishi K, Mori K, Hotta K, Hosomi Y, Yamada K, Tanai C, Tomizawa Y, Inoue A, Hasegawa Y, Nishio M, Ohashi Y, Kunitoh H. **Anticancer Res.** 2017 Mar; 37 (3): 1507-1513.
271. Real-time imaging of mechanically and chemically induced ATP release in human lung fibroblasts. Takahashi K, Ito S, Furuya K, Asano S, Sokabe M, Hasegawa Y. **Respir Physiol Neurobiol.** 2017 Aug; 242:96-101.
272. A case of pulmonary actinomycosis diagnosed by transbronchial lung biopsy. Nakamura S, Kusunose M, Satou A, Senda K, Hasegawa Y, Nishimura K. **Respir Med Case Rep.** 2017 Apr 13; 21: 118-120.
273. CT-determined pulmonary artery to aorta ratio as a predictor of elevated pulmonary artery pressure and survival in idiopathic pulmonary fibrosis. Yagi M, Taniguchi H, Kondoh Y, Ando M, Kimura T, Kataoka K, Furukawa T, Suzuki A, Johkoh T, Hasegawa Y. **Respirology.** 2017 Oct; 22 (7): 1393-1399.
274. Matrix stiffness regulates migration of human lung fibroblasts. Asano S, Ito S, Takahashi K, Furuya K, Kondo M, Sokabe M, Hasegawa Y. **Physiol Rep.** 2017 May; 5 (9). pii: e13281.
275. Smoking Cessation as a Possible Risk Factor for the Development of Aspirin-Exacerbated Respiratory Disease in Smokers. Hayashi H, Fukutomi Y, Mitsui C, Nakatani E, Watai K, Kamide Y, Sekiya K, Tsuburai T, Ito S, Hasegawa Y, Taniguchi M. **J Allergy Clin Immunol Pract.** 2018 Jan - Feb; 6(1):116-125.e3.
276. Depression Is Significantly Associated with the Health Status in Patients with Idiopathic Pulmonary Fibrosis. Matsuda T, Taniguchi H, Ando M, Kondoh Y, Kimura T, Kataoka K, Nishimura K, Nishiyama O, Sakamoto K, Hasegawa Y. **Intern Med.** 2017; 56 (13): 1637-1644.
277. Regional differences in antibiotic-resistant pathogens in patients with pneumonia: Implications for clinicians. Shindo Y, Hasegawa Y. **Respirology.** 2017 Nov; 22 (8): 1536-1546.
278. Pirfenidone as salvage treatment for refractory bleomycin-induced lung injury: a case report of seminoma. Sakamoto K, Ito S, Hashimoto N, Hasegawa Y. **BMC Cancer.** 2017 Aug 7; 17 (1): 526.



279. Frailty and patient-reported outcomes in subjects with chronic obstructive pulmonary disease: are they independent entities?  
Kusunose M, Oga T, Nakamura S, [Hasegawa Y](#), Nishimura K.  
**BMJ Open Respir Res.** 2017 Jul 3; 4 (1): e000196.
280. Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol.  
Takeuchi S, Murayama T, Yoshimura K, Kawakami T, Takahara S, Imai Y, Kuribayashi Y, Nagase K, Goto K, Nishio M, [Hasegawa Y](#), Satouchi M, Kiura K, Seto T, Yano S.  
**J Med Invest.** 2017; 64 (3.4): 317-320.
281. Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J) a study protocol.  
Takeuchi S, Yoshimura K, Fujiwara T, Ando M, Shimizu S, Nagase K, [Hasegawa Y](#), Takahashi T, Katakami N, Inoue A, Yano S.  
**J Med Invest.** 2017; 64 (3.4): 321-325.
282. Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study.  
Goto Y, Tanai C, Yoh K, Hosomi Y, Sakai H, Kato T, Kaburagi T, Nishio M, Kim YH, Inoue A, [Hasegawa Y](#), Isobe H, Tomizawa Y, Mori Y, Minato K, Yamada K, Ohashi Y, Kunitoh H.  
**ESMO Open.** 2017 Sep 14; 2(4):e000214.
283. Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial.  
Tsukuura H, Miyazaki M, Morita T, Sugishita M, Kato H, Murasaki Y, Gyawali B, Kubo Y, Ando M, Kondo M, Yamada K, [Hasegawa Y](#), Ando Y.  
**Oncologist.** 2018 Mar; 23 (3): 367-374.
284. Preoperative six-minute walk distance is associated with pneumonia after lung resection.  
Hattori K, Matsuda T, Takagi Y, Nagaya M, Inoue T, Nishida Y, [Hasegawa Y](#), Kawaguchi K, Fukui T, Ozeki N, Yokoi K, Ito S.  
**Interact Cardiovasc Thorac Surg.** 2018 Feb 1; 26 (2): 277-283.
285. Predominance of Serogroup 19 CC320/271 among Penicillin-Nonsusceptible Streptococcus pneumoniae Isolates after Introduction of the PCV7 Vaccine in Several Regions of Japan.  
Oodate M, Kimura K, Banno H, Yokoyama S, Jin W, Wachino JI, [Hasegawa Y](#), Arakawa Y.  
**Jpn J Infect Dis.** 2018 Jan 23; 71(1):14-20.
286. Th1-related disease development during omalizumab treatment: Two cases with severe asthma.  
Hayashi H, Fukutomi Y, Mitsui C, Watai K, Tomita Y, Kamide Y, Sekiya K, Tsuburai T, Horita A, Saito I, [Hasegawa Y](#), Taniguchi M.  
**Allergol Int.** 2018 Jul; 67 (3): 405-407.
287. Feasibility of tissue re-biopsy in non-small cell lung cancers resistant to previous epidermal growth factor receptor tyrosine kinase inhibitor therapies.  
Uozu S, Imaizumi K, Yamaguchi T, Goto Y, Kawada K, Minezawa T, Okamura T, Akao K, Hayashi M, Isogai S, Okazawa M, Hashimoto N, [Hasegawa Y](#).  
**BMC Pulm Med.** 2017 Dec 6; 17 (1): 175.





288. A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting.  
Tanaka I, Kawada K, Morise M, Hase T, Hayashi H, Sokai A, Fukatsu A, Kondo M, Nomura F, Hasegawa Y.  
**Cancer Chemother Pharmacol**. 2018 Feb; 81 (2): 339-345.
289. Mortality in patients with community-onset pneumonia at low risk of drug-resistant pathogens: Impact of  $\beta$ -lactam plus macrolide combination therapy.  
Okumura J, Shindo Y, Takahashi K, Sano M, Sugino Y, Yagi T, Taniguchi H, Saka H, Matsui S, Hasegawa Y; Central Japan Lung Study Group..  
**Respirology**. 2018 May; 23 (5): 526-534.
290. Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy.  
Omote N, Hashimoto N, Morise M, Sakamoto K, Miyazaki S, Ando A, Nakahara Y, Hasegawa Y.  
**Int J Chron Obstruct Pulmon Dis**. 2017 Dec 11; 12: 3541-3547.
291. Pulmonary tumor thrombotic microangiopathy successfully treated with corticosteroids: a case report.  
Miyazaki S, Ikeda T, Ito G, Inoue M, Nara K, Nishinaga Y, Hasegawa Y.  
**J Med Case Rep**. 2017 Dec 23; 11 (1): 356.
292. Regulation of PD-L1 expression by matrix stiffness in lung cancer cells.  
Miyazawa A, Ito S, Asano S, Tanaka I, Sato M, Kondo M, Hasegawa Y.  
**Biochem Biophys Res Commun**. 2018 Jan 15; 495(3): 2344-2349.
293. Lung Metastases from Bile Duct Adenocarcinoma Mimicking Chronic Airway Infection and Causing Diagnostic Difficulty.  
Sato M, Okachi S, Fukihara J, Shimoyama Y, Wakahara K, Sakakibara T, Hase T, Onishi Y, Ogura Y, Maeda O, Hasegawa Y.  
**Intern Med**. 2018 May 15; 57 (10): 1429-1432.
294. Thin-section computed tomography-determined usual interstitial pneumonia pattern affects the decision-making process for resection in newly diagnosed lung cancer patients: a retrospective study.  
Hashimoto N, Ando A, Iwano S, Sakamoto K, Okachi S, Matsuzaki A, Okada Y, Wakai K, Yokoi K, Hasegawa Y.  
**BMC Pulm Med**. 2018 Jan 5; 18 (1): 2.
295. A scoring system to predict the elevation of mean pulmonary arterial pressure in idiopathic pulmonary fibrosis.  
Furukawa T, Kondoh Y, Taniguchi H, Yagi M, Matsuda T, Kimura T, Kataoka K, Johkoh T, Ando M, Hashimoto N, Sakamoto K, Hasegawa Y.  
**Eur Respir J**. 2018 Jan 18; 51 (1). pii: 1701311.
296. Performance of the St George's Respiratory Questionnaire in patients with connective tissue disease-associated interstitial lung disease.  
Suzuki A, Kondoh Y, Swigris JJ, Ando M, Kimura T, Kataoka K, Yamano Y, Furukawa T, Numata M, Sakamoto K, Hasegawa Y.  
**Respirology**. 2018 Mar 23: 851-859.



297. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study.  
Kobayashi T, Iwama S, Yasuda Y, Okada N, Tsunekawa T, Onoue T, Takagi H, Hagiwara D, Ito Y, Morishita Y, Goto M, Suga H, Banno R, Yokota K, Hase T, Morise M, Hashimoto N, Ando M, Kiyoi H, Gotoh M, Ando Y, Akiyama M, et al.  
**J Endocr Soc.** 2018 Feb 6; 2 (3): 241-251.
298. Pseudomembranous Invasive Tracheobronchial Aspergillosis with Fulminant Hepatitis and Hemophagocytic Syndrome.  
Majima S, Okachi S, Asano M, Wakahara K, Hashimoto N, Sato M, Ishigami M, Hasegawa Y.  
**Intern Med.** 2018 Aug 15; 57(16): 2371-2375.
299. eIF2 $\beta$ , a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer.  
Tanaka I, Sato M, Kato T, Goto D, Kakumu T, Miyazawa A, Yogo N, Hase T, Morise M, Sekido Y, Girard L, Minna JD, Byers LA, Heymach JV, Coombes KR, Kondo M, Hasegawa Y.  
**Cancer Sci.** 2018 Jun; 109 (6): 1843-1852.
300. Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression.  
Hosomi Y, Tanai C, Yoh K, Goto Y, Sakai H, Kato T, Kaburagi T, Nishio M, Kim YH, Inoue A, Hasegawa Y, Isobe H, Tomizawa Y, Mori Y, Minato K, Yamada K, Ohashi Y, Kunitoh H.  
**Expert Opin Pharmacother.** 2018 Jul; 19(10):1049-1056.
301. Japanese guideline for the treatment of idiopathic pulmonary fibrosis.  
Homma S, Bando M, Azuma A, Sakamoto S, Sugino K, Ishii Y, Izumi S, Inase N, Inoue Y, Ebina M, Ogura T, Kishi K, Kishaba T, Kido T, Gemma A, Goto Y, Sasaki S, Johkoh T, Suda T, Takahashi K, Takahashi H, Taguchi Y, et al.  
**Respir Investig.** 2018 Jul; 56 (4): 268-291.
302. Multidimensional improvement in connective tissue disease-associated interstitial lung disease: Two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus.  
Yamano Y, Taniguchi H, Kondoh Y, Ando M, Kataoka K, Furukawa T, Johkoh T, Fukuoka J, Sakamoto K, Hasegawa Y.  
**Respirology.** 2018 Nov; 23 (11): 1041-1048.
303. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.  
Sato M, Matsui A, Shimoyama Y, Omote N, Morise M, Hase T, Tanaka I, Suzuki K, Hasegawa Y.  
**Intern Med.** 2018 Dec 1; 57 (23): 3429-3432.
304. Cyclic stretch enhances reorientation and differentiation of 3-D culture model of human airway smooth muscle.  
Asano S, Ito S, Morosawa M, Furuya K, Naruse K, Sokabe M, Yamaguchi E, Hasegawa Y.  
**Biochem Biophys Rep.** 2018 Sep 22; 16:32-38.





305. Outcomes with newly proposed classification of acute respiratory deterioration in idiopathic pulmonary fibrosis.  
Teramachi R, Kondoh Y, Kataoka K, Taniguchi H, Matsuda T, Kimura T, Yokoyama T, Yamano Y, Furukawa T, Sakamoto K, Hashimoto N, Hasegawa Y.  
**Respir Med.** 2018 Oct; 143:147-152.
306. Sublingual Swelling due to Sublingual Immunotherapy.  
Okumura J, Hashimoto N, Hasegawa Y.  
**J Allergy Clin Immunol Pract.** 2019 Mar; 7 (3): 1032-1033.
307. Validation of the prediction rules identifying drug-resistant pathogens in community-onset pneumonia.  
Kobayashi D, Shindo Y, Ito R, Iwaki M, Okumura J, Sakakibara T, Yamaguchi I, Yagi T, Ogasawara T, Sugino Y, Taniguchi H, Saito H, Saka H, Kawamura T, Hasegawa Y.  
**Infect Drug Resist.** 2018 Oct 11; 11: 1703-1713.
308. Comparison of patient-reported outcomes during acute exacerbations of chronic obstructive pulmonary disease.  
Nishimura K, Nakamura S, Kusunose M, Nakayasu K, Sanda R, Hasegawa Y, Oga T.  
**BMJ Open Respir Res.** 2018 Oct 9; 5 (1): e000305.
309. TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.  
Matsushita A, Sato T, Mukai S, Fujishita T, Mishiro-Sato E, Okuda M, Aoki M, Hasegawa Y, Sekido Y.  
**Oncogene.** 2019 Mar; 38 (11): 1966-1978.
310. Obesity, but not metabolic syndrome, as a risk factor for late-onset asthma in Japanese women.  
Tomita Y, Fukutomi Y, Irie M, Azekawa K, Hayashi H, Kamide Y, Sekiya K, Nakamura Y, Okada C, Shimoda T, Hasegawa Y, Taniguchi M.  
**Allergol Int.** 2019 Apr; 68 (2): 240-246.
311. A 65-nm CMOS Fully Integrated Analysis Platform Using an On-Chip Vector Network Analyzer and a Transmission-Line-Based Detection Window for Analyzing Circulating Tumor Cell and Exosome.  
Niitsu K, Nakanishi T, Murakami S, Matsunaga M, Kobayashi A, Karim NM, Ito J, Ozawa N, Hase T, Tanaka H, Sato M, Kondo H, Ishikawa K, Odaka H, Hasegawa Y, Hori M, Nakazato K.  
**IEEE Trans Biomed Circuits Syst.** 2019 Apr; 13 (2): 470-479.
312. Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations.  
Tanaka I, Morise M, Kodama Y, Matsui A, Ozawa N, Ozone S, Goto D, Miyazawa A, Hase T, Hashimoto N, Sato M, Hasegawa Y.  
**Lung Cancer.** 2019 Jan; 127: 169-171.
313. Photoinduced Ligand Release from a Silicon Phthalocyanine Dye Conjugated with Monoclonal Antibodies: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy.  
Sato K, Ando K, Okuyama S, Moriguchi S, Ogura T, Totoki S, Hanaoka H, Nagaya T, Kokawa R, Takakura H, Nishimura M, Hasegawa Y, Choyke PL, Ogawa M, Kobayashi H.  
**ACS Cent Sci.** 2018 Nov 28; 4 (11): 1559-1569.



314. Longitudinal changes in pulmonary function and respiratory impedance of rheumatoid arthritis. Isobe Y, Ito S, Matsuda T, Iwano S, Uchida A, Takahashi N, Kojima T, Wakahara K, Yamaguchi E, Hasegawa Y. **Respir Physiol Neurobiol**. 2019 Mar; 261:1-8.
315. Effects of Oral Morphine on Dyspnea in Patients with Cancer: Response Rate, Predictive Factors, and Clinically Meaningful Change (CJLSG1101). Takahashi K, Kondo M, Ando M, Shiraki A, Nakashima H, Wakayama H, Kataoka K, Yamamoto M, Sugino Y, Nishikawa M, Imaizumi K, Kojima E, Sumida A, Takeyama Y, Saito H, Hasegawa Y. **Oncologist**. 2019 Jan 18. pii: theoncologist. 2018-0468.
316. Anaplastic lymphoma kinase expression in small-cell lung cancer. Kondoh C, Horio Y, Hayashi Y, Ebi H, Hida T, Hasegawa Y, Yatabe Y. **Histopathology**. 2019 Jul; 75(1):20-28.
317. Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion. Fujisawa T, Mori K, Mikamo M, Ohno T, Kataoka K, Sugimoto C, Kitamura H, Enomoto N, Egashira R, Sumikawa H, Iwasawa T, Matsushita S, Sugiura H, Hashisako M, Tanaka T, Terasaki Y, Kunugi S, Kitani M, Okuda R, Horiike Y, Enomoto Y, Yasui H, et al. **Eur Respir J**. 2019 May 18; 53 (5). pii: 1802243.
318. Performance of the COPD Assessment Test in patients with connective tissue disease-associated interstitial lung disease. Suzuki A, Kondoh Y, Swigris JJ, Matsuda T, Kimura T, Kataoka K, Ando M, Hashimoto N, Sakamoto K, Hasegawa Y. **Respir Med**. 2019 Apr; 150: 15-20.
319. Repressive role of stabilized hypoxia inducible factor 1  $\alpha$  expression on transforming growth factor  $\beta$  -induced extracellular matrix production in lung cancer cells. Ando A, Hashimoto N, Sakamoto K, Omote N, Miyazaki S, Nakahara Y, Imaizumi K, Kawabe T, Hasegawa Y. **Cancer Sci**. 2019 Jun; 110 (6): 1959-1973.
320. BK virus-associated viruria and viremia in a patient with lymphangioleiomyomatosis after lung re-transplantation: A case report and review of the literature on BK virus infection post-lung transplantation. Okumura J, Nakahara Y, Nakaguro M, Shindo Y, Hase T, Wakahara K, Hashimoto N, Hasegawa Y. **J Infect Chemother**. 2019 Apr 23. pii: S1341-321X (19)30095-9.
321. Preoperative six-minute walk distance as a predictor of postoperative complication in patients with esophageal cancer. Inoue T, Ito S, Kanda M, Niwa Y, Nagaya M, Nishida Y, Hasegawa Y, Koike M, Kodera Y. **Dis Esophagus**. 2019 May 20. pii: doz050.



322. Mixed cell type in airway inflammation is the dominant phenotype in asthma patients with severe chronic rhinosinusitis.  
Nishio T, Wakahara K, Suzuki Y, Nishio N, Majima S, Nakamura S, Teranishi M, Nakatochi M, Sone M, Hasegawa Y.  
**Allergol Int.** 2019 Jun 27. pii: S1323-8930 (19)30065-6.
323. Targeting ceramide synthase 6-dependent metastasis-prone phenotype in lung cancer cells.  
Suzuki M, Cao K, Kato S, Komizu Y, Mizutani N, Tanaka K, Arima C, Tai MC, Yanagisawa K, Togawa N, Shiraishi T, Usami N, Taniguchi T, Fukui T, Yokoi K, Wakahara K, Hasegawa Y, Mizutani Y, Igarashi Y, Inokuchi JI, Iwaki S, Fujii S, et al.  
**J Clin Invest.** 2019 Jul 2; 130. pii: 131245.





## 和文業績

1. 下方薫、長谷川好規.  
[肺小細胞癌] 遺伝子治療の開発  
**臨床化学** 29: 613-617; 1993
2. 長谷川好規、恵美宣彦、下方薫.  
肺癌遺伝子療法 — 肺癌治療に突破口をもたらさうか—  
**Medical Practice** 11: 879-881; 1994
3. 長谷川好規、下方薫.  
遺伝子治療の可能性と展望  
**日本胸部疾患学会雑誌** 33: 33-37; 1996
4. 若山尚士、長谷川好規.  
気道過敏性—上気道と下気道の比較—薬剤による気道過敏性の変化  
**アレルギー科** 7: 400-405; 1996
5. 松島敏春、堀江孝之、四元秀毅、長谷川好規、石崎武志、米田尚弘、川根博史、城戸優光.  
結核の制圧と医科大学 その1 (WHO のワークショップの報告)  
**資料と展望** 33: 17-24; 2000
6. 松島敏春、堀江孝之、四元秀毅、長谷川好規、石崎武志、米田尚弘、川根博史、城戸優光.  
結核の制圧と医科大学 その2 (WHO のワークショップの報告)  
**資料と展望** 33: 17-24; 2000
7. 長谷川好規.  
特集 Fc 受容体の基礎と臨床 肺のアレルギー・免疫疾患におけるFc 受容体の役割  
**最新医学** 55: 87-92; 2000
8. 長谷川好規、阿部千代治、飯沼由嗣、鈴木定彦、高橋光良、水口康雄.  
結核—分子遺伝学からのアプローチ  
**結核** 75: 725-728; 2000
9. 長谷川好規.  
講座—呼吸器疾患と分子医学  
**現代医学** 48: 207-213; 2000
10. 安藤雄一、坂英雄、安藤麻紀、下方薫、長谷川好規. 癌化学療法におけるPharmacogenetics —臨床の立場から— **臨床薬理** 32: 479S-480S; 2001
11. 長谷川好規.  
気管支喘息のEBMとDRG/PPS  
**現代医学** 49: 175-178; 2001



12. 今泉和良、長谷川好規、下方薫.  
慢性気管支炎の咳嗽治療  
**総合臨床** 51: 205-206; 2002
13. 長谷川好規、下方薫.  
特集 肺癌治療の個別化「遺伝子多型と肺癌治療」  
**肺癌の臨床** 5: 263-270; 2002
14. 長谷川好規.  
抗がん剤副作用に関する薬理ゲノム研究とテーラーメイド医療  
**癌と化学療法** 30: 325-333; 2003
15. 安藤雄一、安藤麻紀、長谷川好規、下方薫.  
グルクロン酸転移酵素遺伝子多型のタイピング法  
**臨床検査** 48: 177-182; 2004
16. 太田 宏、宮崎 豊、中島捷久、長谷川好規、水野芳樹、飯沼雅朗.  
座談会－新興・再興感染症の新たな展開－新型肺炎SARS(重症急性呼吸器症候群を中心として)  
**現代医学** 51: 441-485; 2004
17. 長谷川好規.  
成人市中肺炎ガイドラインと耐性菌の動向  
**名古屋内科医学会誌** 117: 15-26; 2004
18. 長谷川好規.  
アママシバによる閉塞性細気管支炎  
**医学のあゆみ** 210: 300; 2004
19. 長谷川好規.  
閉塞性細気管支炎の現状と課題  
**日本胸部臨床** 63: 930-935; 2004
20. 長谷川好規.  
「アママシバ」と閉塞性細気管支炎  
**現代医学** 52: 263-270; 2004
21. 長谷川好規.  
イレッサ その光と影  
**日本薬理学雑誌** 125: 233; 2005
22. 長谷川好規.  
臓器移植における末梢気道病変  
**呼吸器科** 7: 238-242; 2005
23. 長谷川好規.  
Pharmacogenomics for Cancer Therapy塩酸イリノテカンの薬理ゲノム学  
**がん分子標的治療** 3: 238-244; 2005





24. 長谷川好規.  
薬剤代謝酵素の遺伝子多型解析－遺伝情報に基づく個別化がん化学療法に向けて－  
**臨床薬理の進歩** 26: 10-19; 2005
25. 長谷川好規.  
特集:この疾患はどう変わってきたか (内科領域) 呼吸器分野  
**現代医学** 52: 379-382; 2005
26. 長谷川好規.  
移植片対宿主病の肺病変  
**日本醫事新報** 4249: 92-93; 2005
27. 長谷川好規.  
遺伝子多型に基づく層別化を用いた抗がん剤毒性回避のための臨床研究  
**がん治療のあゆみ** 25: 53-57; 2005
28. 長谷川好規.  
難治性呼吸器疾患 病態解明と治療の最前線 細気管支炎  
**Modern Physician** 26: 410-413; 2006
29. 長谷川好規.  
基礎(特集)薬理遺伝学と個別化治療  
**'05 CPT-11 Update** 6-7; 2006
30. 長谷川好規.  
遺伝子多型に基づくCPT-11 の副作用の予測  
**コンセンサス癌治療** 5: 222; 2006
31. 長谷川好規.  
ファーマコジェネティクスとファーマコゲノミクス  
**現代医学** 54: 296; 2006
32. 長谷川好規.  
閉塞性細気管支炎の診断と治療  
**内科** 99: 275-278; 2007
33. 安藤雄一、長谷川好規.  
塩酸イリノテカン－その副作用リスクの予測とグルクロン酸転移酵素 (UGT1A1)遺伝子多型－  
**呼吸器科** 11: 135-141; 2007
34. 長谷川好規.  
塩酸イリノテカンの薬物代謝動態と個別化医療  
**分子呼吸器病** 11: 169-175; 2007
35. 今泉和良、長谷川好規.  
特集/ 薬物間相互作用 8. 呼吸器・感染症領域  
**臨床薬理 (Jan J Clin Pharmacol Ther)** 38: 45-50; 2007



36. 近藤征史、長谷川好規.  
臨床遺伝子学 '07 -ゲノム科学の臨床へのインパクト- 薬剤感受性:肺癌におけるEGFR阻害薬を  
中心に  
**最新医学 (9月増刊号)** 62: 2186-2193; 2007
37. 安藤麻紀、安藤雄一、長谷川好規.  
薬理ゲノム情報に基づく個別化治療  
**ゲノム医学** 7: 199-202; 2007
38. 長谷川好規.  
肺癌UPDATE- 研究と臨床の最前線  
**医学のあゆみ** 224: 1171-1174; 2007
39. 長谷川好規.  
〔III〕閉塞性肺疾患、気管支の異常. A 閉塞性肺疾患 細気管支炎.  
**別冊 日本臨床 新領域別症候群シリーズ No8. 呼吸器症候群 (第2版)** 639-641; 2008
40. 長谷川好規.  
薬剤副作用予測のバイオマーカー.  
**医学のあゆみ** 224: 1171-1174; 2008
41. 長谷川好規.  
閉塞性細気管支炎の現状  
**日本内科学会雑誌** 97: 135-139; 2008
42. 今泉和良、橋本泉、長谷川好規.  
「アマメシバ」摂取による閉塞性細気管支炎.  
**いわゆる健康食品・サプリメントによる健康被害症例集** 40-43; 2008
43. 進藤有一郎、長谷川好規.  
HCAP (Healthcare-associated pneumonia: 医療ケア関連肺炎)の対応と治療戦略.  
**MEDICAMENT NEWS** 1965: 2-6; 2008
44. 田村真理子、近藤征史、長谷川好規.  
抗癌剤のPK・PDと遺伝子診断  
**医薬ジャーナル** 44: 67-7; 2008
45. 長谷川好規.  
研究の周辺から 免疫応答の場としての肺とその疾患  
**呼吸** 27: 1-2; 2008
46. 長谷川好規.  
呼吸器疾患の臨床検査 up to date 呼吸器疾患におけるファーマコゲノミクス  
**日本胸部臨床 (増刊)** 67: S283-S287; 2008
47. 長谷川好規.  
がん薬物療法学 V. 抗悪性腫瘍薬の薬理学・薬力学・薬理遺伝学 2. 薬物動態・薬力学  
**日本臨床 (増刊号)** 67: Supple1 332-336; 2009



48. 近藤征史、堀尾美穂子、長谷川好規.  
遺伝子多型、遺伝子変異と肺癌の個別化医療  
**治療学** 43: 290-294; 2009
49. 長谷川好規.  
抗がん剤の薬理遺伝学  
**呼吸器科** 15: 147-151; 2009
50. 長谷川好規.  
分化と統合  
**呼吸と循環** 57: 447; 2009
51. 長谷川好規.  
癌における遺伝子と臨床 抗癌薬の有害事象ーイリノテカンの有害事象を主としてー  
**日本胸部臨床** 68: 628-635; 2009
52. 長谷川好規.  
遺伝子多型診断に基づいた塩酸イリノテカンによる化学療法の至適投与量と副作用予測  
**日本病院薬剤師会雑誌** 45: 1472-1474; 2009
53. 下方智也、長谷川好規.  
診療科で注目される分子標的治療ー呼吸器領域ー  
**現代医学** 57: 17-19; 2009
54. 今井直幸、今泉和良、長谷川好規.  
Quiz 呼吸ケアのための画像診断  
**呼吸器ケア** 8: 31-33; 2009
55. 宮崎雅之、野田幸裕、田中純代、近藤征史、堀尾美穂子、長谷川好規、安藤雄一、山田清文.  
がん疼痛コントロールのための標準プロトコール作成とその臨床評価  
**癌と化学療法** 17: 62-70; 2010
56. 進藤有一郎、長谷川好規.  
医療ケア関連肺炎 (health-care-associated pneumonia; HCAP) 新たな肺炎の概念  
**呼吸器内科** 17: 62-70; 2010
57. 進藤有一郎、長谷川好規.  
HCAP(医療ケア関連肺炎)はCAPやHAPとは対応が異なる感染症 up to date ~ 日常遭遇する感染症への対処法~  
**Modern Physician** 5: 608-614; 2010
58. 長谷川好規.  
新しい診断と治療のABC 胸膜・縦隔・胸壁・横隔膜の疾患 第3章 縦隔疾患 総論  
**最新医学・別冊** 68: 53-58; 2010
59. 長谷川好規.  
新しい診断と治療のABC 胸膜・縦隔・胸壁・横隔膜の疾患 (座談会)  
**最新医学・別冊** 68: 158-165; 2010



60. 長谷川好規.  
臨床遺伝子学'10 呼吸器疾患の遺伝子学  
**最新医学・9月増刊号** 65: 1994-2007; 2010
61. 進藤有一郎、長谷川好規.  
肺炎の分類 CAP(市中肺炎) HCA(医療ケア関連肺炎) HAP(院内肺炎)  
**総合臨床** 59: 2034-2040; 2010
62. 宮崎雅之、近藤征史、長谷川好規.  
肺がん患者における痛みの新しい評価  
**日本薬剤師会雑誌** 62: 81-85; 2010
63. 長谷川好規.  
解説 臨床 閉塞性細気管支炎  
**呼吸** 29: 1169-1172; 2010
64. 進藤有一郎、長谷川好規.  
HCAP (Health-care-associated pneumonia: 医療ケア関連肺炎) 新たな肺炎の概念  
**Geriatric Medicine** 48: 1307-1316; 2010
65. 安藤麻紀、長谷川好規.  
II 角薬剤の臨床薬理学的特徴と使い方 2 抗がん剤 ④プリン拮抗薬1. メルカプトプリン  
**抗悪性腫瘍薬コンサルトブック** 184-188; 2010
66. 今泉和良、長谷川好規.  
造血幹細胞移植後の呼吸器合併症  
**呼吸器疾患最新の治療** 370-373; 2010.
67. 岩田 晋、長谷川好規.  
8. 各種疾患と睡眠障害 4. 呼吸器疾患  
**基礎からの睡眠医学** 373-379; 2010
68. 芝崎正宗、川部勤、長谷川好規.  
CD40 遺伝子欠損と続発性肺胞蛋白症  
**呼吸** 29: 134-140; 2010
69. 下方智也、長谷川好規.  
診療科で注目される分子標的治療 -呼吸器領域-  
**現代医学** 57; 2010.
70. 進藤有一郎、長谷川好規.  
医療ケア関連肺炎: 何を選んでどう使うか?  
**最新抗菌薬療法マニュアル** 56-63; 2010
71. 橋本直純、長谷川好規.  
5. 間質性肺炎と肺線維症 臨床的新展開6 間質性肺炎と発がん  
**治療学** 44: 66-70; 2010



72. 宮崎雅之、近藤征史、長谷川好規.  
肺がん患者における痛みの新しい評価  
**日本薬剤師会雑誌** 62: 81-85; 2010
73. 宮崎雅之、野田幸裕、田中純代、近藤征史、堀尾美穂子、長谷川好規、安藤雄一、山田清文.  
がん疼痛コントロールのための標準プロトコール作成とその臨床評価  
**癌と化学療法** 37: 285-290; 2010
74. 今泉和良、長谷川好規.  
GVHD の肺病変 移植後の閉塞性細気管支炎・肺病変の診断・治療.  
**日本胸部臨床** 69: 915-923; 2010
75. 小栗知世、伊藤理、森下真梨子、阪本考司、近藤征史、長谷川好規.  
インフリキシマブ投与中に急増する胸腹水を伴う粟粒結核を発症した関節リウマチの1例.  
**日呼吸会誌** 48: 192-197; 2010
76. 岸里奈、宮崎雅之、桐山典子、進藤有一郎、近藤征史、今泉和良、毛利彰宏、山田清文、長谷川好規.  
肺がん患者におけるオピオイドによる副作用の増悪因子の探索  
**日本緩和医療薬学雑誌** 3: 85-92; 2010
77. 近藤征史、小栗知世、長谷川好規.  
抗がん剤の副作用予測因子としてのバイオマーカー.  
**呼吸器内科** 17: 241-245; 2010
78. 進藤有一郎、長谷川好規、八木哲也、高橋正樹、吉田 茂.  
ユーザーメイド肺炎データベースと基幹システムとの連携: 診療支援・教育・多施設共同前向き研究ツールへの応用と課題.  
**医療情報学** 30 (Suppl.): 591-594; 2010
79. 進藤有一郎、長谷川好規.  
医療ケア関連肺炎 (Health-Care-Associated Pneumonia: HCAP)の対応と治療戦略.  
**Infection File** 29: 9;2010
80. 長谷川好規.  
胸膜・縦隔・胸壁・横隔膜の疾患 (編集: 下方薫)  
**新しい診断と治療のABC** 68 53-58; 2010
81. 長谷川好規.  
閉塞性細気管支炎  
**成人病と生活習慣病** 40: 708-710; 2010
82. 長谷川好規.  
呼吸器系疾患の遺伝子学  
**臨床遺伝子学** 10: 65: 38-45; 2010
83. 宮崎雅之、野田幸裕、田中純代、近藤征史、堀尾美穂子、長谷川好規、安藤雄一、山田清文.  
がん疼痛コントロールのための標準プロトコール作成とその臨床評価  
**癌と化学療法** 37: 285-290; 2010



84. 宮崎雅之、近藤征史、長谷川好規.  
肺癌患者における痛みの新しい評価 (解説)  
**日本薬剤師会雑誌** 62: 1445-1449; 2010
85. 森瀬昌宏、長谷川好規.  
変異EGFRを伴う非小細胞肺癌に対するゲフィチニブと化学療法の比較 ～世界の医学誌から～  
**Mainichi Medical Journal** 2010
86. 森瀬昌宏、長谷川好規.  
解説 EGFR変異陽性1st lineゲフィチニブ療法の確立  
**MMJ** 7: 19; 2011
87. 長谷川好規  
日本内科学会生涯教育講演会 4. 閉塞性細気管支炎の病態と治療  
**日本内科学会雑誌** 100: 772-776; 2011
88. 橋本直純、長谷川好規  
サプリメントによる薬剤性肺障害  
**呼吸器内科** 20: 153-157; 2011
89. 今泉和良、橋本泉、長谷川好規閉  
塞性細気管支炎  
**総合臨床** 60: 2470-2477; 2011
90. 伊藤理、長谷川好規.  
13章. 気道.  
コリンズ・スターン胸部画像診断エッセンシャル 246-271; 2011
91. 進藤有一郎、長谷川好規.  
第IV章 欧米ガイドラインとの比較 3. クライテリア  
**ガイドラインサポートハンドブック呼吸器感染症** 121-127; 2011.
92. 長谷川好規.  
Annual Review 呼吸器 上皮一問葉転換.  
**中外医薬社** 64-65; 2011
93. 長谷川好規.  
(日本呼吸器学会びまん性肺疾患 診断・治療ガイドライン作成委員会)  
**特発性間質性肺炎診断と治療の手引き 改訂第2版**; 2011.
94. 長谷川好規.  
エビデンスと診療ガイドライン  
**ガイドラインサポートハンドブック 呼吸器感染症** 378-381; 2011
95. 森瀬昌宏、長谷川好規.  
症例から学ぶメディカルオンコロジー局所進行非小細胞肺癌症例.  
**医薬ジャーナル** 30-37; 2011



96. 進藤有一郎、長谷川好規.  
NHCAP の特徴は？ : 重症度と耐性菌のリスクについて.  
**医薬ジャーナル** 47: 113-117; 2011
97. 進藤有一郎、長谷川好規.  
NHCAP の実態.  
**メディカル朝日** 40: 18-19; 2011
98. 進藤有一郎、長谷川好規.  
呼吸器感染症ガイドラインの評価と今後の課題: 医療ケア関連肺炎.  
**化学療法の領域** 27: 117-124; 2011
99. 藤有一郎、長谷川好規.  
新たな肺炎の概念—「医療ケア関連肺炎」の臨床.  
**分子呼吸器病** 15: 58-65; 2011
100. 高橋和久、長谷川好規、佐々木治一郎.  
肺癌: 進行非小細胞肺癌の個別化治療の考え方.  
**カレントセラピー** 29: 1054-1063; 2011
101. 長谷川好規  
閉塞性細気管支炎の病態と治療  
**日本内科学会雑誌** No.3 100: 772-776; 2011
102. 長谷川好規.  
新たな肺炎の治療概念～ NHCAP ～  
**現代医学** 59: 296; 2011
103. 山田真之亮、桑原宏貴、浅井玲名、小谷悠、岸里奈、平林彩、水野智博、長谷川雅哉、毛利彰浩、久米裕昭、伊藤理、長谷川好規、鍋島俊隆、山田清文、野田幸裕.  
外来喘息教室における吸入指導後の症状・アドヒアランス及び患者満足度の評価.  
**Yakugaku Zasshi** 131: 1629-1638; 2011
104. 伊藤理、長谷川好規.  
[特集] 細胞力覚: メカノセンシングが生命機能を生み出す: 呼吸器のメカノバイオロジー.  
**細胞工学** 31: 1014-1029; 2012
105. 稲田めぐみ、下方智也、杉下美保子、長谷川好規、安藤雄一.  
パニツブマブとの関連が疑われた間質性肺疾患の3 例  
**日本呼吸器学会** 1: 46-50; 2012
106. 内田明美、伊藤理、吉子健一、松原宏紀、松本祐之、長谷川好規.  
オシレーション法による呼吸インピーダンス測定におけるマウスピースの影響について.  
**医学検査** 61: 986-990; 2012
107. 島津哲子、武田直也、松井彰、馬嶋俊、宮沢亜矢子、岡田木綿、鈴木嘉洋、加藤聡之、岩田勝、長谷川好規.  
間質性肺炎の進行に肺アスペルギルス症を合併したHermansky-Pudlak 症候群の1 剖検例  
**日本内科学会雑誌** 101: 1072-1074; 2012





108. 進藤有一郎、長谷川好規.  
医療・介護関連肺炎 (NHCAP) 抗菌薬の選択と使い方  
**呼吸器科領域** 244-251; 2012
109. 進藤有一郎、長谷川好規.  
医療・介護関連肺炎の定義と病態  
**月刊ナーシング** 32: 10-13; 2012
110. 進藤有一郎、長谷川好規.  
NHCAP の診断と治療  
**成人病と生活習慣病** 42: 1287-1291; 2012
111. 阪本考司、長谷川好規.  
Bronchiolitis Obliterans (閉塞性細気管支炎)  
**呼吸と循環** 9 (60): 379-384; 2012
112. 阪本考司、橋本直純、長谷川好規.  
閉塞性細気管支炎 1) アマメシバ、GVHD などの臨床  
**日本胸部臨床 増刊号** 71: 204-208; 2012
113. 佐藤光夫、長谷川好規.  
EMT と肺癌  
**SURGERY FRONTIER** 19: 281-290; 2012
114. 田中純代、小谷悠、宮崎雅之、平林彩、室崎千尋、山下加織、岸里奈、毛利彰宏、近藤征史、下方薫、長谷川好規、山田清文、野田幸裕.  
肺癌患者の疼痛緩和治療における胃酸分泌抑制薬の使用状況  
**癌と化学療法** 39: 251-256; 2012
115. 橋本直純、長谷川好規.  
9. 血液疾患および臓器移植後の肺病変  
**間質性肺炎を究める** 275-279; 2012
116. 橋本直純、今泉和良、長谷川好規.  
TGF $\beta$  誘導上皮間葉移行における $\beta$ catenin 細胞質内移行に対するPTEN リン酸化部位制御の重要性  
**厚生労働科学研究費補助金 難治性疾患克服研究事業、びまん性肺疾患に関する調査研究 平成24年度研究報告書** 311-314; 2012
117. 長谷川好規.  
疾患中心の医療から包括的医療への転換  
**呼吸器ケア** 10-8: 99999128; 2012
118. 長谷川好規、河野 茂、浅野和典、吉田雅博.  
肺炎を中心とした呼吸器感染症診療ガイドラインの今後の展望  
**THE JAPANESE JOURNAL OF ANTIBIOTICS** 65-5, 291-304; 2012



119. 長谷川好規、橋本直純.  
びまん性汎細気管支炎・閉塞性細気管支炎 部門報告  
**第2回閉塞性細気管支炎全国調査研究—個別症例検討会—厚生労働科学研究費補助金 難治性疾患克服研究事業、びまん性肺疾患に関する調査研究 平成24年度研究報告書** 399-400; 2012
120. 長谷川好規.  
アレルギー／気管支喘息・過敏性肺炎・サルコイドーシス  
**免疫学コア講義** 3: 224-226; 2012
121. 長谷川好規.  
アレルギーの臨床研究とエビデンスの創出  
**アレルギーの臨床** 425: 13; 2012
122. 伊藤理、長谷川好規.  
気道病変を伴ったIgG4 関連疾患症例の検討.  
**Therapeutic Research** 35: 511-512; 2014
123. 武田直也、伊藤理、指尾豊和、平松哲夫、木村智樹、大林浩幸、馬場研二、若原恵子、若山尚士、今泉和良、川部勤、長谷川好規.  
呼吸器内科医を対象とした喘息治療ステップダウンの実態調査.  
**アレルギー・免疫** 21: 688-696; 2014
124. 十九浦宏明、伊藤準、高木達也、福島 曜、松本政実、満間照之、長谷川好規. 頭  
皮原発血管肉腫による続発性気胸4例の検討.  
**皮膚科の臨床** 56: 120-124; 2014
125. 永井智子、浅井玲名、後藤綾、椿井朋、肥田裕丈、毛利彰宏、宮崎雅之、久米裕昭、伊藤理、長谷川好規、山田清文、野田幸裕.  
薬剤師外来における吸入指導：服薬アドヒアランスに影響を与える要因.  
**医療薬学** 40: 370-382. 2014
126. 永谷元基、伊藤理、麻生裕紀、林尊弘、井上貴行、眞鍋朋誉、加古誠人、鳥山実、水野陽太、石黒直樹、長谷川好規.  
開胸開腹術後の歩行獲得を長期化させる因子の検討.  
**愛知県理学療法学会誌** 26: 8-13; 2014
127. 橋本直純、長谷川好規  
間質性肺炎がもたらす組織微小環境と組織微小環境誘導上皮間葉移行に対するPTEN リン酸化部位制御の重要性.  
**厚生労働科学研究費補助金 難治性疾患克服研究事業、びまん性肺疾患に関する調査研究 平成25年度研究報告書** 263-26; 2014
128. 橋本直純、長谷川好規、今泉和良.  
びまん性汎細気管支炎・閉塞性細気管支炎 部門報告  
**第2回閉塞性細気管支炎全国調査研究 厚生労働科学研究費補助金難治性疾患克服研究事業、びまん性肺疾患に関する調査研究 平成26年度研究報告書** 375-379; 2014



129. 長谷川好規.  
肺癌の病因  
**日本内科学会雑誌** 103: 1261-1266; 2014
130. 長谷川好規、橋本直純、今泉和良.  
びまん性汎細気管支炎・閉塞性細気管支炎 部門報告  
**第2回閉塞性細気管支炎全国調査研究 厚生労働科学研究費補助金 難治性疾患克服研究事業、びまん性肺疾患に関する調査研究 平成25年度研究報告書** 375-379; 2014
131. 森瀬昌宏、長谷川好規.  
環境因子と呼吸器悪性腫瘍.  
**呼吸と循環** 62 (10): 963-968; 2014
132. 伊藤理、長谷川好規.  
機械的ストレス実験  
**呼吸** 34: 963-968; 2015
133. 岡地祥太郎、長谷川好規.  
肺癌の腫瘍随伴症候群.  
**呼吸と循環** 64: 631-635; 2016
134. 佐野将宏、橋本直純、岡田木綿、佐藤光夫、宮崎雅之、長谷川好規.  
クリゾチニブの減感作療法により再投与が可能であった肺腺癌の1例  
**肺癌** 56: 3215-218; 2016
135. 若原恵子、長谷川好規.  
気管支喘息 病気とくすり2016 基礎と実践Expert's Guide  
**薬局** 67 (4): 632-641; 2016
136. 長谷川好規 (作成委員として)  
特発性肺線維症の治療ガイドライン  
**2017 厚生労働科学研究費補助金 難治性疾患政策研究事業 「びまん性肺疾患に関する調査研究」 班特発性肺線維症の治療ガイドライン作成委員会** 74; 2017
137. 進藤有一郎、長谷川好規.  
肺炎における薬剤耐性菌リスクと抗菌治療  
**分子呼吸器病** 21: 52-55; 2017
138. 若原恵子、長谷川好規.  
A. 呼吸器系疾患 気管支喘息  
**薬局2017年3月増刊号 病気とくすり基礎と実践** 68: 646-655; 2017
139. 相編集、矢崎義雄 編集、長谷川好規、他  
9. 呼吸器系の疾患  
**内科学** 11: 707-868; 2017



140. 若原恵子、川部勤、長谷川好規.  
第5章-4 抗アレルギー薬、第5章-5 ステロイド薬、第5章-6 花粉症、第5章-7 気管支喘息、第5章-13 衛生仮説  
**免疫ペディア101のイラストで免疫学・臨床免疫学に強くなる!** 192-193, 196-198, 199-200, 213-214; 2017
141. 橋本直純、長谷川好規.  
**難治性びまん性肺疾患診療の手引き**; 2017
142. 川部勤、長谷川好規.  
アレルギー／気管支喘息・過敏性肺炎・サルコイドーシス・アナフィラキシー・薬物アレルギー・食物アレルギー・アレルギー性鼻炎・花粉症・アレルギー性結膜疾患・血清病  
**免疫学コア講義** 228-237; 2017
143. 長谷川好規、編集: 滝澤始.  
びまん性汎細気管支炎 (DPB)は今もあるんですか?  
**おかしの頭で診ていませんか?呼吸器診療をスッキリまとめました** 42-46; 2017
144. 橋本直純、長谷川好規.  
閉塞性細気管支炎  
**呼吸器内科** 32 (5): 460-463; 2017
145. 阪本考司、橋本直純、長谷川好規  
閉塞性細気管支炎 (GVHD を含めて)  
**呼吸器内科** 31 (5): 436-442; 2017
146. 橋本直純、長谷川好規.  
II. 各疾患のBAL 所見と検査の意義閉塞性細気管支炎」日本呼吸器学会びまん性肺疾患学術部会  
**厚生労働科学研究費補助金難治性疾患政策研究事業「びまん性肺疾患に関する調査研究」班編  
改訂第3版 気管支肺胞洗浄【BAL】法の手引き** 148-150; 2017
147. 進藤有一郎、長谷川好規.  
院内肺炎、医療・介護関連肺炎の抗菌薬治療  
**Medical Practice** 4: 617-622; 2018
148. 阪本考司、長谷川好規.  
器質化肺炎  
**呼吸器疾患 診断治療アプローチ** 4: 198-203; 2018
149. 長谷川好規、佐藤光夫、森瀬昌宏、田中一大.  
大気・室内環境関連疾患  
**予防と対策の手引き (一般社団法人 日本呼吸器学会)**; 2019
150. 長谷川好規.  
第46回内科学の展望 内科医, general physician に必要な免疫・炎症学update  
**日本内科学会誌** 108 (3): 379-380; 201

# 国際学会発表


## シンポジウム

1. Hasegawa Y.  
Pharmacogenomics in cancer chemotherapy.  
1st Japan-Korea Joint Symposium of Clinical and Therapeutics, Beppu, Japan. 2005.
2. Hasegawa Y.  
Translational Pharmacogenomics: Cancer Chemotherapy.  
Impact of UGT and Transporter genes polymorphisms in cancer chemotherapy.  
2008 International Conference on Pharmacogenomics, Busan, Korea. 2012


## 一般演題

1. Lai H, Mizoguchi K, Hasegawa Y., Nagase F, Isobe K, Kawashima K, Shimokata K, Nakashima I.  
Preferential inhibition by antibody of priming for second set rejection of tumor allografts.  
6th International Congress of Immunology. Toronto, Canada. 1986.
2. Hasegawa Y., Bonavida B.  
Calcium independent pathway of TNF-mediated tumor cell lysis.  
2nd International Conference on Tumor Necrosis Factor. Napa Valley, U.S.A. 1989.
3. Hasegawa Y., Jewett A, Bonavida B.  
Monocyte-mediated cytotoxicity is Ca<sup>++</sup> independent.  
7th International Congress of Immunology. Berlin, Germany. 1989.
4. Hasegawa Y., Kawatsu H, Takagi E, Shimokata K.  
Human alveolar macrophages of anergic patients with lung cancer lack the responsiveness to recombinant interferon gamma.  
American Lung Association/American Thoracic Society. Anaheim, U.S.A. 1991.
5. Nomura F, Hasegawa Y., Shimokata K.  
Isobologram analysis of drug interactions between CPT-11 and VP-16/ADM using colorimetric tetrazolium-based (MTT) assay.  
American Lung Association/American Thoracic Society. Anaheim, U.S.A. 1991.
6. Hasegawa Y., Shimokata K, Emi N, Kawabe T, Abe A, Saito H.  
Gene transfer of herpes simplex virus type 1 thymidine kinase gene as a drug sensitivity gene into human lung cancer cell lines using retroviral vectors.  
American Lung Association/American Thoracic Society. Miami, U.S.A. 1992.
7. Watanabe A, Shimokata K, Saka H, Hasegawa Y., Horio Y, Sakai S, Nomura F, Iwahara T, Minami H.  
Hyperfractionated radiotherapy combined with chemotherapy (cisplatin, vinblastine, and mitomycin C) for inoperable, locally advanced non-small cell lung cancer.  
American Lung Association/American Thoracic Society. Miami, U.S.A. 1992.
8. Watanabe A, Saka H, Hasegawa Y., Shimokata K, Senda K, Minami H, Nomura F, Sakai S.  
Fever and bacteremia following transbronchial biopsy.  
7th World Congress of Bronchology. Rochester, U.S.A. 1992.
9. Hasegawa Y., Shimokata K, Emi N, Kirioka T, Abe A, Saito H.  
Inhibitory effect of ganciclovir in vivo for herpes simplex virus thymidine kinase gene transfected tumor clone derived from malignant pleural effusion.  
American Lung Association/American Thoracic Society. San Francisco, U.S.A. 1993.
10. Nakao A, Tsuchiya Y, Hasegawa Y., Shimokata K.  
Immunohistochemical study of endothelial cell adhesion molecules in idiopathic pulmonary fibrosis.  
American Lung Association/American Thoracic Society. San Francisco, U.S.A. 1993.
11. Watanabe A, Saka H, Shimokata K, Nakashima K, Yamada Y, Nomura F, Hasegawa Y., Yamamoto M, Takagi E, Sakai S.

- Prophylactic administration of oral antibiotics for patients undergoing fiberoptic bronchoscopy.  
American Lung Association/American Thoracic Society. Boston, U.S.A. 1994.
12. Watanabe A, Nishiwaki K, Hasegawa Y, Saka H, Shimokata K.  
Effect of Taxotere (Docetaxel) and Irinotecan (CPT-11) combined with radiation on lung cancer cell lines.  
31st American Society of Clinical Oncology. Los Angeles, U.S.A. 1995.
  13. Nozaki Y, Hasegawa Y, Shimokata K.  
Nitric oxide as an inflammatory mediator of radiation pneumonitis in rats.  
American Lung Association/American Thoracic Society. New Orleans, U.S.A. 1996.
  14. Wakayama H, Hasegawa Y, Shimokata K.  
The effect of oral beta2-agonist procaterol to asthma control.  
American Lung Association/American Thoracic Society. New Orleans, U.S.A. 1996.
  15. Nozaki Y, Hasegawa Y, Shimoikata K.  
Nitric oxide dependent killing mechanism of mycobacterium bovis BCG in human alveolar macrophages.  
American Lung Association/American Thoracic Society. San Francisco, U.S.A. 1997.
  16. Imaizumi K, Hasegawa Y, Kawabe T, Wakayama H, Shimokata K.  
Alveolar macrophage mediated tumoricidal activity enhanced by the ligand for CD40.  
American Lung Association/American Thoracic Society. San Francisco, U.S.A. 1997.
  17. Takagi N, Hasegawa Y, Ichiyama S, Shibagaki T, Shimokata K.  
Polymerase chain reaction of pleural biopsy specimen for rapid diagnosis of tuberculous pleuritis.  
American Lung Association/American Thoracic Society. San Francisco, U.S.A. 1997.
  18. Ohara H, Hasegawa Y, Katayama H, Imaizumi K, Shimoikata K.  
Transduction of tumor necrosis factor receptors gene into human lung carcinoma cell line.  
American Lung Association/American Thoracic Society San Francisco, U.S.A. 1997.
  19. Horio Y, Shimokata K, Jack A R, Hasegawa Y.  
In vitro effects of a recombinant p53-expressing adenovirus in combination with anti-cancer agents.  
American Lung Association/American Thoracic Society Chicago, U.S.A. 1998.
  20. Ohara H, Hasegawa Y, Kawabe T, Imaizumi K, Shimokata K, Nishiwaki K.  
Gene transfer of tumor necrosis factor receptors and its mutant receptor into human lung carcinoma.  
American Lung Association/American Thoracic Society Chicago, U.S.A. 1998.
  21. Wakayama H, Hasegawa Y, Kawabe T, Kikutani H, Shimokata K.  
IgG-mediated anaphylaxis via Fcγ-receptor in CD40-deficient mice.  
American Lung Association/American Thoracic Society Chicago, U.S.A. 1998.
  22. Hasegawa Y, Nakane Y, Kawabe T, Imaizumi K, Iinuma Y, Sekido Y, Shimokata K.  
Soluble VCAM-1 in bronchoalveolar lavage fluid in patients with hypersensitivity pneumonitis.  
American Lung Association/American Thoracic Society Toronto, Canada. 2000.
  23. Hara T, Hasegawa Y, Kawabe T, Wakayama H, Hashimoto N, Tokuoka S, Nagai H, Shimokata K.  
Airway hyperresponsiveness and eosinophilic inflammation develop in response to inhaled antigen in CD40-deficient mice.  
American Lung Association/American Thoracic Society Toronto, Canada. 2000.
  24. Kawabe T, Hasegawa Y, Hashimoto N, Shimokata K.  
Growth arrest induced by ligand activation of peroxisome proliferator-activated receptor gamma on human lung cancer cells.  
American Lung Association/American Thoracic Society Toronto, Canada. 2000.



25. Imaizumi K, Noguchi M, Kawabe T, Wakayama H, Horio Y, Hara T, Hashimoto N, Shimokata K, Hasegawa Y.  
Induction of anti-tumor immunity by transduction of CD40 ligand gene into lung cancer cells.  
American Lung Association/American Thoracic Society Toronto, Canada. 2000.
26. Hashimoto N, Kawabe T, Hara T, Imaizumi K, Wakayama H, Shimokata K, Hasegawa Y.  
Inhibitory effect of erythromycin on matrix metalloproteinase-9 (MMP-9) activity and cell migration.  
American Lung Association/American Thoracic Society Toronto, Canada. 2000.
27. Hasegawa Y, Wakayama H, Kawabe T, Shimokata K.  
The role of Fc-receptor in experimental Goodpasture's glomerulonephritis and pneumonitis.  
THE CREST International Symposium on Immunoglobulin-Like Receptors, Sendai, Japan. 2000.
28. Nozaki Y, Hasegawa Y, Shimamoto K, Hashimoto N, Nishiwaki K, Shimokata K, Phan S.  
Telomerase activity in human alveolar fibroblasts from interstitial pneumonias patients.  
American Lung Association/American Thoracic Society Atlanta, U.S.A. 2002.
29. Hashimoto N, Kawabe T, Imaizumi K, Hara T, Shimokata K, Hasegawa Y.  
CD40 plays a crucial role for LPS-induced acute lung injury.  
American Lung Association/American Thoracic Society Atlanta, U.S.A. 2002.
30. Kataoka K, Taniguchi H, Kondoh Y, Kimura T, Nishiyama O, Hasegawa Y, Kume H, Suzuki R, Shimokata K.  
Interstitial pneumonia associated with gefitinib.  
American Lung Association/American Thoracic Society Orlando, U.S.A. 2004.
31. Ando M, Kitagawa C, Ando Y, Sekido Y, Wakai K, Suzuki R, Shimokata K, Hasegawa Y.  
Genetic polymorphisms in the phenobarbital-responsive enhancer module of the UDP-Glucuronosyltransferase (UGT) 1A1 gene and irinotecan toxicity in Japanese patients.  
39th Annual Meeting of American Society of Clinical Oncology Chicago, U.S.A. 2003.
32. Kitagawa C, Ando M, Ando Y, Sekido Y, Usui M, Takahashi K, Shimokata K, Hasegawa Y.  
Genetic polymorphisms of the multidrug resistance-associated protein 2 gene (ABCC2) and irinotecan toxicity.  
40th Annual Meeting of American Society of Clinical Oncology, New Orleans, U.S.A. 2004.
33. Takeda N, Kume H, Kobayashi M, Kondo M, Ito Y, Imaizumi K, Hasegawa Y, Shimokata K.  
Involvement of intrinsic efficacy in  $\beta$ -adrenergic desensitization in trachealis.  
American Lung Association/American Thoracic Society Orlando, U.S.A. 2004.
34. Taga S, Taniguchi Y, Kondoh Y, Kimura T, Nishiyama O, Kataoka K, Kume H, Hasegawa Y, Shimokata K.  
The effect of noninvasive positive pressure ventilation for acute exacerbation of chronic obstructive pulmonary disease in general hospital in Japan.  
American Lung Association/American Thoracic Society Orlando, U.S.A. 2004.
35. Nagao Y, Kume H, Kondo M, Ito Y, Imaizumi k, Hasegawa Y, Shimokata K.  
Possible involvement of IL-13 in causing airway remodeling and  $\beta$ -adrenergic desensitization.  
American Lung Association/American Thoracic Society Orlando, U.S.A. 2004.
36. Kataoka K, Taniguchi H, Kondoh Y, Kimura T, Nishiyama O, Hasegawa Y, Kume H, Suzuki R, Shimokata K.  
Impact of the extent of honeycombing in high-resolution CT on exercise capacity and health-related quality of life in patients with Idiopathic pulmonary fibrosis.  
American Lung Association/American Thoracic Society Orlando, U.S.A. 2004.
37. Suzuki R, Taniguchi H, Kondoh Y, Shindoh J, Matsumoto S, Hiramatsu T, Gonda H, Baba K, Hasegawa Y, Shimokata K.  
A phase II trial of concurrent radiochemotherapy with carboplatin (CBDCA) and weekly docetaxel (TXT) in locally advanced non-small cell lung cancer (NSCLC). 40th American Society of Clinical Oncology New Orleans, U.S.A. 2004.





38. Imaizumi K, Nakanishi T, Kawabe T, Okamoto M, Ito G, Hashimoto N, Sumida A, Kojima, K, Sekido Y, Ito Y, Kume H, Hasegawa Y, Shimokata K.  
Th1/Th2 chemokine expression in Non-Small cell lung cancer tissue: increased expression of CCL22 (MDC) may be associated with better prognosis.  
American Lung Association/American Thoracic Society San Diego, U.S.A. 2005.
39. Kawabe T, Okamoto M, Hara T, Hashimoto N, Imaizumi K, Hasegawa Y, Takagi K, Shimokata K.  
Evaluation on Th1-Type cytokines and chemokines as diagnostic markers of tuberculous pleural effusions.  
American Lung Association/American Thoracic Society San Diego, U.S.A. 2005.
40. Okamoto M, Kawabe T, Hara T, Hashimoto N, Imaizumi K, Hasegawa Y, Ohno T, Nishimura M, Shimokata K.  
Quantitative trait loci analysis on allergic asthma in SMXA RI and consomic mice.  
American Lung Association/American Thoracic Society San Diego, U.S.A. 2005.
41. Hashimoto N, Usui M, Matsuo M, Hashimoto I, Imaizumi K, Hasegawa Y, Shimokata K, S.H. Phan.  
Expression of  $\alpha$ -smooth muscle action in pulmonary veins.  
American Lung Association/American Thoracic Society San Diego, U.S.A. 2005.
42. Takahashi K, Abe T, Yamamoto T, Nakashima K, Ito Y, Imaizumi K, Kume H, Hasegawa Y, Shimokata K.  
*NRANPI* polymorphisms associated with multidrug-resistant tuberculosis.  
American Lung Association/American Thoracic Society San Diego, U.S.A. 2005.
43. Oonakahara K, Machida K, Matsuyama W, Higashimoto I, Kawabata M, Arimura K, Osame M, Hayashi M, Ogura T, Imaizumi K, Hasegawa Y.  
Outbreak of bronchiolitis obliterance associated with consumption of *Sauropus androgynus* in Japan.  
American Lung Association/American Thoracic Society San Diego, U.S.A. 2005.
44. Suzuki R, Hasegawa Y, Baba K, Saka H, Saito H, Taniguchi H, Yamamoto M, Matsumoto S, Kato K, Shimokata K. A phase II study of first-line single agent of gefitinib in patient (pts) with stage IV non-small cell lung cancer (NSCLC).  
2005 American Society of Clinical Oncology Orlando, U.S.A. 2005.
45. Okamoto M, Kawabe T, Hara T, Hashimoto N, Imaizumi K, Hasegawa Y, Shimokata K.  
Th1/Th2 balance in malignant pleural effusions compared to tuberculous pleural effusions.  
American Lung Association/American Thoracic Society San Diego, U.S.A. 2006.
46. Kume H, Ikenouti T, Takeda N, Ito S, Kondo M, Hasegawa Y, Ito Y, Shimokata K.  
Involvement of intrinsic efficacy in the reduced responsiveness to  $\beta$ 2-Adrenergic receptor agonists in reliever medications.  
American Lung Association/American Thoracic Society San Diego, U.S.A. 2006.
47. Hashimoto N, Imaizumi K, Matsuo M, Takagi Y, Hasegawa Y, Shimokata K.  
Distinct matrix metalloproteinases activities in the metastasis of murine lewis lung cancer lines.  
American Lung Association/American Thoracic Society San Diego, U.S.A. 2006.
48. Usui M, Ando M, Kitagawa C, Ando Y, Sekido Y, Imaizumi K, Shimokata K, Hasegawa Y.  
Genetic polymorphisms of the adenosine triphosphate-binding transporters (ABCC2, ABCG2) and irinotecan toxicity in cancer patients.  
American Society of Clinical Oncology Atlanta, U.S.A. 2006.
49. Mori A, Nakayama S, Perrey S, Kakihata K, Ando Y, Hasegawa H.  
Development of the UGT1A1 gene polymorphism detection kit.  
31<sup>st</sup> European Society of Medical Oncology, Istanbul, Turkey. 2006.
50. Hasegawa Y, Ando Y, Usui M, Kitagawa C, Ando M, Shimokata K.

Pharmacogenetic testing for *UGT1A1* gene and transporter gene to estimate the risk of irinotecan toxicity.

31<sup>st</sup> European Society of Medical Oncology, Istanbul, Turkey. 2006.

51. Hashimoto N, Hasegawa Y.  
Evidence of endothelial-derived lung fibroblasts through endothelial-mesenchymal transition in pulmonary fibrosis.  
FASEB Summer Research Conferences, Saxton River, Vermont, U.S.A. 2008.
52. Hasegawa Y.  
Translational Pharmacogenomics: Cancer Chemotherapy.  
Impact of UGT and Transporter genes polymorphisms in cancer chemotherapy.  
2008 International Conference on Pharmacogenomics, Busan, Korea. 2008.
53. Horio M, Fujiwara Y, Kondo M, Tamura M, Yokoyama T, Usami N, Yokoi K, Imaizumi K, Sekido Y, Hasegawa Y.  
Mutational analysis of the epidermal growth factor receptor gene in the serum of resected non-small cell lung cancer patients.  
AACR Annual Meeting 2008, San Diego, USA, 2008.
54. Hashimoto N, Imaizumi K, Matsuo M, Hashimoto I, Honda T, Hayashi Y, Kawabe T, Hasegawa Y.  
Induction of CXCR4 surface expression on microvascular endothelial cells by fourteen-membered ring macrolides.  
ATS 2008 International Conference, Toronto, Canada. 2008.
55. Honda T, Imaizumi K, Hashimoto I, Hashimoto N, Matsuo M, Ito S, Kondo M, Kume H, Kawabe T, Yokoi T, Hasegawa Y.  
Different expression profile of Th1 and Th2 chemokines in UIP and NSIP.  
ATS 2008 International Conference, Toronto, Canada, 2008.
56. Ito S, Kume H, Iwaki M, Sashio T, Iwata S, Kondo M, Imaizumi K, Naruse K, Sokabe M, Hasegawa Y.  
Mechanical stretch activates Ca<sup>2+</sup> influx in human lung microvascular endothelial cells.  
ATS 2008 International Conference, Toronto, Canada, 2008.
57. Iwata S, Ito S, Iwaki M, Sashio T, Kondo M, Sokabe M, Hasegawa Y, Kume H. Role of intracellular Ca<sup>2+</sup> for endothelin-1-induced IL-6 production in human airway smooth muscle cells.  
ATS 2008 International Conference, Toronto, Canada, 2008.
58. Kume H, Tsuji S, Sahio T, Takeda N, Ito S, Kondo M, Hasegawa Y, Shimokata K.  
Involvement of endothelin-1 in migration of human airway smooth muscle cells.  
ATS 2008 International Conference, Toronto, Canada, 2008.
59. Makino Y, Kume H, Shiraki A, Ito S, Hasegawa Y, Honjo H, Kamiya K.  
Role of hydrogen peroxide in beta-adrenergic receptor dysfunction of tracheal smooth muscle.  
ATS 2008 International Conference, Toronto, Canada, 2008.
60. Sashio T, Kume H, Takeda N, Ito S, Kondo M, Hasegawa Y.  
Role of sphingosine-1-phosphate for adhesion molecules expression in human pulmonary microvascular endothelial cells.  
ATS 2008 International Conference, Toronto, Canada, 2008.
61. Ito S, Iwaki M, Morioka M, Kondo M, Aso H, Sokabe M, Hasegawa Y.  
Mechanical stretch enhances IL-8 production via p38 activation in human pulmonary microvascular endothelial cells Actin cytoskeleton regulates mechanical stretch-activated Ca<sup>2+</sup> influx in human lung microvascular endothelial cells.  
ATS 2010 International Conference, New Orleans, Louisiana, USA, May 2010.
62. Ito S, Sokabe M, Naruse K, Hasegawa Y.  
Symposium-Invited Presentation. "Role of stretch-activated Ca<sup>2+</sup> channels in pulmonary cell mechanotransduction."

63. Sakamoto K, Hashimoto N, Hasegawa Y.  
Modulated expression of surfactant protein D in acute lung injury might be associated with epithelial-mesenchymal transition in epithelial cells.  
FASEB Summer Research Conferences 2010: The Lung Epithelium in Health and Disease, Saxtons River, USA. 2010.
64. Sakamoto K, Hashimoto N, Imaizumi K, Nakashima H, Kohnoh T, Aoyama D, Ogawa T, Hasegawa Y.  
EMT-Related Gene, Twist, for Phenotype Change in Lung Cancer Cells.  
American Thoracic Society 2010 International Conference, New Orleans, USA. 2010.
65. Sato M, Takeyama Y, Horio M, Hase T, Yoshida K, Yokoyama T, Nakashima H, Hashimoto N, Sekido Y, Gazdar AF, Minna JD, Kondo M, Hasegawa Y.  
Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells.  
101st AACR annual meeting, Washington D.C. 2010.
66. Hashimoto N, Imaizumi K, Yoshinori Hasegawa.  
Involvement of fibrosis-related growth factors in endothelial-mesenchymal transition.  
American Thoracic Society 2010 International Conference, New Orleans, USA. 2010.
67. Horio M, Sato M, Takeyama Y, Hase T, Yoshida K, Sekido Y, Kondo M, Hasegawa Y.  
Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) inducing gene, suppresses growth of pleural mesothelioma cell lines.  
101st AACR annual meeting, 2010 Washington, D.C. 2010.
68. Yasuda Y, Shimokata T, Ando Y, Maruyama S, Imai E, Hasegawa Y, Matsuo S.  
Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer.  
American Society of Nephrology, Denver, CO, USA. 2010.
69. Aoyama D, Hashimoto N, Imaizumi K, Kohnoh T, Sakamoto K, Ogawa T, Hasegawa Y.  
Inhibition of TGF $\beta$ -induced phenotype alterations through epithelial-mesenchymal transition (EMT) in lung cancer by gene modulation of phosphorylation sites in tumor suppressor PTEN.  
ATS 2011 International Conference, Denver, USA. 2011.
70. Aso H, Ito S, Morioka M, Mori A, Suganuma N, Kondo M, Hasegawa Y. Prostaglandin E2 enhances IL-8 production in human pulmonary microvascular endothelial cells.  
ATS 2011 International Conference, Denver, CO, USA. 2011.
71. Elshazley M, Sato M, Hase T, Takeyama Y, Yoshida K, Oguri T, Toyokuni S, Sekido Y, Yokoi K, Usami N, Kondo M, Hasegawa Y.  
*BMAL1* depletion represses growth of mesothelioma through induction of mitotic catastrophe.  
The 2nd AACR International Conference on Frontiers in Basic Cancer Research. San Francisco, California, USA. 2011.
72. Hase T, Sato M, Yoshida K, Takeyama Y, Elshazley M, Sekido Y, Adi F Gazdar, John D Minna, Kondo M, Hasegawa Y.  
A pivotal role for epithelial cell adhesion molecule (EpCAM) in survival of lung cancer cells.  
AACR annual meeting, Orland, USA. 2011.
73. Hashimoto N, Hasegawa Y.  
Inhibition of Hypoxia-induced phenotype alterations through epithelial-mesenchymal transition (EMT) in lung cancer by gene modulation of phosphorylation sites in tumor suppressor PTEN.  
European Respiratory Society Annual Congress, Amsterdam, Netherlands. 2011.
74. Hashimoto N, Matsuo M, Usami N, Yokoi K, Hasegawa Y.  
Inspiratory capacity is a new preoperative risk predictor in the patients with lung cancer undergoing surgical resection.  
European Respiratory Society Annual Congress, Amsterdam, Netherlands. 2011.

75. Hashimoto N, Usami N, Imaizumi K, Yokoi K, Hasegawa Y.  
A critical involvement of chronic obstructive pulmonary disease as a preoperative risk factor in the patients with 17 lung cancer undergoing surgical resection.  
American Thoracic Society 2011 International Conference, Denver, USA. 2011.
76. Aso H, Ito S, Mori A, Morioka M, Suganuma N, Kondo M, Imaizumi K, Hasegawa Y.  
Mechanisms of IL-8 production induced by prostaglandin E2 in human pulmonary microvascular endothelial cells.  
The 3rd GCOE international symposium 2011, Nagoya, Japan. 2011.
77. Imai N, Imaizumi K, Ogawa T, Tanaka I, Aoyama D, Shindo Y, Morise M, Hashimoto I, Ito S, Hashimoto N, Sato M, Kondo M, Hasegawa Y.  
The echoic features of sarcoidosis via endobronchial ultrasound.  
Chest annual meeting, Honolulu, USA. 2011.
78. Ito S, Mori A, Hasegawa Y.  
Regulation of cell proliferation and intracellular Ca<sup>2+</sup> concentrations by prostanoid EP receptor subtypes in human airway smooth muscle cells.  
7th Young Investigators' Meeting on Smooth Muscle, Winnipeg, Canada. 2011.
79. Ito S, Parameswaran H, Morioka M, Naruse K, Kondo M, Sokabe M, Suki B, Hasegawa Y.  
Essential role for microtubule dynamics in cyclic stretch-induced cell alignment in human airway smooth muscle cells.  
ATS 2011 International Conference, Denver, USA. 2011.
80. Ito S, Suganuma N, Hasegawa Y.  
Role of STIM-1 in regulation of airway smooth muscle functions.  
International Symposium on Mechanobiology, Shanghai, China. 2011.
81. Kondo M, Hase T, Sato M, Yoshida K, Takeyama Y, Elshazley M, Sekido Y, Adi F Gazdar, John D Minna, Hasegawa Y.  
The functional role of epithelial cell adhesion molecule (EpCAM) in the non-small cell lung cancer cell lines.  
14th World Conference on Lung Cancer, Amsterdam, Netherlands. 2011.
82. Sakamoto K, Hashimoto N, Imaizumi K, Taniguchi H, Kondoh Y, Kohnoh T, Aoyama D, Ogawa T, Hasegawa Y.  
Modulated Expression Of Surfactant Protein D In Acute Lung Injury Might Be Associated With Epithelial-Mesenchymal Transition In Epithelial Cells.  
ATS 2011 International Conference, Denver, USA. 2011.
83. Sakamoto K, Taniguchi H, Kondoh Y, Wakai K, Kimura T, Kataoka K, Hashimoto N, Nishiyama O, Hasegawa Y.  
Acute Exacerbation of IPF Following Bronchoalveolar Lavage Procedures.  
Chest 2011 Annual Congress, Honolulu, USA. 2011.
84. Sato M, Horio M, Takeyama Y, Hase T, Elshazley M, Yoshida K, Sekido Y, Kondo M, A.F. Gazdar, J.D. Minna, Hasegawa Y.  
Transient but Not Stable ZEB1 Knockdown Dramatically Inhibits Growth of Malignant Pleural Mesothelioma Cells: Implication of EpCAM Up-regulation Induced by ZEB1 Knockdown.  
14th World Conference on Lung Cancer, Amsterdam, Netherlands. 2011.
85. Aso H, Ito S, Mori A, Morioka M, Suganuma N, Kondo M, Hasegawa Y. Prostaglandin E2 inhibits platelet-derived growth factor-induced cell migration via EP2 and EP4 receptors in human airway smooth muscle cells.  
ATS 2012 International Conference, San Francisco, USA, 2012.
86. Hashimoto N, Aoyama D, Sakamoto K, Hasegawa Y.  
Compensatory induction of mutated phosphorylation sites in the PTEN C-terminal suppresses tumor growth in lung cancers in vivo.  
ATS 2012 International Conference, San Francisco, CA, USA, 2012.

87. Hashimoto N, Kusunose M, Kimura M, Hasegawa Y.  
Inhibition of TGF $\beta$ -induced phenotype alterations through epithelial-mesenchymal transition (EMT) in epithelial cells by gene mutation of phosphorylation sites in PTEN.  
The FASEB Summer Research Conference, "The Lung Epithelium in Health and Disease".  
Saxtons River, USA, 2012.
88. Hashimoto N, Matsuo M, Usami N, Yokoi K, Hasegawa Y.  
Spirometric inspiratory capacity is a useful preoperative assessment in patients undergoing thoracic surgery.  
ATS 2012 International Conference, San Francisco, USA. 2012.
89. Hashimoto N, Sakamoto K, Hasegawa Y.  
Acute and persistent hypoxia differentially induces surfactant protein D modulation and epithelial-mesenchymal transition via hypoxia-inducible factor 1 $\alpha$  and twist stimulation in acute lung injury/fibrosis.  
ATS 2012 International Conference, San Francisco, USA, 2012.
90. Ito S, Suganuma N, Aso H, Kondo M, Sato M, Hasegawa Y.  
STIM1 regulates Ca<sup>2+</sup> influx and migration induced by platelet-derived growth factor in human airway smooth muscle cells.  
ATS 2012 International Conference, San Francisco, USA. 2012.
91. Kimura M, Hashimoto N, Kusunose M, Hasegawa Y.  
Compensatory induction of mutation of phosphorylation sites in PTEN inhibits hypoxia-induced epithelial-mesenchymal transition (EMT) in epithelial cells.  
The FASEB Summer Research Conference, "The Lung Epithelium in Health and Disease", Saxtons River, USA. 2012.
92. Kusunose M, Hashimoto N, Kimura M, Hasegawa Y.  
Various effect of compensatory induction of PTEN wild against TGF $\beta$ -induced epithelial-mesenchymal transition (EMT) in epithelial cells.  
The FASEB Summer Research Conference, "The Lung Epithelium in Health and Disease", Saxtons River, USA. 2012.
93. Masaaki Kusunose, Naozumi Hashimoto, Motohiro Kimura, Yoshinori Hasegawa.  
Various effect of compensatory induction of PTEN wild against TGF $\beta$ -induced epithelial-mesenchymal transition (EMT) in epithelial cells.  
FASEB Summer Research Conferences, USA. 2012.
94. Sato M, Larsen J, Lee W, Shames D, Ignacio I, Gazdar W, Shay J, Minna D, Kondo M, Hasegawa Y.  
The combination of five changes (telomerase, p16/rb bypass, p53 knockdown, krasv12, c-myc) together with serum-induced epithelial mesenchymal transition progresses normal human bronchial epithelial cells to full malignancy  
5th Asia Pacific Lung Cancer Conference, Fukuoka. Japan. 2012.
95. Wakahara K, Baba N, Van VQ, Delespesse G, Hasegawa Y, Sarfati M.  
Human basophils interact with memory T cells to augment Th17 responses.  
Global COE Program The 4th International Symposium, Nagoya, Japan. 2012.
96. Yoshida K, Sato M, Hase T, Momen Elshazley, Yamashita R, Usami N, Taniguchi T, Yokoi K, Kondo M, Girard L, Minna J, Hasegawa Y.  
Timeless is overexpressed in lung cancer and its knockdown induces apoptosis and chemosensitization in lung cancer cells.  
5th Asia Pacific Lung Cancer Conference Fukuoka 2012.
97. Hase T, Morise M, Taniguchi H, Shindoh J, Kojima E, Tanikawa Y, Suzuki R, Ogasawara T, Yamada Y, Kondo M, Saito H, Hasegawa Y.  
A phase II trial of erlotinib for previously treated Japanese patients with advanced non-small cell lung cancer harboring EGFR mutations: results of the Central Japan Lung Study Group trial (CJLSG0904).  
15th World Conference on Lung Cancer, Sydney, Australia. 2013.
98. Hase T, Sato M, Kondo M, Hasegawa Y.

Chemotherapy in the combined modality therapy for stage III NSCLC.  
18th Congress of the Asian Pacific Society of Respiriology, Yokohama, Japan. 2013.

99. Hashimoto N, Aoyama D, Hasegawa Y.  
Modulation of phosphorylation sites In the PTEN C-Terminal inhibits TGF  $\beta$ -induced EMT in lung cancers via blockade of translocation of  $\beta$ -catenin into cytoplasm.  
AThS 2013 International Conference, Philadelphia, USA. 2013.
100. Hashimoto N, Aoyama D, Hasegawa Y.  
Translocation of  $\beta$ -catenin into cytoplasm during TGF $\beta$ -induced EMT is negatively regulated by phosphorylation of the PTEN C-terminus in lung cancers.  
European Respiratory Society Annual Congress 2013, Barcelona, Spain. 2013.
101. Hashimoto N, Aoyama D, Kusunose M, Kimura M, Ogata R, Hasegawa Y.  
A Critical Role Of Phosphorylation Of The PTEN C-Terminus In TGF $\beta$ -Induced B-Catenin Translocation Into Cytoplasm During EMT In Epithelial Cells.  
18th Congress of the Asian Pacific Society of Respiriology, Yokohama, Japan, 2013.
102. Hashimoto N, Osuka S, Usami N, Yokoi K, Hasegawa Y.  
The 0.70 Fixed Ratio And Lower Limit Of Normal Of FEV1/FVC Identify An Postoperative Risk In Patients Undergoing Thoracic Surgery.  
18th Congress of the Asian Pacific Society of Respiriology, Yokohama, Japan. 2013.
103. Ichihara G, Hasegawa Y.  
Continuing Education Course A1 NanoEHS Overview.  
6th International Symposium on Nanotechnology, Occupational and Environmental Health, Nagoya, Japan. 2013.
104. Imaizumi K, Oguri T, Imai N, Nakanishi T, Iaogai S, Yamaguchi T, Minezawa T, Hayashi M, Hasegawa Y.  
Febrile Complications After Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration For Intra-Pulmonary Mass Lesions Of Lung Cancer.  
18th Congress of the Asian Pacific Society of Respiriology, Yokohama, Japan. 2013.
105. Ito R, Shindo Y, Kobayashi D, Tomita Y, Iguchi M, Yagi T, Hasegawa Y.  
Accuracy of Prediction Rules and Risk Factors for Mortality in Patients with Hospital-Acquired Pneumonia.  
28th International Congress of Chemotherapy and Infection, Yokohama, Japan. 2013.
106. Ito S, Takahara N, Furuya K, Sokabe M, Hasegawa Y.  
Real-time imaging of mechanical stress-induced ATP release in airway smooth muscle cells.  
8th Young Investigator Meeting on Airway Smooth Muscle and Fibroblast Biology, Groningen, Netherland. 2013.
107. Ito S, Kondo M, Imaizumi K, Morioka M, Hasegawa Y.  
Bronchial Asthma Preceding IgG4-Related Autoimmune Pancreatitis.  
18th Congress of the Asian Pacific Society of Respiriology, Yokohama. Japan. 2013.
108. Kimura M, Hashimoto N, Hasegawa Y.  
The Effect Of Exogenous PTEN4A Induction On TGF $\beta$ -Induced Epithelial-Mesenchymal Transition (EMT) In Epithelial Cells By Using Adenovirus Delivery System.  
18th Congress of the Asian Pacific Society of Respiriology, Yokohama. Japan. 2013.
109. Kobayashi D, Shindo Y, Ito R, Tomita Y, Iguchi M, Yagi T, Hasegawa Y.  
Prediction of Infection Due to Antibiotic-Resistant Bacteria in Patients with Hospital-Associated and Ventilator-Acquired Pneumonia.  
ICC 2013 International Conference, Yokohama, Japan. 2013.
110. Kusunose M, Hashimoto N, Hasegawa Y.  
The Role of Phosphorylation Sites Of The PTEN C-Terminus For TGF $\beta$ -Induced Translocation Of  $\beta$ -catenin In Lung Cancer Cells.  
18th Congress of the Asian Pacific Society of Respiriology, Yokohama, Japan. 2013.
111. Maruyama E, Morise M, Hase T, Taniguchi H, Saka H, Shindoh J, Suzuki R, Kojima E,

- Ogawa K, Ikeda T, Nozaki Y, Ando M, Kondo M, Saito H, Hasegawa Y.  
Final results of EGFR mutation reanalysis and KRAS mutation screening by Scorpion  
ARMS method: Phase II Study of Erlotinib for EGFR wild type Non-small cell Lung Cancer  
Patients. Central Japan Lung Study Group (CJLSG) 0903 trial.  
IASLC 15th World Conference on Lung Cancer, Sydney, Australia. 2013.
112. Okachi S, Imai N, Imaizumi K, Hase T, Aso H, Wakahara K, Ito S, Hashimoto N, Sato M,  
Kondo M, Hasegawa Y.  
Usefulness And Safety Of Endobronchial Ultrasound-Guided Transbronchial Needle  
Aspiration In Older Patients.  
18th Congress of the Asian Pacific Society of Respiriology, Yokohama, Japan. 2013.
113. Okada Y, Hashimoto N, Matsuzaki A, Yokoi K, Hasegawa Y.  
The prevalence rate of COPD as a comorbidity in Japanese patients with lung cancers  
undergoing bronchoscopy.  
18th Congress of the Asian Pacific Society of Respiriology, Yokohama, Japan. 2013.
114. Sato M, Jill E Larsen, Wochang Lee, Han Sun, David S Shames, Maithili P Dalvi, Ruben D  
Ramirez, Hao Tang, John M Dimaio, Boning Gao, Yang Xie, Ignacio I Wistuba, Adi F  
Gazdar, Jerry W Shay, Kondo M, Hasegawa Y, John D Minna.  
Human Lung Epithelial Cells Progressed To Malignancy Thorough Specific Oncogenic  
Manipulations.  
18th Congress of the Asian Pacific Society of Respiriology, Yokohama, Japan. 2013.
115. Wakahara K, Van VQ, Baba N, Bégin P, Rubio M, Hasegawa Y, Delespesse G, Sarfati M.  
Basophils are recruited to inflamed lungs and exacerbate memory Th2 cell responses in mice  
and humans.  
Keystone symposia, Type 2 Immunity: Initiation, Maintenance, Homeostasis and Pathology,  
Santa Fe, USA. 2013.
116. Ando A, Hashimoto N, Kusunose M, Ogata R, Hasegawa Y. The phosphatase activity of  
unphosphorylated PTEN and hypoxia-induced beta-catenin translocation from the cell  
membrane into the cytoplasm in lung epithelial cells.  
FASEB The Lung Epithelium in Health and Disease, Saxton River, USA. 2014.
117. Hashimoto N, Kusunose M, Kimura M, Hasegawa Y. Inhibition of TGF $\beta$ -induced phenotype  
alterations through epithelial-mesenchymal transition (EMT) in epithelial cells by gene  
mutation of phosphorylation sites in PTEN.  
FASEB The Lung Epithelium in Health and Disease, Saxton River, USA. 2014.
118. Hashimoto N, Kusunose M, Aoyama D, Kimura M, Hasegawa Y. Comprehensive analysis  
of the PTEN domains on TGF $\beta$ -induced aberrant cell motility in lung alveolar/epithelial cells  
by using PTEN constructs with deletion mutants.  
European Respiratory Society Annual Congress 2014, Munchen, Germany. 2014.
119. Ito R, Shindo Y, Kobayashi D, Jin W, Wachino J, Yamada K, Kimura K, Yagi T, Hasegawa  
Y, and Arakawa Y.  
Molecular Epidemiological Characteristics of Klebsiella pneumoniae Associated with  
Bacteremia among Patients with Pneumonia.  
ID Week 2014, Philadelphia, USA. 2014.
120. Ito S, Hasegawa Y.  
Effects of mechanical stresses on airway smooth muscle functions. Japan. International  
Symposium on Mechanobiology 2014, Okayama, Japan. 2014.
121. Ito S, Hasegawa Y.  
Mechanics of airway smooth muscle cells.  
7th World Congress of Biomechanics 2014, Boston, USA, 2014.
122. Kato T, Morise M, Ando M, Kojima E, Ogasawara T, Suzuki R, Shindo J, Matsumoto M,  
Sugino Y, Ogawa M, Nozaki Y, Kondo M, Saito H, Hasegawa Y. Can we predict serious  
adverse events (SAEs) and clarify unfit population for platinum-based chemotherapy in  
elderly patients (over 70 years of age) with advanced Non-small cell lung cancer  
(NSCLC)? (CJLSG 1203 trial).




ESMO 2014 annual meeting, Madrid, Spain. 2014.

123. Kobayashi D, Shindo Y, Ito R, Ando M, Ichikawa M, Yagi T, Tanikawa Y, Sugino Y, Shindoh J, Ogasawara T, Nomura F, Saka H, Yamamoto M, Taniguchi H, Suzuki R, Saito H, Kawamura T, and Hasegawa Y.  
Implication of  $\beta$ -lactam/macrolide combination therapy in each risk group for drug resistance in community-acquired and healthcare-associated pneumonia.  
American Thoracic Society 2014 International Conference, San Diego. 2014.
124. Ogata R, Kimura M, Hashimoto N, Hasegawa Y. The effect of exogenous PTEN4A induction on TGF $\beta$ -induced epithelial-mesenchymal transition (EMT) in epithelial cells by using adenovirus delivery system.  
FASEB The Lung Epithelium in Health and Disease, Saxton River, USA. 2014.
125. Murata N, Ito S, Takahara N, Furuya K, Sokabe M, Hasegawa Y.  
Stretch-activated Ca<sup>2+</sup> influx in human lung fibroblasts.  
International Symposium on Mechanobiology 2014, Okayama, Japan. 2014.
126. Murata N, Ito S, Hasegawa Y. Effects of mechanical stretch on intracellular Ca<sup>2+</sup> concentrations in human lung fibroblasts.  
7th World Congress of Biomechanics 2014, Boston, USA. 2014.
127. Sato M, Yamashita R, Kakumu T, Yogo N, Hase T, Maruyama E, Sekido Y, Kondo M, and Hasegawa Y.  
Tumor suppressive roles of miR-221 and miR-222 in lung cancer.  
ENA-2014 Symposium, Barcelona, Spain, 2014.
128. Shindo Y, Kobayashi D, Ito R, Ando M, Ichikawa M, Yagi T, Tanikawa Y, Sugino Y, Shindoh J, Ogasawara T, Nomura F, Saka H, Yamamoto M, Taniguchi H, Suzuki R, Saito H, Kawamura T, and Hasegawa Y.  
Mortality Risks in Patients with Pneumonia Who Received Appropriate Initial Antibiotics.  
ATS 2014 International Conference, San Diego, UA. 2014.
129. Hashimoto N, Aoyama D, Hasegawa Y.  
The PTEN protein, not lipid, phosphatase activity negatively regulat TGF $\beta$ -induced EMT in lung alveolar cells.  
ATS 2015 International Conference, Denver, USA. 2015.
130. Morishita M, Morise M, Hase T, Sato M, Kondoh M, Hasegawa Y.  
The Efficacy and Safety of Re-Challenge Platinum plus Pemetrexed Combination Therapy for Recurrent Malignant Pleural Mesothelioma.  
16th WCLC annual meeting. Denver, USA. 2015.
131. Morise M, Kondoh M, Hasegawa Y.  
Comparison of the incidence of skeletal related events (SREs) between non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).  
1st ESMO Asia annual meeting. Singapore. 2015.
132. Wakahara K, Suzuki Y, Shiraki A, Sashio T, Abe T, Arakawa Y, Goto D, Shindoh J, Hasegawa Y.  
Airway basophils are increased and correlated with eosinophilic inflammation in asthma and COPD.  
ERS International congress 2015, Amsterdam, Netherlands. 2015.
133. Sato K, S Gorka AP, Nagaya T, Michie MS, Nakamura Y, Nani RR, Coble VL, Vasalatiy OV, Swenson RE, Choyke PL, Hasegawa Y, Schnermann MJ, Kobayashi H.  
Role of charge and its localization on the In Vivo Optical Imaging Properties of Near-Infrared Cyanine Dye/Monoclonal Antibody Conjugates.  
World Molecular Imaging Congress 2016, New York, USA. 2016.
134. Sato K, Sato N, Biying Xu, Choyke PL, Hasegawa Y, Kobayashi H.  
Spatially selective depletion of regulatory T cells with Near Infrared Photoimmunotherapy for syngeneic Lewis lung carcinoma.  
17th World Conference on Lung Cancer 2016, Vienna, Austria, 2016.

135. Suzuki Y, Wakahara K, Nishio T, Ito S, Hasegawa Y.  
Airway basophils are activated and associated with eosinophilic inflammation in asthmatic patients.  
2016 AAAAI Annual Meeting, Los Angeles, USA. 2016.
136. Sano M, Shindo Y, Okumura J, Sakakibara T, Matsuda T, Yagi T, Matsui K, Takahashi K, Matsui S, and Hasegawa Y.  
Risk Factors for Severe Adverse Outcomes in Patients with Hospital-Acquired Pneumonia.  
ATS 2017 International Conference Washington, DC, USA. 2017.
137. Sano M, Shindo Y, Okumura J, Sakakibara T, Murakami Y, Nancy T, Matsuda T, Yagi T, Hasegawa Y.  
Risk Factors for Potentially Drug-Resistant Pathogens in Patients with Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia  
European Respiratory Society International Congress 2017 Milan, Italy. 2017.
138. Sato K, Sato N, Choyke PL, Hasegawa Y, Kobayashi H.  
Development of new photo-activated local cancer immunotherapy: Spatially selective depletion of tumor-associated regulatory T cells with Near Infrared Photoimmunotherapy  
Defence is the best attack,  
2017 EACR. 2017.
139. Hattori K, Hasegawa Y  
Preoperative Six-Minute Walk Distance Is Associated with Complication of Pneumonia after Lung Resection 2017  
18th World Conference on Lung Cancer, Yokohama, Japan. 2017.
140. Sato M, Hasegawa Y.  
Identification of Proteasomal Catalytic Subunit PSMA6 as a Therapeutic Target for Lung Cancer through a Pooled shRnA Screen.  
18th World Conference on Lung Cancer, Yokohama, Japan. 2017.
141. Majima S, Wakahara K, Nishio T, Hasegawa Y.  
Measurement of airway dimensions by 3-D CT in inflammatory bowel disease patients.  
22nd Congress of the APSR, Sydney, Australia. 2017.
142. Wakahara K, Suzuki Y, Nishio T, Majima S, Hasegawa Y.  
Flow cytometric analysis of induced sputum to evaluate eosinophilic inflammation. 22nd Congress of the APSR Sydney, Australia. 2017.
143. Okumura J, Shindo Y, Sano M, Sakakibara T, Matsuda T, Takahashi K, Saka H, Matsui S, Hasegawa Y.  
Implication of  $\beta$ -lactam plus macrolide combination therapy on mortality in patients with community-onset pneumonia at low risk for drug-resistant pathogens.  
22nd Congress of the APSR Sydney, Australia. 2017.
144. Yogo N, Hase T, Kasama T, Ozawa N, Sato M, Kaji N, Tokeshi M, Baba Y, Hasegawa Y.  
Development of the immuno-wall device for rapid, low-cost detection of EGFR mutations in tumor samples from patients with lung cancer.  
European society for medical oncology Asia annual meeting, Singapore. 2017.
145. Suzuki A, Kondoh Y, Brown KK, Kimura T, Kataoka K, Matsuda T, Yokoyama T, Ando M, Hashimoto N, Sakamoto K, Hasegawa Y.  
Acute exacerbations of fibrosing interstitial lung diseases: incidence, risk factors, and outcome.  
ATS International conference 2018, San Diego, USA. 2018.
146. Fukihara J, Kondoh Y, Kimura T, Kataoka K, Yokoyama T, Furukawa T, Johkoh T, Fukuoka J, Sakamoto K, Hashimoto N, Hasegawa Y, Brown KK  
Possible UIP Pattern and Traction Bronchiectasis on HRCT: Prognostic Impact in IIP.  
ATS International conference 2018, San Diego, USA. 2018.

147. Fukihara J, Sakamoto K, Iwano S, Morise M, Hashimoto N, Hasegawa Y  
Risk factor evaluation of programmed death 1 inhibitor related pneumonitis in patients with non-small cell lung cancer  
ATS International conference 2018, SanDiego, USA. 2018.
148. Goto D, Tanaka I, Sato M, Hasegawa Y.  
eIF2 $\beta$ , a Subunit of Translation-initiation Factor EIF2, as a Potential Therapeutic Target for Non-small Cell Lung Cancer.  
IASLC 19th World Conference on Lung Cancer, Toronto, Canada. 2018.
149. Miyazawa A, Tanaka I, Sato M, Hasegawa Y.  
Mechanobiology of Lung Cancer Cells: Regulation of PD-L1 expression by Matrix stiffness.  
IASLC 19th World Conference on Lung Cancer, Toronto Canada 2018
150. Hashimoto N, Hasegawa Y, Keicho N, Takeuchi K, Takase M, Hijikata M, Homma S, Inase N.  
The nation-wide survey of primary ciliary dyskinesia in Japan  
European Respiratory Society Annual Congress, Paris, France. 2018.
151. Nakamura S, Wakahara K, Majima S, Nishio T, Suzuki Y, Shiaraki A, Abe T, Shindoh J, Sashio T, Ono J, Izuhara k, Hasegawa Y.  
Periostin levels in chronic obstructive pulmonary disease (COPD).  
European Respiratory Society Annual Congress, Paris, France. 2018.
152. Wakahara K, Nishio T, Suzuki Y, Majima S, Nakamura S, Hasegawa Y.  
Increasing sputum basophils is a marker for eosinophil-dominant airway inflammation in adult asthma.  
European Respiratory Society Annual Congress, Paris, France. 2018.
153. Ando A, Hashimoto N, Nakahara Y, Sakamoto K, Hasegawa Y.  
The hypoxia-inducible factor 1 $\alpha$  protein stabilizer inhibits transforming growth factor  $\beta$ -induced extracellular matrix proteins beyond cell types and species.  
Asian Pacific Society of Respirology annual meeting, Taipei, Taiwan. 2018.
154. Ozawa, N. Hase T. Hatta A, Sagara, K. Ichikawa K, Miyazaki M, Ando M, Yamada K, Hasegawa Y.  
Retrospective Analysis of Risk Factor of Injection Site Reaction Induced by Infusion of Vinorelbine  
European society for medical oncology Asia annual meeting, Singapore. 2018.
155. Yogo N, Hase T, Kasama T, Hatta T, Ozawa N, Sato M, Kaji N, Tokeshi M, Baba Y, Hasegawa Y.  
Development of the immuno-wall device for rapid detection of ALK and ROS1 fusions in lung cancer.  
European society for medical oncology Asia annual meeting, Singapore. 2018.
156. Hashimoto N, Nakahara Y, Sakamoto K, Hasegawa Y.  
The pathogenesis and unresolved issues of idiopathic pulmonary fibrosis.  
Asian Pacific Society of Respirology annual meeting, Taipei, Taiwan. 2018.
157. Hashimoto N, Hasegawa Y, Keicho N, Takeuchi K, Takase M, Hijikata M, Homma S, Inase N.  
Primary ciliary dyskinesia in Japan  
Asian Pacific Society of Respirology annual meeting, Taipei, Taiwan. 2018.
158. Nishio T, Wakahara K, Suzuki Y, Majima S, Nishio N, Teranishi M, Sone M, Hasegawa Y.  
Mixed cellular inflammation is increased in adult asthma with severe chronic rhinosinusitis.  
American Academy of Allergy Asthma & Immunology annual meeting, San Francisco, USA. 2019.
159. Furukawa T, Oyama S, Yokota H, Kondoh Y, Hasegawa Y.  
Development Of A Machine Learning Combination With Deep Learning For Diagnosing Idiopathic Pulmonary Fibrosis In Interstitial Lung Disease  
ATS International Conference 2019, Dallas, USA. 2019.
160. Sakakibara T, Shindo Y, Takahashi K, Kobayashi D, Okumura J, Sano M, Murakami Y, Thabet N, Kobayashi H, Yagi T, Matsui S, Saka H, Hasegawa Y.



A New Scoring System for Predicting Adverse Events in Hospitalized Patients with  
Community-Onset Pneumonia.

ATS International Conference 2019, Dallas, USA. 2019.

161. Suzuki A, Kondoh Y, Brown KK, Kimura T, Kataoka K, Matsuda T, Yokoyama T, Ando M, Hashimoto N, Sakamoto K, Hasegawa Y.  
Recurrent acute exacerbations of fibrotic interstitial lung diseases.  
ATS International Conference 2019, Dallas, U.S.A. 2019
162. Y. Murakami, Y. Shindo, M. Sano, J. Okumura, T. Sakakibara, H. Kobayashi, N. Thabet, T. Yagi and Y. Hasegawa.  
Severe and Prolonged Lymphopenia Are Associated with Poor Outcome in Patients with Postoperative Pneumonia.  
ATS International Conference 2019, Dallas, USA. 2019.